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Chapter I 
INTRODUCTION 
Vascular System 
 
The Vascular System in Physiology and Disease 
 The human vascular system is indispensable for normal physiological development and 
survival due to its foremost function of being a closed conduit for the circulation of blood. The 
blood imports oxygen, nutrients, ions and water to all organs in the body and exports carbon 
dioxide as well as other noxious molecules from these organs. Few processes in the body have as 
daunting an impact on human health and development as angiogenesis and vasculogenesis; from 
disorders characterized by excessive angiogenesis to diseases resulting from insufficient vessel 
growth and function (1). Vasculature throughout the body undergoes continuous remodeling and 
maturation until a complete circulatory system is formed which measures close to 60,000 miles 
in a normal human if laid continuously end to end (2). This is most apparent in the brain where 
the vascular system establishes an intricate network of blood vessels responsible for sustaining 
the brain with its high metabolic demands. In vivo remodeling and maintenance of the cerebral 
microvasculature has been elegantly documented in a murine model system exhibiting extensive 
expansion and pruning that continues postnatally and declines with age (3).  
Characterization of the vessels that comprise the circulatory system depend on their 
anatomical and functional differences. Arteries that carry blood from a pumping heart and veins 
that carry blood back to the heart form the macrovascular system. Between arteries and veins 
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lays a vast network of tiny blood vessels that form the microcirculation. The microvascular bed 
is comprised of the arterioles, capillaries and venules which possess the largest surface area of 
the circulation. For comparison, the surface area of the skin of a normal 75 kg man is close to 
2 m2 while the surface area of the microcirculation has been estimated at 800-1000 m2 (4,5). This 
expansive microvascular bed is critically involved in blood-tissue exchange (Fig.1) (6,7). The 
diameter of blood vessels within the human body varies from 4 µm to 25 mm (typically lower 
than 300 µm in microvessels) whereas endothelial cell thickness ranges from less than 0.1 µm to 
1 µm (8). These vast differences allow the circulatory system to account for the diverse needs of 
the human body and thus adapt to requirements of each particular organ. Comparatively, red 
blood cells have an approximate diameter ranging from 6 µm to 8 µm while immune cells are 
larger; lymphocyte diameter ranges from 7 µm to 20 µm, monocyte diameter ranges from 15 µm  
to 25 µm and neutrophils diameter ranges from 12 µm to 15 µm (9). These cellular diameters at 
times may be larger than the microvessels through which they travel requiring the 
microvasculature to retain elasticity allowing the passage of these blood cells. 
 
Constituents of the Microvascular System (Microcirculation)  
As depicted in Figure 1, the circulation encompasses blood vessels of multiple sizes and 
characteristics that include differing inner surface area, velocity of blood flow and wall shear 
rate. As blood travels through arteries from the heart, the inner surface area of the vasculature 
increases both at the arterioles and the microcirculation which comprises the largest surface area 
(as indicated by the central peak in Fig.1). Concomitantly, the velocity of the blood flow is 
slowed  
 3 
 
 
 
 
Figure 1. A Global View of the Circulatory System 
Arterial circulation is depicted on the left and venous on the right. Microcirculation comprises 
the greatest endothelial surface area (left axis of the upper panel), as represented by the central 
solid peak. The upper panel right axis represents wall shear rate (s-1), with the curve reaching its 
highest values on the arterial side of the microcirculation (pre-capillary arterioles). The lower 
panel comprises the velocity of blood flow, and indicates that the slowest values correlate with 
post-capillary venules, the terrain of white blood cell emigration. Figure from Hawiger, J. et al, 
2015, J Thromb Haemost 13, 1743-1756. 
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upon entering the microcirculation with minimal velocity occurring at the post-capillary venules 
where the majority of blood-tissue exchange occurs. Furthermore, wall shear rate increases as 
arterial blood flow approaches the microvasculature but then falls as blood moves into the 
venous circulation (7). This organization of blood circulation provides the most efficient 
mechanism for delivery and exchange of water, ions as well as nutrients at the blood-tissue 
interface.   
Endothelial cells comprise the innermost lining of the vascular wall and are instrumental 
in forming the lumen of the vascular system. They work alone or in concert with other 
supporting cells to develop the required characteristics within each organ. At the tiniest blood 
vessels, solitary endothelial cell monolayers comprise the capillary tubes while other larger 
vessels require a more complex cellular organization including vascular smooth muscle cells and 
pericytes. The microvascular endothelium is tasked with sustaining the metabolic requirements 
and diverse functions of a given organ while also maintaining two other major functions: 
preservation of blood fluidity through inherent anti-clotting mechanisms and a second critical 
capacity, formation of the blood-tissue barrier. The microvascular endothelium is able to 
selectively allow the movement of water, nutrients, growth factors, hormones as well as certain 
cells into the surrounding tissues thereby maintaining physiological function of each organ 
systems. Concurrently, the microvascular endothelium excludes any constituents within the 
bloodstream that would prove harmful to the surrounding tissue (6).  
The microvascular endothelium must exhibit specific selectivity and strike a delicate 
balance as each organ system possesses distinct requirements. While the macrovascular 
endothelium is non-fenestrated and continuous thus allowing tightly controlled permeability, 
some microvascular endothelium is discontinuous with open pores (lacking a basal lamina 
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underneath the endothelial cells) allowing cellular trafficking in organs (8). The most dramatic 
example of this occurs in the spleen. The spleen deviates from the standard pattern of arterioles, 
capillaries and venules found in most other organs and employs an “open” microcirculation 
where specialized microvessels exhibit gaps between their endothelial lining cells permitting 
blood cells and blood-borne materials to enter from the circulation (10). The liver also requires 
considerable blood-tissue interaction, thus the microvasculature specific to this organ contains 
endothelial fenestrae which allow dynamic exchange by responding to changes in perfusion and 
blood flow rates. Microvascular circulation in the liver also uniquely contains clusters of pores or 
so called “sieve plates” occupying ~6-8% of the endothelial surface, that lack a diaphragm and a 
basal lamina thus facilitating extensive exchange of material between the blood and liver tissue 
(11). As with the spleen, the liver also permits the interaction of immune cells with the 
surrounding tissue facilitating the development of immune tolerance.  
In contrast to the previous two organs that demonstrate broad exchange between the 
microvasculature and tissue, the microcirculation of the lung exhibits a much tighter barrier 
excluding blood-borne cells. One of the major differences between systemic and pulmonary 
microvascular networks is the organization of capillaries in a dense anastomosing mesh of 
capillary segments (12). In contrast to the brush-like capillary beds common in the systemic 
circulation which are designed to meet minimum respiratory and nutritional requirements, the 
purpose of the alveolar microvascular network is to maximize the surface area available for gas 
exchange (O2 and CO2). In the adult human pulmonary microvascular surface area is on the scale 
of 100 m2 and above (12). Skeletal muscle microvasculature is differently organized with 
capillaries running in parallel to the muscle fibers. Microvascular endothelial cells in the 
capillaries and arterioles play an important part in the regulation of microcirculation by sensing 
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and conducting the initial impulse for dilation during muscle contraction thus adjusting perfusion 
levels leading to heterogeneous blood flow (13). As opposed to the “open” circulation of the 
spleen, the specialized microvasculature of the brain exhibits the most restricted interface with 
the surrounding tissue, essentially excluding most circulating molecules and cells from the 
central nervous system (CNS) (see section below on the Blood Brain Barrier). 
  To recapitulate, microvascular characteristics and functional requirements can vary 
greatly from one organ to another. Endothelial cells, responsible for the formation of the 
microvasculature in each of these organs, are instrumental in regulating the proper exchange of 
water, metabolites and plasma proteins as well as the trafficking of immune cells when their 
recruitment is necessary for an immune or inflammatory response. Many physiological and 
disease conditions contribute to phenotypic changes in the microvasculature that occurs in 
response to diverse factors including shear stress, hypoxia, or molecular mediators (8). As the 
principle cell type responsible for ensuring proper microvascular capacity at the blood-tissue 
interface, endothelial cells must preserve their structural and functional integrity which is of 
paramount importance in maintaining physiologic homeostasis. 
Furthermore, the heterogeneity of endothelial cells comprising the microcirculation in 
specific organs can result in diverse responses when challenged with similar insults. Endothelial 
cells from each particular microvascular bed have distinct and dynamic gene transcription 
profiles resulting in selective involvement in different disease states (14). Despite the shared 
general characteristics, endothelial cells from specific microvascular beds have a number of 
unique features and indeed, many human vascular diseases are restricted to particular vessels (8). 
Understanding endothelial cell response to a multitude of inflammatory insults is critical to 
preserving microvascular stability and organ health (see section below on Inflammation). 
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Blood Brain Barrier 
 
General Features of Brain Circulation 
The brain is a highly vascularized organ due to the extensive metabolic requirement for 
its physiologic function (Fig. 2). Formation of the specialized microvascular system found in the 
brain requires the interaction of a number of cell types including brain microvascular endothelial 
cells, the basement membrane, and various other cell types, including astrocytes, glial cells and 
neurons that are located close to the capillaries. Blood vessels supplying the brain must shield it 
from toxic substances in the blood, deliver nutrients, and allow harmful compounds to diffuse 
from the brain back into the bloodstream. Brain microvasculature is very intricate and reaches 
the deepest areas of the organ. Generally, capillaries in the brain may be as small as 7 µm to 10 
µm in average diameter, and the average intercapillary distance is approximately 40 µm meaning 
that every neuron is within 20 µm of a capillary (15).  Such proximity and compact organization 
ensures that every cell within the CNS is properly oxygenated and maintained. Brain 
microvascular endothelial cells are an essential part of the neurovascular unit that comprises the 
blood brain barrier (see below). 
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         Figure 2. The Brain is a Highly Vascularized Organ 
      A representative casting of the extensive and intricate vascular system in the human brain. 
Larger vessels are apparent on the exterior of the casting while smaller microvessels are 
abundantly localized in the middle of the model. Image from Google Image Search
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Characterization of the Blood Brain Barrier 
 Named for its ability to prevent the uncontrolled leakage of substances from the blood 
into the brain, the blood brain barrier (BBB) has emerged as a complex, dynamic, adaptable 
interface that controls the exchange of substances, including signaling molecules, between the 
CNS and the blood (16). Distinct specialization of the BBB depends on a number of cell types 
working in concert to form the “neurovascular unit” capable of providing the central nervous 
system a demarcation zone accessible to the bloodstream. Brain microvascular endothelial cells 
(BMECs) are surrounded by or closely associated with pericytes, astrocytes, perivascular 
endfeet, microglia and neuronal processes (17). The cells that make up the neurovascular unit 
communicate with the parenchyma of the CNS, adapting their behavior to serve its needs, 
responding to pathological conditions, and in some cases participating in the onset, maintenance 
or progression of disease (16). Microvascular endothelial cells form the lumen of the capillary 
and are surrounded by extracellular basal membrane with pericytes facing the brain parenchyma 
(Fig. 3). For a long time, the existence of pericytes and their function were underappreciated, but 
during recent years, these cells have gained increasing attention as obligatory constituents of 
blood microvessels and important regulators of vascular development, stabilization, maturation, 
and remodeling (18). Astrocytes and neurons are able to interact directly with endothelial cells or 
the encompassing pericytes. The concept of the neurovascular unit emphasizes that BMECs are 
in intimate and constant crosstalk with astrocytes, microglia, neurons, pericytes as well as 
circulating immune cells allowing for the BBB to refine its functions and facilitate brain-body 
communication (16). 
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                      Figure 3. Cellular Constituents of the Blood Brain Barrier 
The blood brain barrier ‘neurovascular unit’ is formed by capillary endothelial cells, surrounded 
by basal lamina, pericytes and astrocytic perivascular endfeet. Astrocytes provide the cellular 
link to the neurons. The figure also shows microglial cells. Adapted from Abbott, N.J. et al, 
2006, Nat Rev Neurosci 7, 41-53.   
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Endothelial Barrier Function 
 The barrier formed between the bloodstream and the CNS is of paramount importance in 
protecting delicate brain structure thereby allowing efficient neural activity. Hence, the 
importance of endothelial barrier function is most pronounced at the BBB that maintains an 
environment allowing proper function of the CNS by tightly controlling the passage of water, 
ions and other molecules while instantaneously delivering nutrients and oxygen according to 
current neuronal needs. Even water molecules, the prerequisite molecules to life, are transferred 
into the brain under strict control. During normal physiologic conditions in the brain the 
movement of water molecules is mainly directed by specific proteins that belong to the 
Aquaporins family, in particular Aquaporin 4 (AQP4). AQP4 protein complexes are strategically 
localized at astrocyte endfoot plasma membranes, in close contact with endothelial cells in the 
neurovascular unit, to constitutively regulate the flux of excess water derived from the metabolic 
breakdown of brain glucose and ions/neurotransmitters released by neural activity (19). While 
water molecules can cross the plasma membrane directly and perhaps, to a small extent through 
some glucose transporters and ion channels, several studies support a major role for AQP4 in 
determining BBB water permeability (20). At this point, it is still unclear to what extent AQP4 
plays a role in the development of increased microvascular permeability during BBB disruption.  
Importantly, the BBB also protects the brain from toxins, certain drugs and pathogens, 
(21). The brain endothelium has a range of passive and active features resulting in a much lower 
degree of endocytosis/transcytosis activity than does peripheral endothelium contributing to this 
transport-barrier property of the BBB (17). The vast majority of hydrophilic drugs, peptides and 
proteins are restricted from entry into the CNS under physiologic conditions. The restriction of 
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small molecule transport into the brain under normal physiologic conditions also extends to 
blood-borne immune cells. 
 
Immune Privilege of the Brain 
Early studies in the brain, in which minimal immunological response to transplanted 
antigenic material was observed, led to the concept of the brain as an “immune privileged site” 
that evolved from separation of immune cells found in the bloodstream from the brain 
parenchyma (22). Presently, it is recognized that “CNS immune privilege” is not absolute and it 
is more accurately described as an immunologically specialized site rather than immunologically 
privileged (23). Under normal conditions, antigen-activated lymphocytes are capable of only 
low-level surveillance throughout the CNS limiting entry to a fraction of the immune cells 
observed in other tissues (24). Larger numbers of immune cells are able to transverse the BBB 
only upon the activation of an inflammatory response. An intact BBB is essential for forming 
and maintaining a microenvironment that allows neuronal circuits to function properly by 
controlling leukocyte trafficking across the BBB (21). The tightly regulated barrier function of 
brain microvascular endothelial cells is formed by endothelial junctional protein complexes. 
 
The Blood Brain Barrier is Maintained by Discrete Protein Complexes 
Intercellular junctions made up of a complex network of adhesive proteins organized into 
adherens junctions (AJ) and tight junctions (TJ) maintain BBB function in brain microvascular 
endothelial cells (25). Each of these junctional complexes is characterized by the presence of 
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proteins from two distinct families, the cadherins and catenins in AJs while claudins and 
occludin make up TJs. Vascular endothelial cadherin (VE-cadherin) is specifically responsible 
for endothelial AJ assembly and barrier architecture as it anchors the transcellular interaction 
between plasma membranes of adjoining cells. VE-cadherin, as a transmembrane protein, 
recruits cytoplasmic catenins through its cytosolic tail, specifically β-catenin and p120-catenin, 
thus facilitating the connection of these protein complexes to the actin cytoskeleton (26). 
Tyrosine phosphorylation of VE-cadherin and β-catenin is strongly reduced in confluent 
monolayers as tyrosine phosphorylation of β-catenin decreases the affinity of its binding to the 
cadherin tail (27). Tight junctions are comprised of the transmembrane proteins occludin and the 
claudin family of proteins (Fig.4) (17). Tight junctions are important due to their primary 
responsibility of limiting movement of molecules across the endothelial barrier. These junctions 
restrict even the movement of small ions such as Na+ and Cl- as well as segregating the apical 
and basal domains of the cell membrane (a “fence-like” function) so that the endothelium can 
take on a polarized state (17). The term “barrier” suggests a relatively fixed structure, but it is 
now known that many features of the BBB phenotype can vary (28). The BBB is not simply a 
barrier that blocks water, small molecules and cells but a complex, interactive, ever-adapting 
interface that serves the signaling needs of the CNS and facilitates communication between the 
brain and peripheral organs (16). Activation of microvascular endothelial cells in the presence of 
a proinflammatory microenvironment leads to the disruption of these protein complexes and 
deterioration of normal physiologic function. A full understanding of the processes underlying 
microvascular disruption could prove pivotal in discovering new therapeutic targets to limit 
neuronal toxicity that underlies a number of neurologic disorders.  
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Figure 4. Simplified Schematic Depiction Showing the Molecular Composition of 
Endothelial Junctions 
In epithelial cells, tight and adherens junctions are strictly separated from each other, but in 
endothelial cells these junctions are intermingled. The most important molecule of endothelial 
adherens junctions is VE-cadherin. In addition, the platelet–endothelial cell adhesion molecule 
(PECAM) mediates homophilic adhesion. The chief linker molecules between adherens 
junctions and the cytoskeleton are the catenins, while desmoplakin and p120 catenin (p120ctn) 
are also involved. Occludin and the claudins — proteins with four transmembrane domains and 
two extracellular loops — are the most important membranous components. The junctional 
adhesion molecules (JAMs) and the endothelial selective adhesion molecule (ESAM) are 
members of the immunoglobulin superfamily. Many first-order adaptor proteins are located 
within the cytoplasm, including zonula occludens 1, 2 and 3 (ZO-1–3) and Ca2+ dependent serine 
protein kinase (CASK), that bind to the intramembrane proteins. Among the second-order 
adaptor molecules, cingulin is important, and junction-associated coiled-coil protein (JACOP) 
may also be present. Signaling and regulatory proteins include multi-PDZ-protein 1 (MUPP1), 
the partitioning defective proteins 3 and 6 (PAR3/6), MAGI-1–3 (membrane-associated 
guanylate kinase with inverted orientation of protein–protein interaction domains), ZO-1-
associated nucleic acid-binding protein (ZONAB), afadin (AF6), and regulator of G-protein 
signaling 5 (RGS5). All of these adaptor and regulatory/signaling proteins control the interaction 
of the membranous components with the actin/ vinculin-based cytoskeleton. Itch, E3 ubiquitin 
protein ligase. Figure from Abbott, N.J. et al, 2006, Nat Rev Neurosci 7, 41-53.  
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Disruption of the Blood Brain Barrier 
Disruption of the BBB leads to increased translocation of water, ions,  plasma proteins as 
well as poorly regulated exchange of other molecules and infiltrating immune cells across the 
BBB affecting the delicate CNS environment (Fig.5) (21). Breakdown of the BBB impacts all of 
the constituents of the neurovascular unit but in particular astrocytes, which are normally tasked 
with a number of housekeeping functions, including regulation of ion homeostasis, water 
transport and amino acid neurotransmitter metabolism (29). Preserving a uniform internal 
environment within the CNS is essential for normal neuronal activity. Lost integrity of the 
neurovascular unit deleteriously impacts the surrounding neural tissue as maintenance of a stable 
osmotic environment is lost and normally excluded biologically active molecules are able to 
enter the CNS (29). It is noteworthy that disruption of physiologic barrier function underlies the 
development of neurodegenerative diseases including Multiple Sclerosis and Neuromyelitis 
Optica (21,30). It remains unknown whether BBB breakdown is an initiating event or a 
downstream consequence in these diseases. 
 The process of increased immune cell infiltration begins with disruption of endothelial 
cell organization and results in a breach of the BBB. Leukocyte extravasation from the 
bloodstream is a multistep process that depends on several factors including fluid dynamics 
within the vasculature and molecular interactions between circulating lymphocytes and 
endothelial cells (23,24,30). These interactions are mediated by emitted cytokines and 
chemokines that are able to initiate a feed-forward auto-regulatory loop. Interaction between 
activated immune cells and the endothelium occurs during the initiation and progression of 
Multiple Sclerosis.  While its initiation is still unresolved, formation of multiple sclerotic lesions 
results from trafficking of autoreactive T cells from the periphery into the CNS parenchyma  
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Figure 5. Blood Brain Barrier Regulation under Normal Physiologic Conditions (top row) 
and BBB Breakdown Following Injury (bottom row) 
Under physiological conditions (top row), pericytes regulate (1) BBB integrity, i.e., tight or 
adherens junctions and transcytosis across the BBB; (2) angiogenesis, i.e., microvascular 
remodeling, stability and architecture; (3) phagocytosis/pinocytosis, i.e., clearance of toxic 
particles and metabolites from the CNS; (4) Cerebral blood flow (CBF) and capillary diameter; 
(5) neuroinflammation manifested by leukocyte trafficking into the brain among other features 
and (6) multipotent stem cell activity. Pericyte dysfunction (bottom row) is characterized by (1) 
BBB breakdown causing leakage of neurotoxic blood-derived molecules into the brain (for 
example, fibrinogen, thrombin, plasminogen, erythrocyte-derived free iron and anti-brain 
antibodies); (2) aberrant angiogenesis; (3) impaired phagocytosis causing CNS accumulation of 
neurotoxins; (4) CBF dysfunction and ischemic capillary obstruction; (5) increased leukocyte 
trafficking promoting neuroinflammation; and (6) impaired stem cell-like ability to differentiate 
into neuronal and hematopoietic cells. Pericyte dysfunction is present in numerous neurological 
conditions and can contribute to disease pathogenesis. Figure from Sweeney, M.D., et al, 2016, 
Nat Rev Neurosci 19, 771-783. 
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leading to their attack of neurons (31).  Recruitment of activated leukocytes can also prove 
destructive to the brain through excessive expression of proinflammatory mediators, cytokines 
and chemokines (30). For instance BMEC stimulation by Interleukin 1 beta (IL-1β) leads to 
fever and lethargy (32), exemplifying the direct impact this cytokine has on the CNS.   
 
Inflammation 
 
Inflammation Affecting the Vascular System 
As stated by Elias Metchnikoff in 1891, ‘The main factor in all inflammatory states 
consists in a lesion of the vessels which are attacked by an irritating cause” (7). These “irritating 
causes” can be microbial, autoimmune, metabolic, and/or physical (trauma, burns and 
irradiation). Inflammatory insults brought on by pathogenic microbes, metabolic products or 
traumatic injury lead to activation of endothelial cells and a loss of their barrier function manifest 
by increased permeability and subsequent swelling of the surrounding tissue (edema). Since 
antiquity, inflammation was recognized and characterized by four cardinal signs: rubor (redness), 
calor (increased heat), tumor (swelling) and dolor (pain) (33). Injury of the vasculature features 
prominently in the development of these signs. Increased blood flow due to vasodilation results 
in development of redness and increased heat at the site of injury. The expression of 
inflammation and hemostasis-related proteins following endothelial activation is notably 
dependent on the vascular bed and the nature of the stimulus (8).  
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Vascular inflammation is a daunting issue in modern medicine because it mediates a 
number of diseases including atherosclerosis, stroke, hypertension and sepsis (7,34-36). 
Cardiovascular disease is the leading global cause of death, accounting for more than 17.3 
million deaths per year, a number that is expected to grow to more than 23.6 million by 2030 
(34). Direct and indirect costs of cardiovascular diseases and stroke including health 
expenditures and lost productivity total more than $316.6 billion (34). About 75 million 
American adults (32%) live with hypertension resulting in direct and indirect costs totaling more 
than $48.6 billion (35).  Sepsis, developing from a collapse of microvascular circulation, is one 
of the ten leading causes of death worldwide (7). Thus, protection of endothelial cells from 
excessive activation due to proinflammatory insults is a chief concern. This protection hinges 
upon a delicate balance between the inducers and physiologic suppressors of inflammation in 
endothelial cells during the course of disease. Physiologic suppressors of inflammation 
encompass ubiquitin modifier A20, suppressors of cytokine signaling (SOCS) 1 and 3 as well as 
caspase and receptor interacting protein adaptor with death domain (CRADD/RAIDD) (37-40). 
Relative deficiency of these physiologic anti-inflammatory regulators may contribute to 
reversible or irreversible endothelial injury, detachment, and cell death known as “anoikis”. 
Anoikis or “homelessness” is a form of programmed cell death due to the loss of contact with the 
extracellular matrix (ECM). Anchorage-dependent cells use ECM derived signals to maintain 
viability and tissue integrity (41). 
Activation of the endothelium leading to increased permeability plays a crucial role in the 
development of vascular injury and its resolution. A proinflammatory environment induces a 
switch in gene transcription from generating a protective anti-coagulant, anti-adhesive and anti-
inflammatory endothelial surface to one that is dominated by pro-coagulant, pro-adhesive and 
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pro-thrombotic mediators (8). Vascular permeability results in accumulation of parenchymal and 
interstitial fluid impairing organ function by increasing the distance required for the diffusion of 
oxygen and compromising microvascular perfusion because of increased interstitial pressure 
(42). Increased microvascular permeability is a characteristic of a multitude of deleterious 
diseases.  
 
Vascular Leak Syndrome: A Complication of Interleukin 2 Action during Cancer 
Immunotherapy 
Another disorder emblematic of the dangers associated with excessive vascular 
permeability is the vascular leak syndrome (VLS). VLS is characterized by a generalized 
increase in extravasation of fluids along with proteins from the capillary vessels into the tissues 
resulting in interstitial edema, a decrease in microcirculatory perfusion and ultimately 
culminating in different types/severities of organ damage in various pathological conditions (43). 
Patients present with transient but severe hypotension that results in vascular collapse and shock, 
hemoconcentration and ultimately anasarca (generalized massive edema) because of the 
accumulation of fluids and macromolecules in tissues (44). Development of this dangerous 
ailment results from loss of endothelial barrier function and may prove fatal if left untreated. 
Treatment of VLS can be difficult as the signs and symptoms widely vary among patients. With 
no defined course of medical care, most patients receive various regimens to decrease systemic 
edema such as diuretics, intermittent exogenous oxygen or intubation with mechanical 
ventilation support  to counteract lung edema or pulmonary insufficiency and vassopressors to 
maintain renal perfusion and blood pressure (43). VLS has been described as the major dose-
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limiting toxicity of cancer immunotherapy with IL2 (Fig.6) (45). Important work has been done 
documenting the effect of IL2 immunotherapy on pulmonary endothelial cells (46). These 
findings suggest that use of IL2-antibody complexes targeting specific IL2 receptor subunits may 
reduce the adverse side effect of severe pulmonary edema. Due to the differences exhibited by 
endothelial cells in specific microvascular beds we were interested in identifying the mechanism 
of IL2 action on brain microvascular endothelial cells. This mechanism of IL2-induced VLS 
affecting the brain and causing neuropsychiatric disorders is still unclear and requires further 
study.  
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Figure 6. Overview of Vascular Leak Syndrome Following Breakdown of the Blood-Tissue 
Barrier 
Vascular Leak Syndrome caused by IL2 immunotherapy induces endothelial damage resulting in 
increased extravasation of water, proteins, ions, and electrolytes culminating in a decrease in 
plasma osmolarity. Vascular activation leads to changes in cellular morphology and loss of cell-
cell interactions at adherens junctions and tight junctions. Tissue edema impacting organs such 
as the liver, brain and lungs reduces capillary circulation resulting in decreased perfusion and 
tissue hypoxia. Loss of microvascular endothelium function is deleterious for the organ systems. 
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Transcription Factor Nuclear Factor κB, a Master Regulator of Immunity 
 
Nuclear Factor κB Signaling 
NFκB (RelA, RelB, cRel, NFκB1 and NFκB2) is a family of transcription factors sharing 
the Rel homology domain (47) and functionally denoted by us as one of the stress-responsive 
transcription factors (SRTFs) along with nuclear factor of activated T cells (NFAT), cFos and 
cJun (forming the AP1 complex) and signal transducer and activator of transcription (STAT) 1 
(48). NFκB p65 (RelA) is known as a pleomorphic transcription factor, expressed in most 
mammalian cells, able to induce hundreds of genes responsible for critical roles in many normal 
physiological processes as well as diverse pathologic conditions most notably, inflammation and 
cancer (49). Activation of NFκB leads to its translocation to the nucleus and transcriptional 
activity upon binding to specific κB target sites within the DNA. This transcription factor is 
sequestered in the cytoplasm when bound to a class of proteins referred to as inhibitors of NFκB 
or IκB proteins. Binding of IκBα obscures the RelA nuclear localization sequence. Release of 
RelA from these inhibitors is initiated by IκB kinase mediated phosphorylation, subsequent 
polyubiquitination and proteasomal degradation of IκB proteins (50). Following removal of IκB, 
the nuclear localization sequence (NLS) is recognized by nuclear transport shuttles that belong to 
the importin/karyopherins alpha family (51). This complex is then guided by importin beta 
toward the nuclear pore, for nuclear translocation. Once inside the nucleus NFκB binds to κB 
regulatory elements and begins transcription (Fig. 7). Post-translational modification of NFκB, in 
particular phosphorylation, has been documented to increase DNA binding capacity (52). A fully 
phosphorylated NFκB transcription factor is then able to transcribe a multitude of target genes 
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impacting a number of cellular processes. Activation of lymphocytes  by IL2 is well known for 
inducing NFκB signaling (53). This fact, along with the prior detailed documentation of 
pulmonary endothelial expression of IL2 receptor, suggests that IL2 signaling in BMEC may 
result in NFκB p65 (RelA) activation. 
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Figure 7. Activation of the Canonical Pathway of NFκB  
Many agonists activate the canonical pathway of NFκB, including proinflammatory cytokines 
such as IL-1β, TNF-α, or pathogen-associated molecular patterns that bind to TLRs, ligands for 
the antigen receptors TCR/BCR, or lymphocyte co-receptors such as CD40, CD30, or receptor 
activator of NFκB (RANK) (1). Activated IKK phosphorylates IκB proteins on 2 conserved 
serine residues and induces IκB polyubiquitinylation (2), which in turn induces their recognition 
by the proteasome and causes successive proteolytic degradation (3). Following the IκB 
degradation, the cytoplasmic NFκB dimers are released, bound by nuclear transport adaptors 
importins/karyophherins alpha/beta and translocated to the nucleus, where gene transcription is 
activated (4). Figure from Jost, P.J. and Ruland, J., 2007, Blood 109, 2700-2707. 
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Activation of Endothelial Cells is Mediated by Nuclear Factor κB Signaling  
Disruption of endothelial barrier function develops following activation of the 
endothelium. The NFκB pathway is an important player in endothelial activation. Cell adhesion 
molecules e.g. intercellular cell adhesion molecule 1 (ICAM1) and selectins, members of the 
immunoglobulin superfamily, are up-regulated by proinflammatory factors and sequentially 
mediate rolling, adhesion, and transmigration of leukocytes from the bloodstream to underlying 
tissues (54). Endothelial cells become activated in response to leukocyte engagement and/or to 
leukocyte-derived cytokines resulting in an upregulation of cell adhesion molecules as well as 
further cytokine expression which leads to an escalation of the inflammatory cascade (24). Genes 
encoding these cell adhesion molecules and other mediators of inflammation are controlled by 
stress-responsive transcription factors exemplified by NFκB, master regulator of immunity and 
inflammation. Increased expression of interleukin 6 (IL6), macrophage chemotactic protein 1 
(MCP1), ICAM1 and vascular cell adhesion molecule 1 (VCAM1) among others, have been 
linked to the NFκB pathway in endothelial cells (47,54,55). The emerging link between IL2, 
NFκB activation and vascular permeability led us to further study these interactions in brain 
microvascular endothelial cells. 
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Interleukin 2 
 
Interleukin 2 Signaling 
IL2, a 15.5 kDa cytokine, was initially discovered as a mediator of expansion and 
maintenance of T lymphocytes (56). The importance of IL2 in immunobiology is well 
documented. IL2 is able to deliver both stimulatory and regulatory signals to lymphocytes by 
interacting with either a trimeric receptor complex consisting of IL2Rα (CD25), IL2Rβ (CD122) 
and IL2Rγ (CD132, γc) or the dimeric IL2Rβγ (57). While both receptor complexes are able to 
transmit signals following IL2 ligation, the trimeric (“high affinity”) complex shows a 10-100 
fold higher affinity than that of the dimeric (“intermediate affinity”) receptor complex (Fig. 8) 
(57,58). The IL2 receptor complex signals through three main signaling pathways, the mitogen-
activated protein kinase (MAPK) pathway, the signal transducer and activator of transcription 
(STAT) pathway and the phosphoinositide 3-kinase (PI3K-AKT) signaling pathway (Fig. 9) 
(59). Pulmonary endothelial cells have been shown to induce an increase in vascular 
permeability following engagement of the trimeric IL2Rαβγ (46). Expression of IL2Rα subunit 
on endothelial cells was identified as the culprit in development of vascular leak in the lungs. 
This led us to postulate that BMECs may also express this receptor complex and be responsible 
for brain edema following IL2 stimulation. While previous studies have been undertaken to 
understand IL2 activation of endothelial cells, particularly pulmonary endothelial cells, to our 
knowledge investigations focusing on IL2 activation of brain microvascular endothelial cells 
have not been described (46,60-62).    
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    Figure 8. Three-way Junction between IL2, IL2Rβ, and γc 
IL2 (yellow ribbon representation), IL2Rβ (cyan), and γc (green) form a three-way 
junction at the heart of the high-affinity IL2 signaling complex. The network of residues that 
mediate these contacts (colored red) provides a compelling structural basis for cooperativity in 
the IL2/IL2R complex assembly. Figure from Stauber, D.J., et al, 2005, Proc. Natl. Acad. Sci. U. 
S. A. 103, 2788-2793. 
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Figure 9. Major Interleukin 2 Signaling Pathways 
IL2 signaling emanating from the trimeric (IL2Rαβγ) or dimeric (IL2Rβγ) receptor complex 
involves three major signaling pathways. Following ligation of IL2 to the receptor complex 
Janus family tyrosine kinases (JAK1 and JAK3) are activated and are responsible for further 
signaling down the signal transducer and activator of transcription (STAT) signaling pathway, 
the phosphoinositide 3-kinase (PI3K-Akt) signaling pathway, and the mitogen-activated protein 
kinase (MAPK) signaling pathway. New evidence points to the activation of NFκB by the PI3K-
Akt pathway through activation of the CARMA 3 signalosome. The MALT1-BCL10-CARMA1 
complex in immune cells is able to drive nuclear NFκB localization resulting in transcription of 
its target genes in addition to the other signaling pathways. 
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Interleukin 2: A Mainstay of Early Cancer Immunotherapy 
The ability to mediate T cell survival and function suggests that IL2 administration would 
drive expansion of tumor infiltrating lymphocytes. This hypothesis led to pioneering efforts to 
harness IL2 for initiation of cancer immunotherapy programs in patients with renal cell 
carcinoma and malignant melanoma. Initial administration in humans was undertaken by Dr. 
Steven A. Rosenberg and his team at the National Cancer Institute in 1985 when twenty patients 
received a wide variety of different regimens and doses of recombinant IL2 (56). Following 
optimization of different administration protocols, IL2 was demonstrated to be a successful 
cancer treatment showing an objective and durable regression in ~20% to ~30% of tumors in 
patients suffering from renal cell carcinoma or melanoma (63,64). More recent advances have 
allowed physicians to utilize adoptive transfer of natural or genetically modified autologous 
human antitumor T cells expanded in vitro to treat a variety of cancer types (64). These 
immunotherapy protocols have been refined and expanded leading to an increase in positive 
outcomes. Thus, IL2 cancer immunotherapy was approved by the U.S. Food and Drug 
Administration (FDA) for the treatment of malignant melanoma and renal cell carcinoma.  
 
Interleukin 2-Induced Vascular Leak Syndrome 
While partially successful, the major dose-limiting toxicity of IL2 immunotherapy is the 
development of vascular leak syndrome (VLS) in treated patients (64). As described above, VLS 
leads to increased vascular permeability that results in extravasation of proteins, water and 
electrolytes culminating in decreases in both serum albumin levels and plasma osmolarity (43). 
VLS is thought to occur secondary to endothelial injury, causing increased vascular permeability 
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which results in patient hypotension, edema and increased body weight endangering a number of 
organ systems (65). VLS of multiple severities has been documented in patients, thus 
entrenching VLS as one of the most dangerous side effects of IL2 cancer immunotherapy 
treatment. Tissue edema is accompanied by elevated tissue pressure, decreasing capillary 
circulation resulting in decreased microcirculatory perfusion and hypoxia (43). Cessation of IL2 
immunotherapy results in rapid resolution of these side effects documenting IL2’s direct 
involvement in the initiation and progression of VLS (32,64). Thus, identification of the 
mechanisms through which IL2 acts may provide new targets to combat this dangerous 
complication of cancer immunotherapy. 
 
Interleukin 2 Immunotherapy’s Impact on the Central Nervous System (CNS) 
As with other organ systems throughout the body, IL2-induced VLS also impacts the 
central nervous system manifested by a rise in brain water content that is attributed to increased 
permeability of the brain microvascular endothelium. CNS toxicity with substantial 
neuropsychiatric presentation has been documented in patients undergoing IL2 immunotherapy 
(32). IL2, as with other cytokines which have been previously shown to impact the CNS (e.g. IL-
1β), influences neural activity. Neuropsychiatric manifestations of IL2 immunotherapy ranged 
from minor agitation requiring minimal supervision to severe agitation and combative behavior 
that necessitated the use of neuroleptic agents (32). Patients also developed a number of 
symptoms over the course of IL2 immunotherapy including delusions, malaise, fatigue, 
confusion and a general depressed level of consciousness (32,66). These adverse effects of IL2 
must be delicately balanced with the positive outcome of IL2 antitumor immune response. Initial 
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onset of psychiatric problems most commonly appeared at the end of each treatment phase, 
particularly on the last day of IL2 administration (32). These observations suggest that 
cumulative and escalating exposure to IL2 becomes deleterious to the CNS through an 
increasingly more disruptive effect of IL2 on the BBB. Furthermore, IL2’s association with 
models of other neurological disorders underscores the negative aspects of IL2 action on the 
CNS. Understanding the mechanistic basis for development of increased brain microvascular 
permeability and neurological toxicity will allow more successful treatments utilizing IL2 while 
reducing deleterious side effects.  
 
Formulation of Working Hypothesis and Experimental Strategy 
 
While much work has been undertaken to identify the role of immune cell signaling in 
the induction of vascular permeability, surprisingly little has been learned about the molecular 
underpinnings of IL2-induced signaling in BMECs that are an integral part of the neurovascular 
unit comprising the BBB. The lack of knowledge regarding IL2-induced dysregulation of brain 
microvasculature motivated me to study the mechanism of IL2 action in BMECs. It is well 
known that there are important phenotypic differences in endothelium throughout the vascular 
tree encompassing major organs such as the brain, lungs, liver and spleen. These organs are all 
impacted by Vascular Leak Syndrome, a complication of cancer immunotherapy with IL2. 
Therefore, my hypothesis is focused on BMECs as the main target of IL2 action in the brain. I 
posited that BMECs would respond to IL2 through its cognate receptor previously not identified 
in these cells. I hypothesized further that binding of IL2 to its putative receptor complex would 
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evoke signaling pathways that are mediated by transcription factor NFκB akin to those noted in 
immune cells e.g. lymphocytes. I also hypothesized that IL2 would induce increased 
permeability in BMECs monolayers. Thus, in an effort to further our understanding of the 
mechanism of disease evoked by IL2, my thesis studies endeavored to provide new insight into 
the initiation and development of brain microvascular permeability induced by IL2 in order to 
allow development of novel treatments for patients suffering from these effects.  
IL2 therapy induces expression of inflammatory cytokines and chemokines in a similar 
pattern to those elicited following challenge with bacterial endotoxin and termed a “cytokine 
storm” (45). The vast majority of these proinflammatory mediators are controlled by the 
transcription factor NFκB (67) further strengthening my hypothesis to focus on the NFκB 
pathway in BMECs. Thus, my first aim was to demonstrate that IL2 stimulation of BMECs 
through the newly identified IL2 receptor complex would lead to activation of the NFκB 
pathway resulting in the expression of proinflammatory cytokines and chemokines. In an effort 
to document NFκB activation I took a three-pronged approach documenting degradation of IκBα,  
increased presence of phosphorylated NFκB in nuclear extracts from IL2 stimulated BMECs and 
by utilizing immunofluorescence to visualize an increase in nuclear NFκB. I further verified 
activation of NFκB by measuring the expression of proinflammatory mediators IL6 and MCP1. 
 IL2 therapy also leads to the induction of VLS characterized by increased systemic organ 
edema and weight gain seen in patients receiving this form of cancer immunotherapy (64). 
Endothelial dysfunction following IL2 stimulation disrupts endothelial interactions and integrity. 
Adherens junctions along with tight junctions are part of the unique network of complex protein 
interactions responsible for forming the endothelial blood-tissue barrier (25).  Hence, my second 
aim was to document changes seen in brain microvascular endothelial monolayer permeability as 
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well as unraveling the underlying mechanism for increased permeability. I evaluated IL2-
induced permeability of the BMEC monolayer in Transwell chambers. The mechanism of 
increased BMEC monolayer permeability was investigated by monitoring the changes in 
adherens junction components, namely VE-cadherin, p120-catenin and β-catenin, using co-
immunoprecipitation as well as immunofluorescence. Further mechanistic documentation was 
performed by monitoring the phosphorylation state of adherens junction proteins as well as 
expression levels of phosphatases associated with adherens junctions.   
Importantly, the microvascular effects of IL2 also play a role in the development of 
Multiple Sclerosis and other chronic neurological disorders. The potential mechanism of IL2-
induced disruption of brain microcirculation has not been previously determined in these 
conditions. Here we report that IL2 is able to directly signal through the intermediate affinity IL2 
receptor complex expressed on BMECs. Furthermore, signaling through this receptor complex 
leads to activation of the transcription factor NFκB resulting in the perpetuation of an 
inflammatory environment characterized by increased expression of pleotropic cytokine IL6 and 
chemokine MCP1. NFκB activation was documented in BMECs following IL2 stimulation and 
in accordance with my hypothesis, activated BMECs led to expression of NFκB dependent 
proinflammatory mediators in a concentration dependent manner. Based on this analysis, a novel 
IL2 signaling pathway activating NFκB and resulting in activation of BMECs is described. 
Concurrently, activation of BMECs ultimately results in increased permeability across BMEC 
monolayers through disruption of the adherens junction protein complex. Increased post-
translational modification of VE-cadherin, in particular phosphorylation, leads to destabilization 
of the adherens junction and formation of intercellular gaps. Loss of tightly organized brain 
microvascular endothelial junctions potentiates an increase in vascular permeability. These 
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studies provide a novel and comprehensive account of IL2 action on BMECs and provide a 
mechanism to explain increased brain edema experienced by patients receiving IL2 cancer 
immunotherapy. 
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Chapter II 
ANALYSIS OF ENDOTHELIAL ACTIVATION BY IL2 
Wylezinski L.S. and Hawiger J., Interleukin 2 Activates Brain Microvascular Endothelial Cells 
Resulting in Destabilization of Adherens Junctions. Journal of Biological Chemistry, 2016. 291, 
22913-22923. 
Synopsis 
 
Perturbation of the endothelium results in deleterious effects on organs and their function. 
Upon disruption, biologically diverse molecules are able to flow into the surrounding tissue 
accompanied by activated immune cells thereby impacting organ homeostasis. The brain is no 
exception as the delicate milieu of the CNS is particularly sensitive to environmental change. 
Dysregulation of brain microvascular endothelial cells, tasked with formation of the BBB, is 
known to result in or potentiate a number of central nervous system maladies. Here we report 
that IL2, a well-known and important cytokine in immunobiology, is able to activate brain 
microvascular endothelial cells leading to the induction of NFκB. IL2 is able to signal through 
the intermediate affinity IL2 receptor complex located on the endothelial cell surface resulting in 
activation of the NFκB signaling pathway. NFκB activation has been shown to induce the 
production of a number of proinflammatory cytokines/chemokines as well as cell surface 
adhesion molecules that further exacerbate injury by increasing immune cell response. Based on 
our results, IL2 is able to initiate endothelial dysregulation and potentiate a proinflammatory 
environment. 
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Introduction 
 
 The development of systemic vascular leak syndrome by patients undergoing IL2 cancer 
immunotherapy underlines the effect of IL2 on the vascular endothelium. Cognizant of the fact 
that IL2 is involved in the development of both vascular leak syndrome as well as neurotoxicity 
we were interested in deciphering the impact of IL2 on brain microvascular endothelial cells. To 
our knowledge no previous work has been done to identify the mechanism of IL2 induced 
activation of BMECs. Understanding the process of activation of BMECs by IL2 would provide 
better insight into the development of brain edema. We utilized both human and murine brain 
microvascular endothelial cell monolayers to replicate a cardinal feature of the BBB. The known 
link between IL2 and NFκB in immune cells as well as the proinflammatory role NFκB plays in 
endothelial cells led us to investigate this axis in BMECs. We hypothesized that binding of IL2 
to its receptor complex would evoke signaling pathways that are mediated by transcription factor 
NFκB akin to those noted in immune cells e.g. lymphocytes. We further hypothesized that NFκB 
would potentiate a proinflammatory environment and ultimately lead to increased microvascular 
permeability.  
 
Results 
 
 In order to validate the phenotypic features of the BMEC lines used in this study, we 
documented expression of two well-known endothelial markers. Platelet cell adhesion molecule 
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1 (PECAM1), a member of the immunoglobulin gene superfamily that concentrates at 
intercellular junctions (68). Additionally, von Willebrand factor (vWF) is a multimeric plasma 
glycoprotein constitutively expressed by endothelial cells (69). Utilizing real time PCR (Table 1; 
Table 2), I was able to show that constitutive expression of both PECAM1 and vWF are 
significantly displayed in human and murine BMECs compared to control cell types, human 
embryonic kidney cells (HEKs) and murine embryonic fibroblasts (MEFs) (Fig. 10). These 
results verify the phenotypic features of brain microvascular endothelial cells thereby allowing 
us to use them for experimental modeling of the endothelial interactions at the BBB. 
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Table 1. Human Oligonucleotide Primer Sequences 
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Table 2. Oligonucleotide Primer Sequences 
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Figure 10. Expression of Endothelial Cell Markers vWF, PECAM1  
Constitutive transcript levels of endothelial cell markers vWF and PECAM1 were assessed by 
qPCR. Following normalization to GAPDH, mRNA levels are presented as increased-fold 
change from species-specific non-endothelial cells: HEK 293 cells and MEFs. 
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Interleukin 2 Receptor Complex 
We embarked on identification of IL2 receptors on BMECs as a prerequisite for their 
activation by IL2. Trimeric high affinity IL2 receptor complexes (IL2Rα, IL2Rβ  and IL2Rγ) 
were initially documented to activate the NFκB signaling pathway in lymphocytes (53). Ensuing 
work has reported that other cell types, including lung endothelial cells, are able to respond to 
IL2 stimulation through the intermediate affinity dimeric IL2 receptor complex (IL2Rβ and 
IL2Rγ) (46,57). We established that both human and murine BMECs express the intermediate 
affinity IL2 receptor (IL2Rβγ) (Fig. 11). These cells constitutively express IL2Rβ and IL2Rγ 
transcripts at a significantly higher level than comparative controls comprising human and 
murine cells (HEKs and MEFs). Correspondingly, I showed the expression of IL2Rβ and IL2Rγ 
proteins by immunoblotting cellular lysates of human and murine BMECs. Significantly, 
expression of IL2Rα, the high affinity subunit, was only observed after prolonged stimulation of 
endothelial cells with IL2 (Fig. 11). These results are in agreement with previous work 
documenting IL2-induced expression of the IL2Rα subunit following NFκB activation in murine 
lymphocytes (70). Consistent with these results, a κB regulatory element binding site within the 
promoter region of IL2Rα is conserved between humans and murine genes (70). Thus, I 
established the existence of a constitutively expressed dimeric IL2Rβγ and an inducibly 
expressed trimeric IL2αβγ receptor complex on human and murine BMECs. 
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Figure 11. Expression of IL2 Receptor Complex in Human and Murine BMECs 
Transcript levels of IL2R subunits were determined by qPCR, and protein expression was 
documented by immunoblotting. IL2Rβ (CD122) and IL2Rγ (CD132) were constitutively 
expressed in both human and murine BMECs. Transcript and protein levels for IL2Rα (CD25) 
were only detected following 24-h stimulation with 300 kilounits/ml of species-specific IL2. The 
level of mRNA transcript is presented as relative expression comparing human and murine 
BMECs. Error bars represent mean ±S.E. of three independent experiments performed in 
triplicates. Statistical significance was determined by Student’s t test (*, p <0.05). 
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IL2 Induces Degradation of IκBα, an Inhibitor that Sequesters NFκB in the 
Cytoplasm of BMECs 
In an effort to demonstrate that the intermediate affinity dimeric IL2 receptor complex 
was competent and able to transduce NFκB activation in BMECs, we employed a three pronged 
approach. NFκB sequestration in the cytosol is controlled by interaction with IκBα. That restricts 
NFκB from interacting with the nuclear import machinery by concealing the nuclear localization 
signal (NLS), thereby preventing NFκB translocation to the nucleus. Dissociation of IκBα from 
NFκB occurs following phosphorylation of IκBα at Ser-32 and Ser-36 (71,72). Subsequent 
polyubiquitination of IκBα leads to degradation by the proteasome that allows NFκB nuclear 
translocation.  
Our first approach documented the degradation of IκBα in IL2-stimulated human and 
murine BMECs and was comparable to the results evoked by a known endothelial agonist, 
lipopolysaccharide (LPS). Due to the very rapid turnover kinetics of IκBα (73), we included the 
protein synthesis inhibitor cycloheximide to prevent re-accumulation of newly synthesized IκBα. 
Constitutive turnover was measured following addition of cycloheximide and compared with 
degradation in BMECs stimulated with agonist. Stimulation with IL2 caused time-dependent 
degradation of IκBα with a loss of 30-70% of its basal level, mimicking IκBα degradation 
following activation with LPS (Fig. 12). Degradation and release of NFκB is the first step in 
translocation to the nucleus and activation. We show that IL2 stimulation can directly lead to 
IκBα degradation suggesting that NFκB can be translocated to the nucleus in BMECs. 
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    Figure 12. IL2 Activates the NFκB Pathway in Human and Murine BMECs  
Degradation of IκBα in BMECs. Human (hCMEC/D3) and murine (bEnd.3) BMECs were left 
unstimulated (Unstim) (0) or stimulated with 300 kilounits/ml of species-specific IL2 or 1µg/ml 
LPS, a positive control, for the indicated times after pretreatment for 30 min with the protein 
synthesis inhibitor cycloheximide (CHX) (10 µg/ml) to block de novo protein synthesis. 
Cytosolic extracts were isolated, separated by SDS-PAGE, and immunoblotted for the 
degradation of IκBα. Protein levels were quantified by immunoblotting, and values at each time 
point were normalized to the β-actin loading control. Error bars represent mean ±S.D. of at least 
four independent experiments. Statistical significance was determined using an unpaired t test 
with Welch’s correction (*, p <0.05; **, p <0.005; ***, p <0.0005).  
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IL2-Induced Phosphorylation of NFκB p65 (RelA) and Nuclear Localization 
Following degradation of IκBα, the NFκB p65/RelA subunit becomes phosphorylated 
conferring enhanced DNA binding capacity. It is shuttled to the nucleus through nuclear 
transport adaptors, importins/karyopherins alpha, that recognize the unmasked NLS. By isolating 
nuclear lysates from human and murine BMECs stimulated with or without IL2 we were able to 
demonstrate an increase in the proportion of phosphorylated RelA as compared to non-
phosphorylated RelA implying activation of this transcription factor (Fig. 13). Both human and 
murine BMECs showed a time-dependent response to IL2, resulting in a 50% increase in Tyr-
536 phosphorylation of NFκB RelA following agonist stimulation. Nuclear localization of NFκB 
was verified by immunofluorescence microscopy (Fig. 14). Indeed, as compared to unstimulated 
control, we noted elevated levels of nuclear NFκB in BMECs stimulated with IL2 or 
comparative control TNFα, which is a known inducer and activator of the NFκB pathway. 
Nuclear translocation of phosphorylated NFκB leads to the transcription of a number of target 
genes, including proinflammatory cytokines and chemokines.  
 
 
 
 
 
 
 
 48 
 
 
 
 
 
Figure 13. IL2-Induced Nuclear Translocation and Phosphorylation of NFκB 
Translocation and phosphorylation of NFκb to the nucleus. Human and murine BMECs were 
stimulated with 300 kilounits/ml of species-specific IL2 or 1 μg/ml LPS for the indicated times, 
and nuclear extracts were isolated, separated by SDS-PAGE and immunoblotted for the presence 
of total NFκB and Tyr-536 phosphorylated NFκB (p-RelA). TATA-binding protein (TBP) serves 
as a loading control for nuclear lysates. Quantification of signal is shown as -fold change 
compared with the unstimulated control. Error bars represent mean ±S.D. of at least four 
independent experiments. Statistical significance was determined using an unpaired t test with 
Welch’s correction (*, p <0.05). 
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Figure 14. Detection of NFκB in the Nucleus by Immunofluorescence  
Murine (bEnd.3) BMECs were analyzed following 24-h stimulation with 300 kilounits/ml of 
murine IL2 or 30 ng/ml murine TNFα. Cells were immunostained with anti-RelA antibodies 
(red), and nuclei were counterstained with DAPI (blue). Arrows indicate strong nuclear staining 
of RelA. Images are representative of three independent experiments. Quantification was 
determined using MetaMorph imaging software. Statistical significance was determined using an 
unpaired t test with Welch’s correction (*, p <0.05). Magnification, x63. Scale bars, 5 µm. Error 
bars represent mean ±S.D. 
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IL2-Induced Expression of Proinflammatory Cytokine and Chemokine 
Productive transcription and translation of NFκB target genes were confirmed by 
measuring endothelial expression of cytokine interleukin 6 (IL6) and chemokine macrophage 
chemoattractant protein 1 (MCP1) upon IL2 stimulation. These two mediators of inflammation 
have been previously implicated in the activation and loss of barrier function in other endothelial 
barrier models (74-77). Both IL6 and MCP1 were elicited by IL2 in a concentration-dependent 
manner in human and murine BMECs (Fig. 15).  Thus, IL2 signaling through the intermediate 
affinity receptor located on BMECs led to degradation of IκBα, nuclear translocation of NFκB 
p65 (RelA) and ultimately, to transcription of two NFκB-regulated genes, IL6 and MCP1. 
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Figure 15. IL2-Induced Expression of Proinflammatory IL6 and MCP1 in Human and 
Murine BMECs  
IL6 (A) and MCP1 (B) are expressed by activated BMECs in a dose-dependent manner. Protein 
levels of IL6 and MCP1 in culture media were measured 24 h after stimulation of hCMEC/D3 
and bEnd.3 cells with increasing concentrations of species-specific IL2 as indicated (kilounits 
(kU)) or 1µg/ml LPS in hCMEC/D3 cells and 0.5µg/ml LPS in bEnd.3 cells. Error bars 
represent mean ±S.D. from three independent experiments performed in duplicate or triplicate. 
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Chapter III 
INTERLEUKIN 2-INDUCED DISRUPTION OF ADHERENS JUNCTIONS 
Synopsis 
 
Harnessing the power of IL2 to stimulate the immune system to treat renal cell carcinoma 
and malignant melanoma has proven to be successful. However, these beneficial effects of IL2 
are curtailed by the development of multi-organ edema including brain edema, a prominent 
manifestation of vascular leak syndrome. Some patients receiving IL2 immunotherapy begin 
experiencing these symptoms within a couple of days of initiation of treatment and a reversal of 
these side effects is seen upon cessation of therapy indicating its direct role in this serious 
complication. Moreover, IL2 has been documented to play a significant role in a number of 
chronic neurological autoimmune diseases, including Multiple Sclerosis, Neuromyelitis Optica 
and Neuropsychiatric Systemic Lupus Erythematosus (30,78,79). Disruption of the BBB is a 
critical step in the development of these neurological conditions but in many cases complete 
understanding of how this occurs is unknown. Gaining a better understanding of the effect of IL2 
on BMECs may prove beneficial not only for patients receiving IL2 immunotherapy but also 
those suffering other autoimmune disease affecting the CNS. Here we report that IL2 increases 
BMEC monolayer permeability through the formation of intercellular gaps. IL2 induces 
disruption of adherens junctions responsible for maintaining the tight organization of BMECs. 
This occurs by increasing the phosphorylation state of VE-cadherin an important constituent of 
the adherens junction protein complex. The increase in phosphorylation of VE-cadherin is 
accompanied by concomitant loss of SHP2 phosphatase protein responsible for maintaining 
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adherens junction stability. Phosphorylation of VE-cadherin destabilizes the adherens junction 
complex and IL2 ultimately leads to dissociation of VE-cadherin, p120-catenin and β-catenin 
resulting in formation of intercellular gaps and increased permeability. 
 
Introduction 
 
 The BBB is formed through the specialized properties of brain endothelial cells along 
with associated cell types which create a highly selective barrier protecting the CNS. While the 
term “barrier” implies a rigid structure, it is now known that many features of the BBB can be 
modulated. The maintenance of the BBB is largely vested in the cell-cell interactions which 
allow for exclusion of water, ions and plasma proteins from the CNS. A complex network of 
intercellular adhesion proteins are organized into adherens junctions (AJs) and tight junctions. 
They form the “physical barrier” limiting paracellular diffusion between adjoining endothelial 
cells. These junctions are intermingled in endothelial cells, whereas in epithelial cells, adherens 
and tight junctions are strictly separated from each other. (17). Adherens junctions are 
ubiquitously expressed in the vascular tree (80) and are of particular importance in microvascular 
circulation, which provides the largest surface area of exchange between blood and tissue (7). 
Furthermore, post-capillary venules comprise the main endothelial surface for blood-tissue 
exchange and have shown to be particularly vulnerable to opening by inflammatory mediators 
(17). Formation of AJs is dependent on the homotypic interaction of cell surface transmembrane 
proteins termed cadherins whose cytoplasmic tails associate with intracellular binding partners 
termed catenins. Destabilization of this interaction leads to dissociation of the complex and 
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internalization of VE-cadherin disrupting the barrier function of these proteins (81-83). IL2 
administered during cancer immunotherapy causes vascular leak syndrome, manifested by a raise 
in brain water content that is attributed to increased permeability of the brain microvascular 
endothelium (84). Therefore, we hypothesize that IL2 is able to induce increased permeability of 
the BMEC monolayer through the disruption of the adherens junction protein complex leading to 
a loss of barrier function.  
 
Results 
 
IL2-Induced Increase in the Permeability of Human Microvascular Endothelial Cell 
Monolayers 
 Endothelial dysfunction following IL2 stimulation was measured by monitoring the 
passage of fluorescein labeled molecules as they pass across the endothelial monolayer. 
Fluoroscein isothiocyanate (FITC) conjugated dextran (FITC-dextran, 10kDa) was added to the 
upper chambers of Transwell chambers following stimulation with IL2 or with another known 
inducer of permeability, TNFα. Lower chamber supernatants were then sampled at multiple time 
points. IL2 induced a significant increase in the movement of FITC-dextran across the IL2-
stimulated human BMEC monolayer compared with the non-stimulated control, indicating a 
gradual loss of endothelial barrier function and increased permeability (Fig. 16). As IL2-induced 
permeability can potentially be enhanced by other cytokines, namely IL6 and/or MCP1 both 
concurrently induced in BMECs, we utilized species-specific neutralizing antibodies against IL6 
and MCP1. Neutralizing these two potential permeability agonists did not significantly alter an 
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Figure 16. IL2-Induced Permeability of Human BMEC Monolayer  
Human (hCMEC/D3) cells were grown to confluence on Transwell inserts and left unstimulated 
(Unstim) or stimulated with 300 kilounits (kU)/ml of human IL2 or 30 ng/ml human TNFα for 24 
h as indicated. Shown are representative permeability tracings. To assess permeability, 10-kDa 
FITC-dextran was added to the top chamber of each insert, and fluorescence in the lower 
chamber was measured at the indicated times. 
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 IL2-induced increase in permeability, although a trend toward lower permeability was observed. 
In contrast, IL2-induced permeability enhancement was countered in human BMECs by species-
specific IL2Rβ-neutralizing antibody (Fig. 17). These significant results indicate that the IL2-
induced increase in endothelial monolayer permeability is solely due to its signaling via the IL2 
receptor. Consistent with these findings in human cells, we also documented increased BMEC 
monolayer permeability following IL2 stimulation in murine cells (Fig. 18). No significant 
decrease in permeability was noted following treatment with species-specific IL6 or MCP1 
neutralizing antibodies in murine BMECs either (Fig. 19). An IL2Rβ antibody neutralizing 
experiment could not be performed in murine cells due to a lack of species-specific antibody 
against murine IL2Rβ. Murine bEnd.3 cells demonstrated greater change in endothelial 
permeability as compared to human hCMEC/D3 cells most likely due to constitutively higher 
expression of IL2Rβ as documented in Figure 11.  
 
 
 
 
 
 
 
 
 57 
 
 
 
 
Figure 17. Human BMEC Monolayer Permeability following Cytokine and Chemokine 
Neutralizing Antibody Treatment 
Human (hCMEC/D3) cells were grown to confluence on Transwell inserts and left unstimulated 
(Unstim) or stimulated with 300 kilounits (kU)/ml of human IL2 or 30 ng/ml human TNFα for 24 
h as indicated. Concurrent with stimulation, a portion of the Transwell inserts were treated with 
species-specific neutralizing antibodies against IL6 and MCP1 as indicated. Shown are 
quantitative representation of all permeability tracings recorded at 120 min. To assess 
permeability, 10-kDa FITC-dextran was added to the top chamber of each insert, and 
fluorescence in the lower chamber was measured at the indicated times. Error bars represent 
mean ±S.D. of -fold change relative to the unstimulated control from five independent 
experiments performed in at least duplicate; p values shown were determined by an unpaired t 
test with Welch’s correction of the area under the curves from each individual experiment (*, p 
<0.05; **, p <0.005). 
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Figure 18. IL2-Induced Permeability of Murine BMCEC Monolayer  
Murine (bEnd.3) cells were grown to confluence on Transwell inserts and left unstimulated 
(Unstim) or stimulated with 300 kilounits (kU)/ml of murine IL2 or 30 ng/ml murine TNFα for 
24 h as indicated. Shown are representative permeability tracings. To assess permeability, 10-
kDa FITC-dextran was added to the top chamber of each insert, and fluorescence in the lower 
chamber was measured at the indicated times. 
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Figure 19. Murine BMEC Monolayer Permeability following Cytokine and Chemokine 
Neutralizing Antibody Treatment 
Murine (bEnd.3) cells were grown to confluence on Transwell inserts and left unstimulated 
(Unstim) or stimulated for 24 h with 300 kilounits (kU)/ml of murine IL2 or 30 ng/ml murine 
TNFα as indicated. Concurrent with stimulation, a portion of the Transwell inserts were treated 
with species-specific neutralizing antibodies against IL6 and MCP1 as indicated. Shown are  
quantitative representation of all permeability tracings recorded at 120 min. To assess 
permeability, 10-kDa FITC-dextran was added to the top chamber of each insert, and 
fluorescence in the lower chamber was measured at the indicated times. Error bars represent 
mean ±S.D. of -fold change relative to the unstimulated control from at least three independent 
experiments performed in at least duplicate; p values shown were determined by unpaired t test 
with Welch’s correction of the area under the curves from each individual experiment (*, p 
<0.05; **, p <0.005). 
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IL2-Induced Disruption of Adherens Junctions 
To gain a better understanding of the mechanism of increased permeability we initiated 
experiments identifying changes associated with BMEC adherens junctions. Thus, we analyzed 
IL2’s impact on the adherens junction protein complex by immunofluorescence after completion 
of the permeability analysis. VE-cadherin and p120-catenin, the main constituents of AJs, were 
labeled and the complex visualized by immunofluorescence microscopy. In quiescent human 
BMECs, immunostained VE-cadherin and p120 displayed a well-defined, contiguous border 
between adjoining endothelial cells. This border was strikingly lost after treatment with IL2 or 
TNFα, a comparative positive control (Fig. 20). Membrane-associated VE-cadherin•p120 
complexes were disrupted with a concomitant reduction of these proteins along the periphery of 
the cells. These immunofluorescence images correlated with immunostaining of murine BMECs 
which showed a similar outcome with a significant loss of VE-cadherin•p120 complexes at the 
cellular border (Fig. 21). These results establish that the adherens junction is negatively impacted 
by IL2 stimulation and may be the key to increased BMEC microvascular permeability.  
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Figure 20. Loss of Cell Border Adherens Junctions in Human BMECs  
Adherens junctions were observed by immunofluorescence of VE-cadherin (VE-cad) and p120 
following agonist stimulation. hCMEC/D3 cells were grown to confluence and then left 
unstimulated or stimulated with 300 kilounits/ml of human IL2 or 30 ng/ml human TNFα for 24 
h. Cells were immunostained with anti-p120 antibodies (red) and anti-VE-cadherin antibodies 
(green). Nuclei were counterstained with DAPI (blue). Arrows indicate openings between 
neighboring cells and disruption of both proteins at the cell membrane in agonist-stimulated 
human BMECs. Magnification, x63. Scale bars, 5 µm 
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Figure 21. Loss of Cell Border Adherens Junctions of Murine BMECs 
Adherens junctions were observed by immunofluorescence of VE-cadherin (VE-cad) and p120 
following agonist stimulation. bEnd.3 cells were grown to confluence and then left unstimulated 
or stimulated with 300 kilounits/ml of murine IL2 or 30 ng/ml murine TNFα for 24 h. Cells were 
immunostained with anti-p120 antibodies (red) and anti-VE-cadherin antibodies (green). Nuclei 
were counterstained with DAPI (blue). Arrows indicate openings between neighboring cells and 
disruption of both proteins at the cell membrane in agonist-stimulated murine BMECs. 
Magnification, x63. Scale bars, 5 µm 
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Disruption of Adherens Junctions in Brain Microvascular Endothelial Cells 
Parallels their Activation 
We verified that endothelial activation corresponded to the time course of increased 
permeability in human and murine BMECs by analyzing cytokine and chemokine expression in 
supernatant from the upper Transwell chamber prior to addition of FITC-dextran. In agreement 
with our prior analysis in a different culture system, we documented significantly higher levels 
of IL6 and MCP1 following IL2 stimulation compared with unstimulated controls (Fig. 22). 
However, within the time frame of our antibody-neutralizing permeability experiments, these 
two proinflammatory agonists evoked by IL2 did not significantly contribute to its effect on 
microvascular permeability. These results suggest that IL2 is concomitantly potentiating a 
proinflammatory environment through expression of IL6 and MCP1 while also disrupting AJs 
leading to increased microvascular permeability. 
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Figure 22. Agonist-Induced Expression of Cytokine IL6 and Chemokine MCP1 in 
Transwell Permeability Inserts  
Human and murine cell activation state was assessed prior to initiation of the permeability assay 
utilizing identical cells for multiple analyses. Cells were grown to confluence on Transwell 
inserts and left unstimulated or stimulated with 300 kilounits/ml of species-specific IL2 or 30 
ng/ml species-specific TNFα for 24 h as indicated. The supernatants were collected and analyzed 
for cytokine/chemokine production prior to addition of FITC-dextran for permeability analysis. 
Error bars represent mean ±S.D. of at least three independent experiments performed in 
duplicates or triplicates. Statistical significance was determined by unpaired t test with Welch’s 
correction (*, p  <0.05; **, p  <0.005; ***, p  <0.0005). 
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IL2-Induced Cytoskeletal Reorganization Manifested by an Increase in F-Actin 
Stress Fiber Formation  
In addition to a loss of peripheral VE-cadherin•p120 complexes along the cell membrane, 
IL2 stimulation also resulted in striking changes in cellular morphology. Modification of 
bordering BMEC cellular membrane organization led to the formation of apparent gaps between 
neighboring endothelial cells. These changes are coupled to cytoskeletal reorganizations 
(62,85,86). We documented an increase in F-actin fiber bundles prominently displayed in IL2-
activated murine bEnd.3 cells (Fig. 23). These cells exhibited thicker and more prominent F-
actin fiber bundles compared with thin F-actin fibers sparsely crossing the cell body in 
unstimulated controls. Activation of endothelial cells, as well as loss of adherens junctions 
between adjoining cells, spur their detachment and initiate “anoikis” thereby contributing to 
microvascular injury (41). Endothelial injury manifested by an increased number of endothelial 
cells in the blood is being considered as a useful marker for vascular damage in a number of 
human diseases as well as in animal models (87-89). Indeed, we documented IL2-induced 
detachment and apoptosis in both human and murine BMECs (Fig. 24).  
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Figure 23. F-Actin Polymerization Changes in Agonist-Stimulated Murine BMECs 
Murine bEnd.3 cells were grown to confluence and then left unstimulated (Unstim) or stimulated 
with 300 kilounits/ml of murine IL2 or 30 ng/ml murine TNFα for 24 h. Cells were stained with 
Alexa Fluor 488-labeled phalloidin (green) to visualize F-actin. Nuclei were counterstained with 
DAPI (blue). Images are representative of at least three independent experiments. Magnification, 
x63. Scale bars, 5 µm 
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  Figure 24. IL2-Induced Endothelial Cell Detachment and Apoptosis 
Increased BMEC detachment and apoptosis following agonist stimulation from Transwell 
inserts. Both human and murine BMECs were grown to confluence on Transwell permeability 
inserts and then left unstimulated or stimulated with 300 kilounits/ml IL2 or 30 ng/ml of species-
specific TNFα for 24 h. Supernatants were collected, and free floating endothelial cells detached 
from the Transwell membranes were counted. Error bars represent mean ±S.D. of at least three 
independent experiments performed in duplicates. Statistical significance was determined by 
unpaired t test with Welch’s correction (*, p <0.05; **, p <0.005). 
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Analysis of Adherens Junction Protein Complex Composition 
The striking disruption of the AJ protein complex following IL2 stimulation led us to 
analyze changes in AJ protein complex composition. In a series of co-immunoprecipitation 
experiments, we demonstrated that IL2-induced activation of BMECs results in a loss of 
interaction between VE-cadherin and p120 (Fig. 25). These results complement the findings that 
there was loss of co-localization of both junctional proteins following IL2 stimulation of BMECs 
analyzed by immunofluorescence (see Fig. 20 and 21). In addition to the two main components 
of the AJ complex, VE-cadherin and p120, we analyzed the interaction of β-catenin that also 
binds to VE-cadherin, stabilizing the complex and allowing its interaction with F-actin. Loss of 
both p120 and β-catenin leads to destabilization of adherens junctions and ultimately results in 
endocytosis of VE-cadherin (83,86,90). As documented with the VE-cadherin•p120 interaction, 
the VE-cadherin•β-catenin interaction was also disrupted following stimulation of both human 
and murine BMECs with IL2 (Fig. 26). Thus, IL2-induced dissociation of the AJ complex 
demonstrated by co-immunoprecipitation explains the loss of VE-cadherin•p120 immunostaining 
at cellular borders seen in agonist-stimulated BMECs contributing to an increase in monolayer 
permeability. The observed difference in the extent of measured adherens junction complex 
disruption by co-immunoprecipitation as compared to the more striking immunofluorescent 
images (compare Figures 20 and 25) can be attributed to the culturing conditions of these 
BMECs. The immunofluorescent images were obtained from BMECs grown on Transwell 
membranes while the co-immunoprecipitation results were derived from BMECs grown in tissue 
culture dishes. The latter comprise of a more abundant population of non-synchronized BMECs 
vs. monolayers grown in a smaller area on Transwell membranes. These differences may account 
for the variation in amplitude of junctional protein disruption observed between these two 
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experimental conditions. Nevertheless, these concordant results indicate IL2-induced 
dissociation of adherens junction protein complexes encompassing the main proteins responsible 
for AJs stability, VE-cadherin, p120-catenin and β-catenin. 
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Figure 25. IL2-Induced Disruption of the p120-Catenin•VE-Cadherin Protein Complex 
Analysis of the VE-cadherin•p120 complex. Human (hCMEC/D3) and murine (bEnd.3) 
endothelial cells were grown to confluence and left unstimulated (Unstim) or stimulated with 300 
kilounits/ml of species-specific IL2 or 30 ng/ml species-specific TNFα for 24 h. Protein 
complexes in cytosolic lysates precipitated with anti-p120 (IP) or treated with control IgG were 
quantified by immunoblotting (IB) with protein-specific antibodies. Cell lysates serve as input 
controls prior to immunoprecipitation. Error bars represent mean ±S.D. of at least three 
independent experiments. Statistical significance was determined by Student’s t test (*, p <0.05; 
**, p <0.005; ***, p <0.0005). 
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     Figure 26. IL2-Induced Disruption of the β-Catenin•VE-Cadherin Protein Complex 
Analysis of the VE-cadherin•β-catenin complex. Human (hCMEC/D3) and murine (bEnd.3) 
endothelial cells were grown to confluence and left unstimulated or stimulated with 300 
kilounits/ml of species-specific IL2 or 30 ng/ml species-specific TNFα for 24 h. Protein 
complexes in cytosolic lysates precipitated with anti-VEcadherin (IP) or treated with control IgG 
were quantified by immunoblotting (IB) with protein-specific antibodies. Cell lysates serve as 
input controls prior to immunoprecipitation. Error bars represent mean ±S.D. of four 
independent experiments. Statistical significance was determined by Student’s t test (*, p  <0.05; 
**, p <0.005). VE-cad, VE-cadherin. 
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IL2-Induced Phosphorylation of VE-cadherin  
  To further our understanding of the dissociation of VE-cadherin and its associated 
adaptor proteins, in particular p120 and β-catenin, we analyzed the mechanism responsible for 
this process. Post-translational modifications, such as phosphorylation events, contribute to 
destabilization of the AJ complex and loss of endothelial barrier function in various endothelial 
subsets (83,91-93). We documented that IL2 evoked an increase in phosphorylation of Tyr-685 
of VE-cadherin in both human and murine BMECs (Fig. 27). This process was time-dependent 
with maximal phosphorylation levels reached between 6 and 24 hours. Consistent with more 
robust activation and increased permeability recorded in murine bEnd.3 cells, we noted higher 
VE-cadherin phosphorylation in those cells than that of human hCMEC/D3 cells. Increased 
phosphorylation of VE-cadherin following stimulation of BMECs with IL2 leads to 
destabilization of the AJ complex. These results are consistent with findings obtained with other 
endothelial agonists. (26,92). 
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             Figure 27. IL2-Induced Phosphorylation of VE-Cadherin 
Analysis of VE-cadherin phosphorylation. Human (hCMEC/D3) and murine (bEnd.3) BMECs 
were left unstimulated or stimulated with 300 kilounits/ml of species-specific IL2 or 1 µg/ml 
LPS for 24 h prior to isolation of cytosolic extracts. Samples were separated by SDS-PAGE and 
immunoblotted for the presence of total VE-cadherin (VE-cad) and Tyr-685 phosphorylated VE-
cadherin (p-VE-cad). β-Actin is a loading control for cytosolic lysates. Quantification of signal is 
shown as a ratio of p-VE-cadherin to total VE-cadherin as –fold change compared with 
unstimulated control. Error bars represent mean ±S.D. of seven independent experiments. 
Statistical significance was determined using one-way ANOVA with Bonferroni correction for 
multiple comparisons for IL2 and an unpaired t test with Welch’s correction for LPS (*, 
p <0.05). 
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IL2-Induced Degradation of SHP2 
 In an effort to identify proteins responsible for an increased VE-cadherin phosphorylation 
state we analyzed a number of kinases and phosphatases known to be associated with the IL2R 
or VE-cadherin. Src-homology domain containing phosphatase 2 (SHP2) was identified as one 
possible target for IL2 action. SHP2 phosphatase has been shown to counteract VE-cadherin 
phosphorylation, thereby contributing to the maintenance of lung microvascular endothelial 
barrier function (25,81,94). We found a significant decrease in expression of SHP2 phosphatase 
in IL2-stimulated BMECs that paralleled increased phosphorylation of VE-cadherin (Fig. 28). 
SHP2 protein levels were reduced by 40-50% in both human and murine BMECs following IL2 
stimulation. In contrast, transcript levels of SHP2 phosphatase remained at the same level or 
were increased and SHP2 protein levels were not rescued following proteasomal inhibition. This 
result is in agreement with a published report suggesting that SHP2 is post-translationally 
degraded through the lysosome (25). Thus, degradative loss of SHP2 phosphatase accompanies 
an increase in the phosphorylation state of AJ-associated proteins and destabilization of the 
adherens junction complexes. This finding supports our proposed mechanism of adherens 
junction destabilization through increased phosphorylation of VE-cadherin and disruption of its 
association with adaptor proteins p120-catenin and β-catenin. 
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Figure 28. IL2-Induced Degradation of SHP2 
Analysis of SHP2 expression. Human (hCMEC/D3) and murine (bEnd.3) BMECs were left 
unstimulated (Unstim) or stimulated with 300 kilounits/ml of species-specific IL2 or 1 µg/ml 
LPS for 24 h, and cytosolic extracts were isolated, separated by SDS-PAGE, and immunoblotted 
for the presence of SHP2. β-Actin is a loading control for cytosolic lysates. Normalized 
quantification of proteins is shown as a percent compared with the unstimulated control. Error 
bars represent mean ±S.D. of five independent experiments. Statistical significance was 
determined using one-way ANOVA with Bonferroni correction for multiple comparisons for IL2 
and an unpaired t test with Welch’s correction for LPS (*, p <0.05; **, p <0.005). 
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Chapter IV 
DISCUSSION AND CONCLUSIONS 
Interleukin 2 Activation of Brain Microvascular Endothelial Cells 
 
 Administration of IL2 as part of adoptive immunotherapy has been proven to be an 
effective cancer treatment but it is limited by serious, though infrequently lethal, systemic side 
effects. Importantly, many of these side effects are directly related to increased systemic 
capillary permeability. This endothelial dysfunction extends to the CNS where neuropsychiatric 
toxicity has been documented during IL2 therapy. The initial onset of neuropsychiatric 
symptoms appear toward the end of each treatment phase particularly on the last day and is 
dosage dependent (32). Furthermore, there is rapid recovery from neuropsychiatric toxicity upon 
cessation of treatment underscoring the specific effect of IL2. Interleukin 2 may directly affect 
CNS function by impacting neuronal activity. Alternatively, IL2 may indirectly affect brain 
function by enhancing the accumulation of behaviorally active substance or by increasing the 
permeability of the BBB, thereby exposing the CNS to behavior activating factors (32). While a 
number of suggested mechanisms of action have been proposed, the underlying mechanism of 
IL2-induced CNS toxicity has not been elucidated (65). Our work decodes the process through 
which IL2 activates BMECs and leads to loss of BMEC barrier function. As brain microvascular 
endothelial cells are the cardinal constituent of the “neurovascular unit” comprising the BBB, 
understanding the action of IL2 on these endothelial cells would be potentially beneficial for 
patients suffering from these side effects of IL2 immunotherapy as well as for patients suffering 
from autoimmune neurological disorders where IL2 plays an important role. 
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 The ability of IL2 to sustain lymphocyte survival and function suggested that its 
administration could be harnessed to potentially stimulate functional lymphocytes in vivo. This 
rationale set the stage for IL2 cancer immunotherapy and spurred continued research into the 
properties of this molecule. Initial characterization of the IL2 receptor was undertaken in T cells 
and suggested the presence of an IL2 receptor complex (95). As presented above (see Figures 11-
14), we established that brain microvascular endothelial cells express a competent IL2 receptor 
complex thereby adding them to a number of cells responding to IL2 signaling (see Table 3). The 
high affinity trimeric receptor complex is constitutively found on immune cells and was reported 
on lung endothelial cells (46). However, BMECs express IL2Rα only following 24hr stimulation 
with IL2. This result is consistent with previous discoveries that IL2 is able to modulate the 
expression of its own receptor α subunit in immune cells (96,97). Establishing that human and 
murine BMECs express a competent IL2 receptor complex suggests that IL2 immunotherapy can 
directly affect brain microvasculature. 
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Cell Type IL2Rα (CD25) 
IL2Rβ 
(CD122) 
IL2Rγ 
(CD132;γc) Refs 
Thymocyte -/+ -/+   ++ (98,99) 
Naïve T Cell† - -/+ + (100-104) 
Effector T Cell§ +++ ++ + (100-104) 
Memory T Cell# - +/++ + (46,100,102,104-106) 
TFH Cell - ? + (103,104) 
TReg Cell +++ + + (107) 
Immature B Cell¶ + - + (98,108) 
Mature B Cell - - + (98,108) 
NK Cell - ++ + (46) 
NKT Cell* -/+ -/+ + (109,110) 
Dendritic Cell†† -/+ - + (111-117) 
Langerhans Cell + ? + (118) 
Lung Endothelial 
Cell + + + 
(46,61) 
Brain 
Microvascular 
Endothelial Cell 
- + + 
This project 
(119) 
Fibroblast + + - (120,121) 
 
Table 3. IL2 Receptor Expression by Immune and Non-Immune Cells 
-, background expression level; +, low expression level; ++ high expression level; +++ very high 
expression level; γc, common cytokine receptor γ-chain; TFH, follicular helper T cell; TReg, 
regulatory T cell; NK natural killer cell; NKT, natural killer T cell. † CD122 expression is 
undetectable on naïve CD4+ T cells, whereas CD8+ T cells have low but significant levels of 
CD122. § CD25 and CD122 are transiently upregulated on effector T cells. # CD122 expression 
levels are low on memory CD4+ cells but high on memory CD8+ T cells. ¶ Pre-B cells express 
significant levels of CD25 but no CD122. * NKT cells from the spleen express low to 
intermediate levels of CD25 †† There exists controversial data regarding CD 122 expression on 
human DCs; in mice, mature DCs do not express CD122, although CD122 may be present on 
DC precursors. Table adapted from Boyman, O., 2012. Nat Rev Immunology 12, 180-190. 
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Interleukin 2 Signaling in Brain Microvascular Endothelial Cells 
 
 Signaling emanating from the IL2 receptor in lymphocytes involves the activation of the 
NFκB pathway (53). Likewise, NFκB was identified as a major mediator of Interleukin 15 action 
in BMECs (122). IL15 utilizes the IL2Rβ and IL2Rγ subunits as well as its specific IL15Rα 
subunit. Activation of the NFκB pathway following IL2Rβ and IL2Rγ engagement by IL15 
suggests that IL2 signaling through this intermediate affinity IL2 receptor complex may also 
initiate NFκB signaling. Consequently, we endeavored to identify activation of the NFκB 
pathway by IL2 in BMECs. We were able to document IκBα degradation, NFκB RelA 
phosphorylation and nuclear localization following IL2 stimulation in BMECs (see Figures 13 
and 14). NFκB activation and translocation to the nucleus is governed by its release from 
inhibitor, IκBα (123). Phosphorylation at Ser-536 of RelA has been documented to occur 
following NFκB activation and increases its transcriptional activity (124). These three lines of 
evidence support the activation of the NFκB pathway by IL2 in human and murine BMECs.   
 Proinflammatory cytokines and chemokines, in particular IL6 and MCP1, have been 
implicated in activating endothelial cells resulting in damage to the vasculature (47,55). We 
demonstrated that these two NFκB-regulated genes, IL6 and MCP1, are expressed following IL2 
stimulation (see Figure 15). Induction of these two pleiotropic mediators of inflammation 
potentiates an inflammatory environment facilitating additional recruitment of immune cells 
capable of prolonged disruption of endothelial barrier function (74-77). IL2-evoked NFκB 
activation in lymphocytes is well known (53) but to our knowledge has not been previously 
reported in non-immune cells such as BMECs. 
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 IL2 stimulation can potentially lead to the production of other proinflammatory mediators 
effecting endothelial activation and permeability. In particular, Interleukin 1 beta (IL1-β) is 
known to be expressed by endothelial cells (125) and IL2 is able to induce expression of IL1-β in 
immune cells (126). Furthermore, Vascular Endothelial Growth Factor (VEGF) that was initially 
discovered and named vascular permeability factor, is well known to destabilize adherens 
junctions through induction of VE-cadherin phosphorylation (127). In addition, TNFα is a potent 
inducer of vascular activation and is expressed following NFκB signaling in immune cells (128). 
TNFα production has also been documented in endothelial cells (129). With this in mind, it is 
important to realize that these mediators may play a role in the activation of BMECs and ultimate 
induction of permeability. 
 Structural and functional integrity of brain microvascular endothelial cells is of 
paramount importance in maintaining the physiologic function of the BBB (17,130). Patients 
receiving IL2 immunotherapy develop manifestations of capillary leak such as edema, weight 
gain and pulmonary congestion which are progressive with resolution of these side effects 
occurring quickly following termination of IL2 therapy (131). We hypothesized that IL2 
activation of BMECs would also lead to loss of their ability to provide an effective barrier. In 
fact, we were able to document a direct IL2-induced increase in BMEC monolayer permeability 
(see Figures 16-19). Blocking proinflammatory mediators IL6 and MCP1 did not abate the 
significant increase in permeability induced by IL2 stimulation. These results confirm the direct 
role of IL2 in activating endothelial cells and causing an increase in monolayer permeability. 
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Destabilization of the Adherens Junction 
 
To gain a better understanding of increased microvascular permeability we focused on 
IL2’s effect on adherens junctions. Endothelial cell junctions are composed of tight junctions and 
adherens junctions with many reports suggesting that AJs and TJs are interconnected and 
influence their overall organization (132). These protein complexes work in tandem to restrict 
paracellular transport of molecules from the bloodstream into the surrounding tissues. We 
observed that IL2 stimulation led to disruption of the adherens junction protein complex with a 
distinct loss of VE-cadherin and p120 staining along the cellular border (see Figures 20 and 21). 
Disruption of the adherens junction protein complex leads to the internalization of VE-cadherin 
and dissociation of its adaptor proteins (26,86). Furthermore, changes in expression or 
organization of AJ proteins, in particular VE-cadherin, have been suggested to impact protein 
levels of claudin 5, a tight junction protein, leading to changes in barrier function and vascular 
permeability (27). Thus, disruption of adherens junctions may act, in turn, on TJs resulting in an 
endothelial dysregulation feed-forward loop. While we have not yet further investigated the 
effect of AJ disruption on the integrity of TJs in BMECs additional studies to corroborate this 
effect would be informative. Moreover, previous work has documented VE-cadherin 
redistribution in pulmonary endothelial cells treated with human sera from patients undergoing 
IL2 immunotherapy (62). These results lend support to our findings that IL2 signaling is 
operational in non-immune cells. Moreover, they offer the mechanism of adherens junction 
disruption in lung microvascular endothelial cells as the mechanism responsible for increased 
vascular permeability.  
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Adherens junction stability relies on the association of p120-catenin as well as β-catenin 
with VE-cadherin. Intriguingly, previous reports demonstrate that these adaptor proteins are 
critical regulators of VE-cadherin cell surface localization in endothelial cells (86) but may also 
be involved in further transcriptional activation, modifying endothelial activation and 
permeability (27,133). We were able to document the dissociation of the adherens junction 
protein complex (see Figures 25 and 26). There is growing evidence that p120 is associated with 
inflammation and in particular its ability to modulate NFκB activation in inflammatory responses 
(133). Furthermore, β-catenin has been reported to mediate the repression of tight junction 
proteins following release from the adherens junction complex (27). Thus, studying the nuclear 
translocation of these adaptor proteins following IL2 stimulation may allow for delineation of 
additional signaling pathways that are detrimental to endothelial barrier function.  
Adherens junctions are stabilized in the plasma membrane through their anchoring to the 
F-actin cytoskeleton (26). Alteration of the F-actin cytoskeleton disrupts adherens junction 
complexes weakening cell-cell interactions. Stress fibers composed of bundles of polymerized 
actin and myosin filaments are the primary elements of the contractile machinery of endothelial 
cells (134). Edemagenic agonists rapidly induce actin reorganization from cortical actin into 
actin stress fibers, which induces AJ disruption and leads to interendothelial gap formation, 
resulting in increased endothelial permeability (85,86,135). The formation of these paracellular 
gaps is regulated by a balance of competing contractile forces intimately linked to the actin-
based endothelial cytoskeleton where centripetal tension, adhesive cell-cell and cell-matrix 
tethering forces together regulate changes in cell shape (136). In concert with adherens junction 
alteration, cellular cytoskeleton architecture is changed following IL2 stimulation (see Figure 
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23). An increase in polymerized F-actin organized in thick bundles visually indicates an 
activated endothelial phenotype that promotes disruption of junctional protein complexes. 
While the primary focus of this project was the barrier function of brain microvascular 
endothelial cells based on the stability of adherens junctions, it is important to note that other 
cellular constituents within the neurovascular unit depend on adherens junctions. Neural cadherin 
(N-cadherin) is abundantly expressed throughout the brain (137) and is responsible for 
intercellular contacts in a variety of cell types. They include pericyte-endothelial cell interactions 
during brain angiogenesis (138). Moreover, disruption of the N-cadherin•β-catenin complex 
leads to the activation of astrocytes within the brain (139). These findings suggest that adherens 
junctions other than VE-cadherin may contribute to dysregulation of the neurovascular unit. 
Therefore, it is plausible that IL2 can disrupt not only junctions between endothelial cells but 
also in the other constituents of the neurovascular contingent on identification of the IL2 receptor 
complex in these cells. 
  
Mechanism of Adherens Junction Protein Complex Disruption 
 
To investigate the underlying mechanism responsible for dissociation of the adherens 
junction complex we studied post-translational modification of VE-cadherin. Prior investigations 
of post-translational modifications of VE-cadherin have mostly focused on tyrosine 
phosphorylation sites and the effect these changes impart on vascular permeability and 
endothelial activation (27,83,91,92). Phosphorylation of catenins is associated with 
destabilization of adherens junction cell contacts (27,91). A complete consensus has yet to be 
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reached on the role of each specific phosphorylation site, although a number of proinflammatory 
mediators have been reported to preferentially lead to phosphorylation of Tyr-685 resulting in 
increased permeability (91,92). Thus, we focused on the potential of IL2 to increase 
phosphorylation of VE-cadherin at Tyr-685. Indeed, we documented increased phosphorylation 
of this residue (see Figure 27). Therefore, we conclude that IL2 can be added to the list of 
proinflammatory mediators able to induce Tyr-685 phosphorylation resulting in destabilization 
of the adherens junction complex.  
A number of different kinases have been reported to be responsible for Tyr-685 
phosphorylation VE-cadherin (91,92,140).  In an effort to identify the kinase responsible for VE-
cadherin phosphorylation in BMECs we analyzed a panel of IL2-associated and VE-cadherin 
associated kinases reported in the literature. They included focal adhesion kinase (FAK), src 
protein tyrosine kinase (src), spleen tyrosine kinase (syk) and zeta-chain-associated protein 
kinase 70 (ZAP70). To this end, we were unable to produce conclusive results. Changes in 
tyrosine phosphorylation are often transient by being regulated through the tandem action of 
kinases as well as phosphatases. Phosphorylation of VE-cadherin appears to be regulated in this 
way as multiple protein tyrosine phosphatases (PTP) including PTPµ, PTP1, VE-PTP and SHP2 
have been implicated in the regulation of the adherens junction protein complex (81,141-143). 
We documented that SHP2 phosphatase expression was significantly reduced following IL2 
stimulation (see Figure 28). These results suggest that an alteration in phosphatase expression 
may be the basis for VE-cadherin phosphorylation levels. Unlike kinases, which are recruited to 
the phosphorylation site, protein tyrosine phosphatase activity is largely determined by the 
expression level or proximity to the phosphorylation site and not by a specific recruiting event 
(25). Previous reports corroborate the role SHP2 phosphatase plays in regulation of the adherens 
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junction complex and in particular the phosphorylation state of VE-cadherin and its adaptor 
proteins (25,81,94,144). While identification of the kinase responsible remains elusive, our 
finding of decreased expression of SHP2 phosphatase in response to IL2 opens up an intriguing 
mechanistic link to dysregulation of adherens junctions in BMECs.  
 
The Role of Adherens Junctions in other Diseases Affecting the BBB 
 
The importance of adherens junction importance in maintaining a healthy CNS becomes 
apparent when one considers their potential involvement in other brain diseases mediated by 
inflammation caused by microbial, autoimmune and physical insults. Development of Multiple 
Sclerosis (MS), a well-known autoimmune disease, has been associated with disruption of 
adherens junctions. Decreased expression of VE-cadherin in endothelial cells following exposure 
to sera taken from MS patients experiencing an exacerbation in disease has been documented 
(145). Furthermore, MS leads to increased expression of VEGF, a well-known inducer of VE-
cadherin phosphorylation, thereby disrupting adherens junctions (146). Dissociation of 
endothelial adherens junctions can also be initiated in the brain by hypoxia. Ischemic stroke 
results from a transient or persistent reduction in blood flow due to localized thrombosis or an 
embolism. In a murine model of transient middle cerebral artery occlusion, VE-cadherin protein 
levels were reduced by 33% suggesting disruption of the adherens junction complex subsequent 
to an ischemic episode (147). Moreover, developmental abnormalities of the brain 
microvasculature, in particular cerebral cavernous malformation, is linked to the destabilization 
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of adherens junctions (148). These diverse brain disorders underline the importance of adherens 
junctions in maintaining the integrity of the BBB and taming excessive brain inflammation. 
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Chapter V 
FUTURE DIRECTIONS 
Thesis Summary 
 
Cumulatively, this work provides new evidence that a pleiotropic immune cytokine, IL2, 
activates brain microvascular endothelial cells and leads to deterioration of their barrier function 
(Fig. 29). A better understanding of IL2 action on brain microvascular endothelium, one of the 
cardinal components of the BBB, may aid in the development of new cytoprotective measures to 
protect the central nervous system from blood-borne mediators of endothelial injury. Developing 
new strategies to combat IL2-evoked vascular permeability would benefit patients suffering from 
VLS that complicates high dose IL2 immunotherapy as well as those afflicted with neurological 
autoimmune diseases in which IL2 plays a prominent role. 
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Figure 29. Diagrammatic Depiction of IL2-Induced Activation of BMECs 
IL2 interacts with the constitutively expressed intermediate affinity IL2R complex (IL2Rβ and 
IL2Rγ), leading to degradation of IκBα and freeing NFκB to be translocated to the nucleus. 
Therein NFκB initiates transcription of its target genes, including two proinflammatory 
mediators, namely cytokine IL6 and chemokine MCP1, culminating in a feed-forward 
enhancement of the inflammatory process (left). In parallel, IL2 induces destabilization of 
adherens junctions through an increase in VE-cadherin (VE-cad) phosphorylation concomitant 
with a decrease in SHP2 phosphatase protein levels. An elevated VE-cadherin phosphorylation 
state results in diminished interaction between the constituents of the adherens junction complex, 
in particular p120 and β-catenin (β-cat). Furthermore, activation of the brain microvascular 
endothelial monolayer leads to increased F-actin stress fiber formation. Loss of adherens 
junction interaction between adjoining endothelial cells increases monolayer permeability 
(right). Thus, IL2 interaction with its cognate receptor on BMECs leads to a shift from a 
quiescent to an “activated” phenotype of BMECs and an increase in endothelial monolayer 
permeability. 
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Contribution of Alternative IL2 Receptor Signaling Pathways in Brain Microvascular 
Endothelial Cell Activation 
 
This work has provided the foundation for understanding IL2’s impact on brain 
microvascular endothelial cells. By identifying that BMECs express a competent IL2R complex 
which is able to activate the NFκB pathway we developed evidence to document induction of 
one of the signaling pathways emanating from the IL2R in BMECs. Prior work in immune cells 
documented the IL2R complex initiating three major signaling pathways: (i) the signal 
transducer and activator of transcription (STAT) pathway, (ii) the phosphoinositide 3-kinase 
(PI3k-Akt) pathway and (iii) the mitogen-activated protein kinase (MAPK) signaling pathway 
(59). Further investigation into which of these major signaling pathways leads to the activation 
of BMECs and disruption of adherens junctions would provide a more complete picture of IL2 
signaling in BMECs. It is of significant note that activation of the NFκB pathway emanating 
from the IL2R complex in immune cells has been previously associated with the PI3K-Akt 
signaling pathway (149). Utilizing Akt-specific inhibitors would provide evidence that induction 
of this signaling pathway in BMECs also results in NFκB activation. Moreover, it was identified 
that signaling through the Akt pathway involved BCL10, a known mediator of canonical NFκB 
signaling in T and B lymphocytes (149). Importantly, we have previously reported activation of 
BCL10 in lung microvascular endothelial cells following proinflammatory stimuli (Appendix B) 
(85). We were able to show that knockdown of BCL10 resulted in reduction of NFκB signaling. 
This may be applicable to IL2 stimulation of BMECs. Further investigation into the role of 
BCL10 along with its physiologic suppressor CRADD/RAIDD would provide a distinct 
signaling pathway originating from the IL2 receptor complex culminating in activation of NFκB 
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in brain microvascular endothelial cells. Alternatively, potential IL2 signaling through the 
MAPK and STAT pathways could be probed in order to identify the extent of their specific 
activation and transcriptional targets. There have been reports of various agonists that increase 
vascular permeability following MAPK as well as STAT activation suggesting that these 
pathways may indeed be involved in IL2’s action (150-153). These signaling intermediates can 
also be analyzed by single cell proteomics with cytometry by time of flight (CyTOF) (154). 
 
Potentiation of Inflammation by p120-Catenin and β-Catenin 
 
Documentation of IL2 induced adherens junction dissociation may allow alternative 
signaling by VE-cadherin associated adapter proteins. While principally responsible for 
stabilizing cell-cell interactions, p120 and β-catenin, in particular may have an alternative action. 
Emerging evidence has suggested that p120-catenin may function in an expanded role mediating 
both transcriptional regulation and inflammatory activation (133,155). p120 has been shown to 
interact with RhoA thereby modulating NFκB activation (133). As IL2 activates NFκB, p120 
release from the protein complex may be directly impacting this transcription factor. p120 acts in 
the nucleus as a transcriptional repressor of proinflammatory genes (155). A disruption of p120 
homeostasis following IL2 stimulation may disable its second function to attenuate a 
proinflammatory state. A more detailed investigation into the role of p120 following IL2 
activation in BMECs may identify cooperative or secondary signaling capacity influencing the 
development of vascular permeability. 
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In addition to its role in stabilizing adherens junctions, β-catenin has been implicated in 
cross-talk with NFκB activation. β-catenin has been documented to positively influence the 
proinflammatory environment during NFκB signaling in pulmonary inflammation and colonic 
tumorigenesis (156,157). Increased nuclear localization of β-catenin enhances NFκB signaling 
potentiating a proinflammatory environment. As with p120, disruption of the VE-cadherin 
complex may increase the available pool of cytosolic β-catenin eligible for nuclear translocation. 
Further investigation of β-catenin in IL2 stimulated BMECs would determine a possible role in 
potentiating the proinflammatory NFκB signaling environment. Identifying other targets of β-
catenin’s transcriptional activity may unravel a new proinflammatory gene regulatory network.  
 
Analysis of Adherens Junction and Tight Junction Crosstalk Following IL2 Stimulation 
 
Further investigation on the crosstalk between adherens junctions and tight junctions 
would be necessary to gain a complete understanding of the effect of IL2 stimulation on the brain 
microvasculature. VE-cadherin associated with the adherens junction protein complex has been 
shown to upregulate the gene encoding claudin 5, a tight junction adhesive protein (27). IL2 
action on the endothelium leading to dissociation of VE-cadherin from its adaptors p120 and β-
catenin may magnify the deleterious process resulting in increased brain microvascular 
permeability. It has also been suggested that an increase in β-catenin localization to the nucleus 
leads to down regulation of claudin 5 expression (27). Experiments identifying β-catenin 
localization following dissociation from the adherens junction complex could potentially unlock 
a new avenue of investigation into crosstalk between AJs and TJs at the BBB. Due to the 
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functional and structural relationship between AJs and TJs an unraveling of any potential 
crosstalk between these crucial protein complexes would provide a more global picture of IL2 
action on brain microvascular endothelial cell barrier function. 
 
Analysis of Nuclear Transport Modifiers in NFκB Blockade 
 
Conversely, further investigation into restricting NFκB activation may present potential 
therapeutic value. We have not yet been able to separate or directly link the activation of NFκB 
to the increase in monolayer permeability. Increased expression of proinflammatory cytokines 
and chemokines potentiate an environment conducive to increased endothelial monolayer 
permeability. Reducing endothelial NFκB activation would promote recovery of the endothelial 
monolayer. Our laboratory has developed a nuclear transport modifier which has been shown to 
reduce nuclear translocation of several stress responsive transcription factors (SRTFs), including 
NFκB (67,158,159). We have preliminary data suggesting that impairing nuclear transport of 
SRTFs reduces IL2-induced permeability in brain microvascular endothelial cells. Additionally, 
BAY 11-7082 a more selective inhibitor of the NFκB pathway (160) may be investigated to tease 
apart the specific role that NFκB activation plays in brain microvascular endothelial cell 
permeability. An alternative approach could involve the use of physiologic negative regulators of 
NFκB. We have previously been able to produce recombinant cell penetrating proteins able to 
control NFκB activation in response to proinflammatory signaling (38,40,85). These strategies 
would provide insight into the role of IL2-induced NFκB activation and its impact on the 
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development of BMEC permeability. Ultimately, these further studies may lead to the 
development of potential therapeutic approaches to counteract increased BBB permeability.  
 
Further Analysis of IL2 Receptor Associated Kinases 
 
In parallel with NFκB activation we observed disruption of the adherens junction leading 
to formation of intercellular gaps. Increased dissociation of VE-cadherin and its adapter proteins 
occurred due to the increased phosphorylation state of VE-cadherin. Further investigation into 
the link between the IL2 receptor and increased phosphorylation of VE-cadherin would provide a 
more robust story. While we investigated a number of kinases associated with the IL2 receptor 
(ZAP-70, syk and src) other VE-cadherin associated kinases should be examined for their 
potential activation in response to IL2 stimulation. One VE-cadherin associated kinase we have 
not yet analyzed is Rho kinase. VE-cadherin regulation has been associated with Rho kinase 
which has a duel role in modulating endothelial barrier function by both inducing barrier-
protective and barrier-disruptive activity (161). Due to its association with endothelial barrier 
function it may prove to be involved in VE-cadherin phosphorylation. Again, these signaling 
events can be analyzed by single cell proteomics with cytometry by time of flight (CyTOF) 
(154).  
A separate approach to get a better understanding of the association between activation of 
the IL2 receptor complex and the phosphorylation state of VE-cadherin would be to utilize newly 
developed IL2/anti-IL2 antibody complexes designed to target specific subunits of the IL2 
receptor (46). Employing this tool in our model of brain microvascular permeability would allow 
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selective modulation of the IL2 receptor at the BBB. These complexes have been shown to 
activate the immune system yet spare the endothelium by avoiding interaction with IL2Rα (46). 
Identification of any differences in signaling, phosphorylation and adherens junction stability as 
compared to IL2 could provide a clue towards potential residues and/or proteins responsible for 
barrier dysfunction. Changes in endothelial permeability identified using these molecules may 
provide evidence to suggest other kinases and/or phosphatases as well as their target tyrosine 
residues implicated in barrier disruption.  
Additionally, we have documented the importance of SHP2 in regulating VE-cadherin 
phosphorylation state.  Investigating the recruitment and stabilization of SHP2 at the adherens 
junction would be important to analyze. Degradation of SHP2 could be a result of dissociation 
from adaptor/associated proteins which localize SHP2 at the adherens junction. Further 
investigation into other phosphatases associated with adherens junctions is potentially significant 
as regulation of VE-cadherin phosphorylation has been suggested to involve multiple protein 
tyrosine phosphatases including PTPµ, PTP1 and VE-PTP (81,141-143). Furthermore, 
identification of other proteins associated with the IL2 receptor complex may provide a clue to 
its signaling mechanism(s). These investigations would provide a better understanding of the link 
between the IL2 receptor and the phosphorylation state of VE-cadherin. 
 
In Vivo Analysis of IL2-induced Brain Microvascular Endothelial Cell Permeability 
 
Ultimately, the new knowledge gained from this study would be advanced with its 
application to in vivo models of VLS thus providing an integrated picture of IL2’s role in 
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disrupting the BBB. Increased brain vascular permeability has been documented in human 
patients and murine models necessitating the development of a much needed new therapeutic 
approaches (32,45). Monitoring mice for increased BBB permeability following IL2 
administration as well as their response to inhibitors of NFκB and other SRTFs would provide 
the basis for developing potential treatments to counter VLS. Employing physiologic negative 
regulators of inflammation or nuclear transport modifiers (NTMs) to reduce the level of NFκB 
and other SRTFs activation has been shown to be effective in other models of inflammation (37-
39,67,85,158,162) and suggests that reducing NFκB signaling following IL2 activation of 
endothelial cells may prove beneficial. Utilizing new in vivo intravital microscopy techniques to 
track activation and disruption of the BBB would build on the results presented here. Protecting 
endothelial cell function following injury or insult is crucial to reducing collateral damage in 
adjoining brain tissue and preserving or restoring its function. 
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Chapter VI 
MATERIALS AND METHODS 
Cell Culture 
 
The human BMEC line hCMEC/D3 was provided through the courtesy of Professor 
Babette Weksler (Weill Cornell Medical College, New York, NY) (163). hCMEC/D3 cells were 
cultured at 37 °C in 5% CO2 in EBM-2 (Lonza) supplemented with 5% HI-FBS, 1% 
penicillin/streptomycin (Mediatech), 1.4 µM hydrocortisone (Sigma), 5 µg/ml of ascorbic acid 
(Fisher Scientific), chemically-defined lipid concentrate (Invitrogen) diluted 1:100, 10 mM 
HEPES (Mediatech) and 1 ng/ml of human b-FGF (Sigma). Cells used for experiments were 
between passages 20 and 30. The murine brain endothelioma cell line bEnd.3 (164) was 
purchased from American Type Culture Collection and cultured at 37 °C in 5% CO2 in 
Dulbecco’s Modified Eagle’s Medium (Mediatech) supplemented with 10% heat-inactivated 
fetal bovine serum (HI-FBS) and 1% penicillin/streptomycin. Murine embryonic fibroblasts 
(MEF) and the human embryonic kidney cell line (HEK) were cultured at 37 °C in 5% CO2 in 
Dulbecco’s Modified Eagle’s Medium supplemented with 10% HI-FBS and 1% 
penicillin/streptomycin. 
 
 
 
 
 97 
 
Quantitative Real Time PCR Analysis 
 
Total RNA was isolated for quantitative real time PCR (qPCR) analysis using RNeasy 
Mini Kit (Qiagen) following manufacturer’s instructions and reverse-transcribed utilizing the 
iScript cDNA synthesis kit (Bio-Rad). Targets were amplified by CFX96 Touch real-time PCR 
detection system (Bio-Rad) using the iQ SYBR Green Supermix kit (Bio-Rad) with specific 
primers listed in Table 1 and 2 for the indicated mRNAs. Results were analyzed by CFX 
Manager (Bio-Rad). Following normalization to GAPDH cDNA, relative levels were calculated 
using the 2-ΔΔCt method (165). 
 
Preparation of Cytosolic and Nuclear Extracts 
 
 Confluent BMEC monolayers were cultured and then stimulated for the indicated times 
in complete growth medium. Following stimulation, BMECs were washed with ice-cold PBS 
and then lysed using a cytosolic lysis buffer (10 mM HEPES [pH 7.9], 10 mM KCl, 0.1mM 
EDTA, 0.1 mM EGTA, 1% NP-40, 1mM DTT) containing phosphatase (Roche) and protease 
(Sigma) inhibitors as previously described (85). Nuclei were pelleted by centrifugation, 
supernatant was saved as the cytoplasmic extract, and the nuclear pellet was washed with 
cytosolic lysis buffer. Nuclear fractions were prepared by resuspension of the nuclear pellet in a 
high salt nuclear extraction buffer (20mM HEPES [pH 7.9], 400 mM NaCl, 1 mM EDTA, 1 mM 
EGTA, 1 mM DTT, with protease (Sigma) and phosphatase (Roche) inhibitor mixture) under 
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constant shaking for 30 min, centrifugation, and removal of genomic DNA as previously 
described (39).  
 
Immunoblotting Analyses 
 
The protein concentration of cytosolic and nuclear extracts was quantified using the 
Bradford Protein Assay (Bio-Rad) for equivalent protein loading. Samples were then separated 
by 10% SDS-PAGE, transferred onto nitrocellulose membranes (Bio-Rad), blocked with 
Odyessy Blocking Buffer (LI-COR) and incubated with the appropriate antibodies. Antibodies 
against NFκB p65 (Rel A; 1:1000; Santa Cruz), p120-catenin (p120; 1:1000; Santa Cruz), VE-
cadherin (VE-cad; 1:1000; Santa Cruz), SHP2 (1:1000; Santa Cruz), β-catenin (1:1000; BD 
Biosciences), phospho-β-catenin (p-β-catenin; 1:500; Cell Signaling), IκBα, phospho-NFκB p65 
(p-RelA; 1:500; Cell Signaling) and phospho-VE-cadherin (p-VE-cad; 1:500; ECM Biosciences) 
were used for immunoblot analyses. Obtained values were normalized in reference to β-actin 
(1:10,000; Abcam) or TATA-binding protein (TBP; 1:10,000; Abcam) detected with their 
cognate antibodies in cytosolic and nuclear extracts as indicated. Immunoblots were 
quantitatively analyzed by the LI-COR Odyssey Infrared Imaging System following incubation 
with appropriate secondary antibodies as previously described (39,85). 
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Immunoprecipitation Analyses 
 
Adherens junction protein complexes were immunoprecipitated from cytosolic extracts 
with antibodies against p120 or VE-cadherin (Santa Cruz). The lysates we pre-cleared with 
protein A/G-agarose beads (Thermo) for 1hr at 4oC prior to overnight incubation of antibodies or 
control IgG at 4oC. Species specific IgG (Santa Cruz) was used as control. The immune 
complexes were then captured with protein A/G-agarose beads and analyzed by quantitative 
immunoblotting using antibodies against p120, VE-cadherin and β-catenin with the LI-COR 
Odyssey Infrared Imaging System as previously described (39,85) .  
 
Cytokine and Chemokine Protein Expression Assay 
 
Cytokines and chemokines in tissue culture medium supernatants were assayed by 
cytometric bead array (BD Biosciences) in the Vanderbilt Flow Cytometry Shared Resource 
according to manufacturer’s instructions as previously described (85). During time- and 
concentration- dependent titration experiments, supernatant samples were taken following 
stimulation as indicated. Cytokine and chemokine expression was also analyzed in media from 
BMEC monolayers cultured in Transwell chambers for permeability experiments. Medium 
samples were taken from the upper chamber following stimulation as indicated but prior to 
addition of FITC-dextran tracer. 
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Immunofluorescence Staining 
 
Human hCMEC/D3 or murine bEnd.3 cells grown to confluency on Transwell 
permeability supports were stimulated with species-specific IL2 (BD Biosciences, Prometheus) 
or TNFα (Invitrogen) as indicated. After stimulation, cells were fixed in 4% paraformaldehyde 
(Electron Microscopy Sciences), washed with PBS and permeabilized with 0.1% Triton X-100 
(Invitrogen). For immunostaining, cells were blocked with 5% normal goat serum (Jackson 
ImmunoResearch) before overnight incubation at 4 °C with primary antibodies to NFκB p65 
(Abcam) or VE-cadherin and p120 (Santa Cruz), followed by incubation with Alexa 488-
(Invitrogen), Cy3- or Cy5-labeled (Jackson ImmunoResearch) secondary antibodies. F-actin 
polymerization was visualized in permeabilized cells with Alexa 488-labeled phalloidin 
(Cytoskeleton, Inc.). After staining, the semi-permeable membranes were removed from the 
Transwell permeability supports and mounted on slides with ProLong Gold Antifade reagent 
containing DAPI (Invitrogen) to counterstain nuclei.  
 
Immunofluorescence Microscopy 
 
Images were captured and analyzed with MetaMorph software on an Axioplan widefield 
microscope in the Vanderbilt Cell Imaging Core facility using a ×63 oil immersion objective. 
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Endothelial Cell Permeability Assay 
 
Human hCMEC/D3 cells or murine bEnd.3 (1×105) were seeded onto 24-well Transwell 
semi-permeable supports (Costar) pre-coated with type 1 collagen (Cultrex) and incubated until 
confluent. Upon confluence, as verified by microscopy, growth media was exchanged for serum-
depleted media that comprised growth media with a low concentration (0.5%) of HI-FBS. 
Following 24 h culture in low serum media, cells were left unstimulated or stimulated for 24 h 
with species-specific 300 kU/ml IL2 (kU=1000 U), or 30 ng/ml TNFα. In experiments utilizing 
neutralizing antibodies, species-specific murine anti-IL6, anti-MCP1 (R&D Systems) as well as 
human anti-IL6 (R&D Systems) and anti-MCP1 (Sigma) were added concomitantly with IL2. 
Human anti-IL2Rβ antibody (R&D Systems) was added 30 minutes prior to IL2 stimulation. 
Antibody concentrations necessary for neutralization were calculated from the levels of 
cytokine/chemokine expression during titration of IL2. Monolayer permeability was assessed by 
detection of FITC-dextran passage across an intact monolayer into the lower chamber. The lower 
chamber supernatant was sampled at the indicated time points after addition of 1mg/ml 10 kDa 
FITC-dextran (Sigma) to the upper chamber. 
 
Cellular Detachment and Apoptosis Assay 
 
Human and murine BMECs were cultured and stimulated as previously described during 
the permeability experiments. Following 24hr stimulation, the supernatant was removed from the 
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Transwell chambers and cellular detachment/apoptosis was measured using the trypan blue 
exclusion assay. 
 
Statistical Analyses 
 
Data analysis and statistical calculations were performed using Prism statistical software 
(GraphPad). Cytokine and chemokine levels in cultured cell supernatants were analyzed using an 
unpaired t test with Welch’s correction. Quantified immunoblot results correlated to comparative 
controls were analyzed using Student’s t test as indicated. Western blot quantifications of 
multiple time points were analyzed by one-way ANOVA with Bonferroni correction for multiple 
comparisons or by an unpaired t test with Welch’s correction as indicated. Quantification of real 
time PCR results was calculated as a fold-change in transcripts compared to non-stimulated 
samples and statistical differences were determined by Student’s t test. For permeability 
experiments, p values shown represent comparison of the area under the curve calculated for 
each experiment and/or condition analyzed by unpaired t test with Welch’s correction. In all 
experiments, a p value of <0.05 was considered significant. 
  
 103 
 
APPENDIX 
A. “Interleukin 2 Activates Brain Microvascular Endothelial Cells Resulting in Destabilization of 
Adherens Junctions.” by Lukasz Wylezinski and Jacek Hawiger, Journal of Biological 
Chemistry, 2016. 291, 22913-22923. 
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The pleiotropic cytokine interleuki n 2 (IL2) disrupts the
blood-brain barrier and alters brain microcirculation, underly-
ing vascular leak syndrome that complicates cancer immuno-
therapy with IL2. The microvascular eects of IL2 also play a
role in the development of multiple sclerosis and other chronic
neurological disorders. The mechanism of IL2-induced disrup-
tion of brain microcirculation has not been determined previ-
ously. We found that both human and murine brain microvas-
cular endothelial cells express constituents of the IL2 receptor
complex. Then weestablished that signaling through this recep-
tor complex leads to activation of the transcription factor,
nuclear factor B, resulting in expression of proinammatory
interleuki n 6 and monocyte chemoattractant protein 1. We also
discovered that IL2 induces disruption of adherens junctions,
concomitant with cytoskeletal reorganization, ultimately lead-
ing to increased endothelial cell permeability. IL2-induced phos-
phorylation of vascular endothelial cadherin (VE-cadherin), a
constituent of adherens junctions, leads to dissociation of its
stabilizing adaptor partners, p120-catenin and -catenin.
Increased phosphorylation of VE-cadherin was also accompa-
nied by a reduction of Src homology 2 domain-containing pro-
tein-tyrosine phosphatase 2, known tomaintain vascular barrier
function. These results unravel the mechanism of deleterious
eects induced by IL2 on brain microvascular endothelial cells
and may inform the development of new measures to improve
IL2 cancer immunotherapy, as well as treatments for autoim-
mune diseases aecting the central nervous system.
The blood-brain barrier (BBB) 3 is formedbyendothelialcells
that line themicrocirculation and are part of the “neurovascu-
lar unit” composed of brain microvascular endothelial cells
(BMECs), astrocytes, andneurons (1). BMECs play an essential
role in these functional units, even prompting neurological
changesfollowing endothelial activation. For example, BMECs
are stimulated by inammatory mediator interleukin 1 , caus-
ing feverandlethargy(2). Likewise, IL2, themainstayof therst
eective cancer immunotherapy, induces neuropsychiatric
changes in patients through a hitherto undenedmechanism
(3). This therapy consists of IL2-induced activation and prolif-
eration of tumor-inltrating lymphocytes that lead to remis-
sion of renal cell carcinoma and malignant melanoma (4).
However, these benecial eects of IL2 are curtailed by the
developmentof brain edema, a prominentmanifestationof vas-
cular leak syndrome (VLS). Brain edemasubsides upon cessa-
tion of IL2 immunotherapy, indicating its direct role in this
serious complication. Thus, IL2-induced vascular permeability
in the central nervous system and other organs represents an
undesirable o-target eect (5). Moreover, IL2 plays a signi-
cant role in several chronic neurological autoimmunediseases,
including multiple sclerosis, neuromyelitis optica, and neuro-
psychiatric systemic lupus erythematosus(6– 8). Disruption of
the BBB is a critical step in developmentof these neurological
conditions. However, the mechanism of adverse action of IL2
on the barrier function of brain microvascular endothelial cells
remains unknown.
The maintenanceof BBB function is largely vestedin BMEC
intercellular junctions, a complex network of adhesiveproteins
organizedinto adherensjunctions (AJs) and tight junctions (9).
AJs are ubiquitously expressedin the vascular tree (10) and are
of particular importance in microvascular circulation, which
provides the largest surface area of exchange betweenblood
and tissue (11). Furthermore, postcapillary venules comprise
the main endothelial surface for activation and emigration of
immune cells that mediate inammatory reactions (12). For-
mation of AJs is dependenton thehomotypic interaction of cell
surface transmembraneproteins termedcadherinswhosecyto-
plasmic tails associate with intracellular binding partners
termedcatenins. Thus, the stability of AJs dependson complex
formation between vascular endothelial cadherin (VE-cad-
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herin), p120-catenin (p120), -catenin, and plakoglobin (9). In
contrast, destabilization of AJs is due to a loss of p120 and
-catenin binding,which causesthe internalization of VE-cad-
herin (13–15). This process is induced by increased phosphor-
ylation of VE-cadherin accompanied by a decrease in Src ho-
mology domain-containing protein-tyrosine phosphatase 2
(SHP2), which maintains vascular barrier function (15). Ulti-
mately, disruption of AJs leads to leakiness of endothelial cell
monolayers (9, 15–17).
In general,activationof endothelialcells results in expression
of cell adhesion molecules along with proinammatory cyto-
kines and chemokines, enhancing an autoregulatory feed-for-
ward loopthat leadsto further recruitment of immune cells and
escalation of the inammatory response (18). Genes encoding
thesemediators of inammation are controlled by nuclear fac-
tor B (NF B), master regulator of immunity and inamma-
tion. Increased expression of interleukin 6 (IL6), macrophage
chemoattractant protein 1 (MCP1/CCL2), intercellular adhe-
sion molecule 1, and vascular cell adhesionmolecule 1 among
others has been linked to the NF B pathway (19, 20). In lym-
phocytes, IL2-evoked signalingmediatedby its highanity tri-
meric receptor (IL2R ) has beenpreviously coupledto acti-
vation of the NF B pathway(21).
Here weanalyze themechanismof IL2-induced activation of
human and murine brain microvascular endothelial cells and
the resulting disruption of BMEC barrier function. We report
that IL2 induces activation of the NF B pathway, leading to
increased expression of proinammatory mediators. In paral-
lel, IL2 causes disruption of AJs through an increase in VE-
cadherin phosphorylation. As a consequence, microvascular
endothelial monolayer permeability was increased. Whereas
IL2-induced disruption of theBBB changesthe central nervous
systemmilieu and leads to subsequentbrain edema,our study
may contribute to the developmentof new strategies for pro-
tectingbrain function from this deleteriousprocess.
Experimental Procedures
Cell Culture—The human BMEC line hCMEC/D3 was pro-
videdthroughthecourtesyof Professor BabetteWeksler (Weill
Cornell Medical College, New York, NY) (22). hCMEC/D3 cells
were cultured at 37 °C in 5% CO 2 in EBM-2 (Lonza) supple-
mentedwith 5%heat-inactivated fetal bovine serum (HI-FBS),
1% penicillin/streptomycin (Mediatech), 1.4 M hydrocorti-
sone (Sigma), 5 g/ml ascorbic acid (Fisher Scientic), chemi-
cally dened lipid concentrate (Invitrogen) diluted 1:100, 10
mM HEPES (Mediatech), and 1 ng/ml human basic FGF
(Sigma). Cells used for experiments were betweenpassages20
and 30. The murine brain endothelioma cell line bEnd.3 (23)
was purchased from American Type Culture Collection and
cultured at 37 °C in 5% CO 2 in Dulbecco’s modied Eagle’s
medium (Mediatech) supplemented with 10% HI-FBS and
1% penicillin/streptomycin. Murine embryonic broblasts
(MEFs) and the human embryonic kidney (HEK) cell line
were cultured at 37 °C in 5% CO 2 in Dulbecco’s modied
Eagle’s medium supplemented with 10% HI-FBS and 1%
penicillin/streptomycin.
Quantitative Real Time PCR Analysis—Total RNA was iso-
lated for quantitative real time PCR (qPCR) analysis using the
RNeasy Mini kit (Qiagen) followingthemanufacturer’s instruc-
tions and reverse transcribed utilizing the iScript cDNA syn-
thesis kit (Bio-Rad). Targets were amplied by the CFX96
Touch real time PCR detection system (Bio-Rad) using the iQ
SYBR Green Supermix kit (Bio-Rad) with specic primers listed
in Table 1 for the indicated mRNAs. Results were analyzed by
CFX Manager (Bio-Rad). Following normalization to GAPDH
cDNA, relative levelswere calculatedusing the 2 Ct method
(24).
Immunoblotting and Immunoprecipitation Analysis—Anti-
bodies against NF B p65 (RelA), p120, VE-cadherin, SHP2
(Santa Cruz Biotechnology), -catenin (BD Biosciences), phos-
pho- -catenin, I B , phospho-NF B p65 (phospho-RelA)
(Cell Signaling Technology), and phospho-VE-cadherin (ECM
Biosciences) wereusedfor immunoblottinganalyses.Obtained
valueswerenormalized in reference to -actin or TATA-bind-
ing protein detectedwith their cognateantibodies (Abcam) in
cytosolic and nuclear extracts as indicated. Adherens junction
protein complexeswere immunoprecipitated from cell lysates
with antibodies against p120 or VE-cadherin. Species-specic
IgG (Santa Cruz Biotechnology) was used as a control. The
lysates were precleared with protein A/G-agarose beads
(Thermo) prior to addition of antibodies or control IgG. The
immune complexeswere then capturedwith protein A/G-aga-
rose beadsand analyzedbyquantitative immunoblottingusing
antibodies against p120, VE-cadherin, and -catenin with the
LI-COR Odyssey infrared imaging system as described previ-
ously (25).
Cytokine/ChemokineAssays—Cytokines and chemokines in
tissue culture medium supernatantswere assayedby cytomet-
ric beadarray (BD Biosciences) in the Vanderbilt Flow Cytom-
etry Shared Resource according to the manufacturer’s in-
structions as described previously (25). During time- and
concentration-dependent titration experiments, supernatant
samples were taken following stimulation as indicated. Cyto-
kine and chemokine expression was also analyzed in medium
from BMEC monolayers cultured in Transwell chambers for
permeability experiments. Medium samples were taken from
TABLE 1
Oligonucleotide PCR primer sequences used in current study
h, human;m, murine.
Gene Primer sequences
h vWF Forward, 5 -TGCTGACACCAGAAAAGTGC-3
Reverse, 5 -AGTCCCCAATGGACTCACAG-3
m vWF Forward, 5 -TTCATCCGGGACTTTGAGAC-3
Reverse, 5 -AGCCTTGGCAAAACTCTTCA-3
h PECAM1 Forward, 5 -GATAATTGCCATTCCCATGC-3
Reverse, 5 -GGGTTTGCCCTCTTTTTCTC-3
m PECAM1 Forward, 5 -ATGACCCAGCAACATTCACA-3
Reverse, 5 -CACAGAGCACCGAAGTACCA-3
h IL2R Forward, 5 -ATCAGTGCGTCCAGGGATAC-3
Reverse, 5 -GTGACGAGGCAGGAAGTCTC-3
m IL2R Forward, 5 -TACAAGAACGGCACCATCCTAA-3
Reverse, 5 -TTGCTGCTCCAGGAGTTTCC-3
h IL2R Forward, 5 -GCTGATCAACTGCAGGAACA-3
Reverse, 5 -TGTCCCTCTCCAGCACTTCT-3
m IL2R Forward, 5 -GGCTCTTCTTGGAGATGCTG-3
Reverse, 5 -GCCAGAAAAACAACCAAGGA-3
h IL2R Forward, 5 -CCACTCTGTGGAAGTGCTCA-3
Reverse, 5 -AGGTTCTTCAGGGTGGGAAT-3
m IL2R Forward, 5 -CTGGGGGAGTCATACTGTAGAGG-3
Reverse, 5 -AGGCTTCCGGCTTCAGAGAAT-3
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theupper chamber followingstimulation as indicatedbutprior
to addition of FITC-dextran tracer.
Immunouorescence Staining and Fluorescence Micro-
scopy—Human hCMEC/D3 or murine bEnd.3 cells grown to
conuence on Transwell permeability supports were stimu-
latedwith species-specic IL2 (BD Biosciences, Prometheus) or
TNF (Invitrogen) as indicated. After stimulation, cells were
xed in 4%paraformaldehyde(Electron Microscopy Sciences),
washedwith PBS, and permeabilized with 0.1% Triton X-100
(Invitrogen). For immunostaining, cells were blocked with 5%
normal goat serum (Jackson ImmunoResearch Laboratories)
beforeovernight incubation at 4 °C with primary antibodies to
NF B p65 (Abcam) or VE-cadherin and p120 (Santa Cruz Bio-
technology)followedbyincubationwith Alexa Fluor 488 (Invit-
rogen)-, Cy3-, or Cy5-labeled (Jackson ImmunoResearch Lab-
oratories) secondary antibodies. F-actin polymerization was
visualized in permeabilized cells with Alexa Fluor 488-labeled
phalloidin (Cytoskeleton, Inc.). After staining, the semiperme-
ablemembraneswere removedfrom the Transwell permeabil-
ity supportsandmountedon slideswith ProLong Gold antifade
reagent containing DAPI (Invitrogen) to counterstain nuclei.
Imageswere capturedand analyzedwith MetaMorph software
on an Axioplan wideeld microscope in the Vanderbilt Cell
Imaging Core facility using a 63 oil immersion objective.
Endothelial Cell Permeability—Human hCMEC/D3 or
murine bEnd.3 cells (1 105) were seededonto 24-well Tran -
swell semipermeable supports (Costar) precoatedwith type 1
collagen(Cultrex) and incubateduntil conuent. Upon conu-
ence,asveriedbymicroscopy, growthmediumwasexchanged
for serum-depleted medium that comprised growth medium
with a low concentration (0.5%) of HI-FBS. Following 24-h cul-
ture in lowserummedium, cells were left unstimulatedor stim-
ulated for 24 h with species-specic 300 kilounits/ml IL2 or 30
ng/ml TNF . In experiments utilizing neutralizing antibodies,
species-specic murine anti-IL6 and anti-MCP1 (R&D Sys-
tems) and human anti-IL6 (R&D Systems) and anti-MCP1
(Sigma) were added concomitantly with IL2. Human anti-
IL2R antibody (R&D Systems) was added30 min prior to IL2
stimulation. Antibody concentrations necessary for neutraliza-
tion were calculated from the levels of cytokine/chemokine
expressionduring titration of IL2. Monolayer permeabilitywas
assessedbydetectionof FITC-dextran in the lower chamber at
various times after addition of 1 mg/ml 10-kDa FITC-dextran
(Sigma) to the upper chamber.
Cellular Detachment and Apoptosis—Human and murine
BMECs were cultured and treated as described previously for
permeability experiments. Following 24-h stimulation, the
supernatant was removed from the Transwell chambers, and
cellular detachment/apoptosiswas measured using the trypan
blue exclusion assay.
Statistical Analyses—Data analysis and statistical calcula-
tions were performed using Prism (GraphPad). Cytokine and
chemokine levels in cultured cell supernatants and Western
blotting quantication of comparative controls were analyzed
using an unpaired t test with Welch’s correction or Student’s t
test as indicated. Western blotting quantications of multiple
time points were analyzed by one-way ANOVA with Bonfer-
roni correction for multiple comparisons. Quantication of
real time PCR results was calculated as a -fold changein tran-
scripts comparedwith non-stimulated samples, and statistical
dierencesweredeterminedbyStudent’s t test. For permeabil-
ity experiments, p values shown represent comparison of the
area under the curve calculated for each experiment and/or
condition analyzedby unpaired t test with Welch’s correction.
In all experiments, a p value of 0.05 was considered
signicant.
Results
Characterization of BMECs and Their Expression of the IL2
ReceptorSubunits—In an eort to ensure that the endothelial
cell phenotypewas maintained in this study, we analyzed two
well known markers specic for endothelial cells, von Will-
ebrandfactor (vWF) andplateletendothelialcell adhesionmol-
ecule 1 (PECAM1) (26). As expected,bothhuman hCMEC/D3
andmurine bEnd.3 cells constitutively expressedhigh levels of
vWF and PECAM1 transcripts compared with human and
murine non-endothelial cells (HEK cells andMEFs) whenana-
lyzed by qPCR (Fig. 1A). Our qPCR results in both human
hCMEC/D3 and murine bEnd.3 cells complement previous
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FIGURE 1. Expression of endothelial cell markers vWF, PECAM1, and IL2R
subunits in human and murine BMECs. A, constitutive transcript levels of
endothelial cell markers vWF and PECAM1were assessed by qPCR. Following
normalization to GAPDH, mRNA levels are presented as increased -fold
change fromspecies-specic non-endothelial cells: HEK293 cells andMEFs.B,
transcript levels of IL2R subunits were determined by qPCR, and protein
expression was documented by immunoblotting. IL2R (CD122) and IL2R
(CD132) were constitutively expressed in both human and murine BMECs.
Transcript and protein levels for IL2R (CD25) were only detected following
24-h stimulationwith species-specic 300 kilounits/ml IL2. The level ofmRNA
transcript is presented as relative expression comparing human and murine
BMECs. Error bars represent mean S.E. of three independent experiments
performed in triplicates. Statistical signicance was determined by Student’s
t test (*, p 0.05).
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characterization in terms of protein expression of vWF and
PECAM1 (22, 23, 27). Next, we assessedIL2 receptor subunit
expressionbyqPCR andWestern blottingto ascertain whether
BMECs can respond to IL2. The IL2 receptor complex com-
prises thehighanity trimeric conguration (IL2R ) or the
intermediate anity dimer (IL2R ) (28). We documented
that IL2R (CD122) and IL2R (CD132) are expressedconsti-
tutively at both the transcript and protein levels. Conversely,
these transcripts were barely detectablein control cell lines of
humanandmurine origin (HEK cells andMEFs). IL2R (CD25)
transcripts wereonly detectedin BMECs, but not control cells,
after agoniststimulation for 24 h and corroboratedwith detec-
tion of the protein byWestern blotting (Fig. 1B). Without con-
stitutive expression of CD25 and formation of the trimeric
receptor complex, anity for IL2 is reduced10–100 times (29).
Therefore, we basedour experimental protocol on using su-
ciently high concentrations of IL2 to stimulate naïve BMECs
and overcometheir lower signalingcapacity via the intermedi-
ate anity receptor complex (IL2R ). As compared with
human hCMEC/D3 cells, murine bEnd.3 cells displayedsignif-
icantly higher transcript levels of IL2R , the receptor subunit
most attributed to mediating positive signal transduction (28,
30). No signicant dierencebetweenhuman andmurine cells
was detectedin transcript levels of inducible IL2R subunit or
constitutive IL2R subunit. However, a trend toward higher
expressionof IL2R wasobservedin murine bEnd.3 cells. Thus,
these results establish the expression of the IL2 intermediate
anity receptor complex on both human andmurine BMECs.
IL2-induced Activation of theNF B Pathway—We hypothe-
sized that IL2-induced activation of BMECs entails signaling
through the NF B pathway akin to IL15 (31). Therefore, we
usedthree experimental approachesto analyzeNF B signaling
in IL2-stimulated BMECs and compared the results with those
evoked by a known endothelial agonist, lipopolysaccharide
(LPS) , a potent activator of the NF B pathway (32). First, we
determined that I B , the inhibitory protein responsible for
sequestering NF B p65 (RelA) in the cytoplasm, becomes
degradedfollowing IL2 stimulation in bothhuman andmurine
BMECs (Fig. 2A). Due to the very rapid turnover kinetics of
I B (33), we included the protein synthesis inhibitor cyclo-
heximide to prevent reaccumulation of newly synthesized
I B . Constitutive turnover was measured following addition
of cycloheximide and compared with degradation in BMECs
stimulated with agonist. Stimulation with IL2 caused time-de-
pendentdegradationof I B with a loss of 30–70% of its basal
level, mimicking I B degradation following activation with
LPS. Notably, the kinetics of I B degradation was faster in
human hCMEC/D3 cells compared with murine bEnd.3 cells
likely due to constitutively higher expression of physiologic
suppressors of the NF B signaling pathway such as A20 in
murine cells (34). As a result of I B degradation, RelA is no
longer sequesteredin the cytoplasm, becomesphosphorylated,
and is able to translocate into the nucleus. RelA phosphoryla-
tion enhances DNA binding and results in the activation of a
number of proinammatory genes (35). Accordingly, we
detected an increase in phosphorylated RelA compared with
total RelA in the nucleus (Fig. 2B). Both human and murine
BMECs showed a time-dependentresponseto IL2, resulting in
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degradation of I B in BMECs. Human (hCMEC/D3) and murine (bEnd.3)
BMECswere left unstimulated (Unstim) (0) or stimulatedwith species-specic
300 kilounits/ml IL2 or 1 g/ml LPS, a positive control, for the indicated times
after pretreatment for 30 min with the protein synthesis inhibitor cyclohexi-
mide (CHX) (10 g/ml) to block denovoprotein synthesis. Cytosolic extracts
were isolated, separated by SDS-PAGE, and immunoblotted for the degrada-
tion of I B . Protein levels were quantied by immunoblotting, and values at
each time point were normalized to the -actin loading control. Error bars
represent mean S.D. of at least four independent experiments. Statistical
signicancewas determined using an unpaired t test withWelch’s correction
(*, p 0.05; **, p 0.005; ***, p 0.0005). B, translocation of RelA to the
nucleus. Human and murine BMECs were stimulated with 300 kilounits/ml
species-specic IL2 or 1 g/ml LPS for the indicated times, and nuclear
extracts were isolated, separated by SDS-PAGE, and immunoblotted for the
presence of total RelA and Tyr-536 phosphorylated RelA (p-RelA). TATA-bind-
ingprotein (TBP) serves as a loading control for nuclear lysates. Quantication
of signal is shown as -fold change compared with the unstimulated control.
Error bars represent mean S.D. of at least four independent experiments.
Statistical signicance was determined using an unpaired t test with Welch’s
correction (*, p 0.05). C, detection of RelA in the nucleus by immunouo-
rescence. Murine (bEnd.3) BMECs were analyzed following 24-h stimulation
with 300 kilounits/mlmurine IL2 or 30 ng/mlmurine TNF . Cells were immu-
nostained with anti-RelA antibodies (red), and nuclei were counterstained
with DAPI (blue). Arrows indicate strong nuclear staining of RelA. Images are
representative of three independent experiments. Quantication was deter-
minedusingMetaMorph imaging software. Statistical signicancewas deter-
mined using an unpaired t test with Welch’s correction (*, p 0.05).Magni-
cation, 63. Scalebars, 5 m. Errorbars represent mean S.D.
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a 50% increase in Tyr-536 phosphorylation of RelA in nuclear
extracts of agonist-treated cells. Finally, we veried nuclear
translocation of RelA using immunouorescence. Indeed, as
compared with the unstimulated control, we noted elevated
levels of nuclear RelA in BMECs stimulatedwith IL2 or TNF ,
another known inducer and activator of the NF B pathway
(Fig. 2C ). Taken together,our multiprongedapproachdemon-
strates that IL2 activatestheNF B signalingpathwayin human
andmurine BMECs.
IL2 Induces Expression of Proinammatory Cytokines and
Chemokines—Several proinammatory cytokines and chemo-
kines havebeenpreviously implicated in endothelial activation
and loss of barrier function, including IL6 andMCP1 (36–39).
Both are regulatedby the NF B pathway (20, 40). Given that
IL2 activated this pathway, we hypothesized that IL2 stimula-
tion would also induce expression of these two proinamma-
tory mediators. Indeed, both pleiotropic cytokine IL6 and
chemokine MCP1 were elicited by IL2 in a concentration-de-
pendentmanner in human and murine BMECs (Fig. 3). Thus,
IL2 inducesproinammatory agoniststhat can alsoamplify sig-
naling events involved in the potentiation of microvascular
injury.
IL2-induced Permeability of the BMEC Monolayer—IL2
administeredduring cancer immunotherapy causesVLS, man-
ifested by a rise in brain water content that is attributed to
increasedpermeabilityof thebrain microvascular endothelium
(5). Therefore, we next analyzed the potential mechanism of
IL2-induced disruption of endothelial barrier function in
BMEC monolayers in Transwell chambers. We monitored the
passageof FITC-labeled dextran across an intact monolayer.
FITC-dextran was addedto the upper Transwell chamber fol-
lowing 24-h stimulation of BMECs with species-specic IL2.
The lower chamber supernatantwas then sampledat the indi-
cated time points. IL2 induced a signicant increase in the
movement of FITC-dextran across the IL2-stimulated BMEC
monolayer comparedwith thenon-stimulated control, indicat-
ing agradual loss of endothelial barrier function and increased
permeability (Figs. 4A and 5A). As IL2-induced permeability
can potentially be enhancedby IL6 and/or MCP1, we utilized
species-specic neutralizing antibodiesagainst IL6 andMCP1.
Neutralizing these two potential permeability agonists did not
signicantly alter an IL2-induced increase in permeability,
although a trend toward lower permeability was observed. In
contrast, IL2-induced permeability enhancementwas counter-
acted in human hCMEC/D3 cells by species-specic IL2R -
blocking antibody (Fig. 4A). These results indicate that IL2 can
directly increase endothelialmonolayerpermeability. A similar
blockingexperiment could not beperformed in murine bEnd.3
cells due to a lack of species-specic antibody against IL2R .
Murine bEnd.3 cells demonstrated a greater change in endo-
thelial permeability than human hCMEC/D3 cells most likely
due to constitutively higher expression of IL2R . Even though
permeability increases in the hCMEC/D3 monolayer were not
as robust, these results were signicant and consistent. Endo-
thelial monolayer conuence and integrity were checked by
microscopy prior to initiating permeability assays. To this end,
extending culture time from 24 to 72 h without agonist treat-
ment in the Transwell system of both human hCMEC/D3 and
murine bEnd.3 endothelial cells did not change their baseline
permeability level for FITC-labeled dextran.
We veried changes in endothelial barrier function by
immunostaining the adherens junction protein complex that
includes VE-cadherin and one of its adaptors, p120-catenin.
In quiescent human and murine BMECs, immunostained VE-
cadherin and p120displayed awell dened, contiguousborder
betweenadjoining cells. This border was strikingly lost after
treatment with IL2 or TNF , a comparative positive control.
Membrane-associated VE-cadherin p120 complexes were dis-
rupted with a concomitant reduction of these proteins along
the periphery of the cells (Figs. 4B and 5B). We veried that
endothelial cell activation correlated with the time course of
increased permeability in human hCMEC/D3 and murine
bEnd.3 cells by analyzing cytokine and chemokine expression
in supernatant collected from the upper Transwell chamber
prior to addition of FITC-dextran. In agreement with prior
analysis in a dierent culture system (see Fig. 3), we docu-
mented signicantly higher levels of IL6 and MCP1 following
IL2 stimulation comparedwith the unstimulated control (Figs.
4C and 5C ). However, within the time frame of our antibody-
neutralizing permeability experiments, these two proinam-
matory agonists evokedby IL2 did not signicantly contribute
to its eect on microvascular permeability (see above;Figs. 4A
and 5A).
IL2-induced Disruption of the Adherens Junction—Disrup-
tion of the AJ protein complex is accompanied by changes in
cell morphology and resulted in the opening of gaps between
neighboring cells. These changes in endothelial monolayer
integrity are coupledto cytoskeletal reorganization (25, 41, 42).
Indeed, an increase in F-actin ber bundles was prominently
displayedin IL2-activated murine bEnd.3 cells (Fig. 6A). These
cells displayed thicker and more prominent F-actin ber bun-
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dlescomparedwith thin F-actin bers sparsely crossing thecell
body in unstimulated controls. Moreover, agonist-inducedcell
loss due to detachment and apoptosis was documented (Fig.
6B). Agonist stimulation resulted in signicantly higher levels
of cellular detachment and apoptosis in human and murine
BMECs. Detached circulating endothelial cells have been
described in a number of human diseases as well as in animal
models of vascular injury (43, 44).
IL2 ChangestheCompositionof theAJ Complex—The strik-
ing disruption of the AJ protein complex following IL2 stimu-
lation as demonstrated by immunostaining led us to analyze
changes in AJ protein complex composition. In a series of co-
immunoprecipitation experiments, wedemonstratedthat IL2-
induced activation of BMECs results in a loss of interaction
betweenVE-cadherin and p120 as reected by their ratio (Fig.
7A). -Catenin also binds to VE-cadherin, stabilizing the com-
plex andallowingits interaction with F-actin. Loss of bothp120
and -catenin leads to destabilization of adherens junctions
and endocytosis of VE-cadherin (12, 14, 42). Indeed, the
VE-cadherin -catenin complex is also altered due to IL2
activation in both human and murine BMECs (Fig. 7B).
Thus, IL2-induced dissociation of the AJ complex docu-
mentedby co-immunoprecipitation explains the loss of VE-
cadherin immunostaining at cellular borders seen in ago-
nist-stimulated BMECs (Figs. 4B and 5B).
IL2-induced PhosphorylationofVE-cadherin—We next ana-
lyzed themechanism bywhich VE-cadherin and its associated
adaptorproteins (p120 and -catenin) are dissociateduponIL2
stimulation. Post-translational modications, such as phos-
phorylation events,contribute to destabilizationof theAJ com-
plexandloss of endothelialbarrier function in various endothe-
lial cell subsets(14, 16, 17, 45). Indeed, IL2 evoked a signicant
increase in Tyr-685 phosphorylation of VE-cadherin in these
cells (Fig. 8A). This processwas time-dependentwith maximal
phosphorylation levels reachedbetween 6 and24 h. Consistent
with more robust activation and increased permeability
recorded in murine bEnd.3 cells, wenotedhigher VE-cadherin
phosphorylation than in human hCMEC/D3 cells. Thus, IL2-
inducedphosphorylationof VE-cadherin leadsto thedestabili-
zation of the AJ complex most likely through dissociation of
VE-cadherin from its adaptor proteins as documented above
(Fig. 7, A and B).
IL2-induced Loss of SHP2 Phosphatase—SHP2 phosphatase
counteracts VE-cadherin phosphorylation, thereby contribut-
ing to the maintenance of lungmicrovascular endothelial bar-
rier function (9, 15, 46). We found a signicant decrease in
expressionof SHP2 phosphatasein IL2-stimulated BMECs that
paralleled increased phosphorylation of VE-cadherin (Fig. 8B).
SHP2 protein levels were reduced by 40–50% in both human
and murine BMECs following IL2 stimulation. In contrast,
observedtranscript levelsof SHP2 phosphataseremainedat the
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at the cell membrane in agonist-stimulated human BMECs. Magnication,
X63; scale bars, 5 m. C, agonist-induced expression of cytokine IL6 and
chemokine MCP1 in hCMEC/D3 cell monolayer lining Transwell inserts. The
hCMEC/D3 cell activation state was assessed prior to initiation of the perme-
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same level or were increased.4 Thus, degradativeloss of SHP2
phosphataseaccompanies an increase in the phosphorylation
state of AJ-associated proteins and destabilization of the
complex.
Discussion
Taken together, our results decode the process through
which IL2 activates BMECs and causes the loss of their barrier
function. We found that human andmurine BMECs constitu-
tively express the intermediateanity IL2 receptor comprising
subunits and (IL2R ), whereassubunit (CD25) is induc-
4 L. S. Wylezinski and J. Hawiger, unpublished data.
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FIGURE 6. IL2-induced F-actin polymerization in BMECs and increased
detachment following stimulation. A, F-actin polymerization changes in
agonist-stimulated murine BMECs. bEnd.3 cells were grown to conuence
and then left unstimulated (Unstim) or stimulated with 300 kilounits/ml
murine IL2 or 30 ng/ml murine TNF for 24 h. Cells were stained with Alexa
Fluor 488-labeled phalloidin (green) to visualize F-actin. Nuclei were counter-
stained with DAPI (blue). Images are representative of at least three indepen-
dent experiments. Magnication, 63. Scale bars, 5 m. B, increased BMEC
detachment and apoptosis following agonist stimulation from Transwell
inserts. Both human and murine BMECs were grown to conuence on Tran-
swell permeability inserts and then left unstimulated or stimulated with spe-
cies-specic IL2 (300 kilounits/ml) or TNF (30 ng/ml) for 24 h. Supernatants
were collected, and free oating endothelial cells detached from the Tran-
swell membranes were counted. Errorbars represent mean S.D. of at least
three independent experiments performed in duplicates. Statistical signi-
cancewas determined by unpaired t test withWelch’s correction (*, p 0.05;
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ibly expressedfollowing IL2 stimulation. We documentedthat
IL2-induced signaling in BMECs involves transcription factor
NF B through (i) degradation of NF B inhibitor I B , (ii)
phosphorylationof NF B p65 (RelA), and (iii) its nuclear trans-
location. Subsequently, we demonstrated that among NF B-
regulatedgenesin BMECs twopleiotropicmediators of inam-
mation, cytokine IL6 and chemokine MCP1 (CCL2), are
expressed following IL2 stimulation. Both IL6 and MCP1 are
known inducers of endothelial instability (19, 20). IL2-evoked
NF B activation in lymphocytes is well known (21) but to our
knowledgehas not been reported previously in non-immune
cells.
Furthermore, we demonstrated that IL2 causes the loss of
barrier function of BMECs. Their stimulation disrupts the
interaction of AJ complex proteins by inducing phosphoryla-
tion of VE-cadherin alongwith a concomitant decline in SHP2
phosphatase.Thus, IL2 changesthephenotypeof BMECs from
basalphysiologicquiescenceto an activatedstate, contributing
to an inammatory milieu aecting brain neurovascular units
that comprise the BBB (1). As schematically depictedin Fig. 9,
IL2 interaction with its intermediateanity receptorexpressed
on brain microvascular endothelial cells activates signaling
mediatedby the transcription factor NF B, master regulator of
inammation. This feed-forward loop results in expression of
proinammatory mediators exemplied by IL6 and MCP1. In
parallel, IL2 destabilizesadherensjunctions throughphosphor-
ylation of VE-cadherin and dissociation of its complex with
p120 and -catenin. This process is enhanced by an IL2-in-
duced decrease in SHP2 phosphatase expression and stress
ber formation. Increased microvascular permeability ensues,
****
IP:p120
Lysates
24h
IL2 TNFαUnstim
Murine (bEnd.3)
IP:p120
Lysates
IB:p120
IB:VE-cad
IL2 TNFαUnstim24h
****
IL2 TNFαUnstim
Human (hCMEC/D3)
(%
 o
f U
ns
tim
)
R
at
io
 V
E-
ca
d/
p1
20
IP: VE-cadherin
IL2 TNFαUnstim
24h
IL2 TNFαUnstim
0%
50%
100%
150%
**
Lysates
IB: VE-cad
IB:β-catenin
IL2 TNFαUnstim
A
(%
 o
f U
ns
tim
)
R
at
io
 V
E-
ca
d/
p1
20
IB:p120
IB:VE-cad
IB:p120
IB:VE-cad
IB:p120
IB:VE-cad
B
IP: VE-cadherin
24h
R
at
io
   
-c
at
en
in
/V
E-
ca
d
(%
 o
f U
ns
tim
)
β
IB: VE-cad
IB:β-catenin
R
at
io
   
-c
at
en
in
/V
E-
ca
d
(%
 o
f U
ns
tim
)
β
Lysates
IB: VE-cad
IB:β-catenin
IB: VE-cad
IB:β-catenin
0%
50%
100%
150%
*
IL2 TNFαUnstim
**
IgG 
IgG 
0%
50%
100%
150%
0%
50%
100%
150%
IL2 TNFαUnstimIgG 
IgG 
FIGURE 7. IL2-induced dissociation of the VE-cadherin p120 and VE-
cadherin -catenin complexes in human and murine BMECs. A, analysis of
the VE-cadherin p120 complex. Human (hCMEC/D3) andmurine (bEnd.3) endo-
thelial cells were grown to conuence and left unstimulated (Unstim) or stimu-
latedwith300kilounits/ml species-specic IL2or 30ng/ml species-specicTNF
for 24 h. Protein complexes in cell lysates precipitated with anti-p120 (IP) or
treated with control IgG were quantied by immunoblotting (IB) with protein-
specicantibodies. Cell lysates serve as input controls prior to immunoprecipita-
tion.Errorbars representmean S.D.of at least three independentexperiments.
Statistical signicance was determined by Student’s t test (*, p 0.05; **, p
0.005; ***,p 0.0005). B, analysis of the VE-cadherin -catenin complex. Human
(hCMEC/D3) and murine (bEnd.3) endothelial cells were grown to conuence
and left unstimulated or stimulated with 300 kilounits/ml species-specic IL2 or
30 ng/ml species-specic TNF for 24 h. Protein complexes in cell lysates precip-
itated with anti-VE-cadherin (IP) or treated with control IgG were quantied by
immunoblotting (IB) with protein-specic antibodies. Cell lysates serve as input
controls prior to immunoprecipitation. Errorbars represent mean S.D. of four
independent experiments. Statistical signicancewasdeterminedbyStudent’s t
test (*, p 0.05; **, p 0.005). VE-cad, VE-cadherin.
*
Human (hCMEC/D3)
VE-Cadherin Phosphorylation
*
Murine (bEnd.3)
*
0
1
2
3
4
5
0%
50%
100%
150%
Time (h)     0 1         6        24       24
- +      + +       -IL2
LPS - - - - +     
SHP2
β-actin
*** **
0%
50%
100%
150%
Time (h)   0         1        6         24       24
- +       + + -IL2
LPS - - - - +     
** *
Time (h)     0 1        6        24       24
- +      + +       -IL2
LPS - - - - +     
Time (h)     0 1        6        24       24
- +      + +       -IL2
LPS - - - - +     
A
B
p-
V
E
-c
ad
/V
E
-c
ad
(F
ol
d 
C
ha
ng
e)
β-actin
p-VE-Cad
VE-Cad
β-actin
p-VE-Cad
VE-Cad
p-
V
E
-c
ad
/V
E
-c
ad
(F
ol
d 
C
ha
ng
e)
S
H
P
2 
E
xp
re
ss
io
n
(%
 o
f U
ns
tim
)
SHP2
β-actin
S
H
P
2 
E
xp
re
ss
io
n
(%
 o
f U
ns
tim
)
SHP2 Degradation
**
0.0
0.5
1.0
1.5
2.0
2.5
FIGURE 8. IL2-induced phosphorylation of VE-cadherin and degradation
of SHP2 phosphatase in human and murine BMECs. A, analysis of VE-cad-
herin phosphorylation. Human (hCMEC/D3) and murine (bEnd.3) BMECs
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S.D. of seven independent experiments. Statistical signicance was deter-
mined using one-way ANOVA with Bonferroni correction for multiple com-
parisons for IL2 and an unpaired t test with Welch’s correction for LPS (*, p
0.05). B, analysis of SHP2 expression. Human (hCMEC/D3) and murine
(bEnd.3) BMECs were left unstimulated (Unstim) or stimulated with 300 kilo-
units/ml species-specic IL2 or 1 g/ml species-specic LPS for 24 h, and
cytosolic extractswere isolated, separatedbySDS-PAGE, and immunoblotted
for the presence of SHP2. -Actin is a loading control for cytosolic lysates.
Normalized quantication of proteins is shown as a percent compared with
the unstimulated control. Error bars represent mean S.D. of ve indepen-
dent experiments. Statistical signicance was determined using one-way
ANOVA with Bonferroni correction for multiple comparisons for IL2 and an
unpaired t test with Welch’s correction for LPS (*, p 0.05; **, p 0.005).
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thereby explaining vascular leak syndrome and brain edema
observedduring IL2 cancer immunotherapy.
As was initially reported (3), neuropsychiatric eects of IL2
are both dose- and time -dependentduring IL2 cancer immu-
notherapy.The latencyperiod in developmentof IL2 neurotox-
icity points to a cumulative eect and/or increased availability
of the inducible IL2R subunit (CD25). Therefore, in an eort
to overcome this receptor limitation on naïve BMECs, we uti-
lized a much higher agonist concentration range of IL2 in
BMEC-based experiments.
Consistent with our study, expression of the IL2 receptor
complex has beenpreviously documentedin pulmonary endo-
thelial cells studied in a lung edemamodel (29, 41). Signaling
through the IL2 receptor complex expressed on BMECs
induces activation of the NF B pathwaysimilarly to the previ-
ously reported action of IL15, anothermember of the IL2 fam-
ily. IL15 utilizes twosubunitsof IL2 receptor, IL2R and IL2R ,
in addition to the IL15-binding subunit (31).
The structural and functional integrity of brain microvascu-
lar endothelium is of paramount importance for maintaining
the physiologic function of the BBB (1, 47). IL2 stimulation of
BMECs causedsignicant andconsistent increases in endothe-
lial monolayer permeability. VE-cadherin, the transmembrane
protein responsible for homotypic interactions betweenadja-
cent endothelial cells, is stabilized by a group of cytoplasmic
adaptor proteins, including p120 and -catenin. We estab-
lished that IL2 stimulation of BMECs disrupts this interaction
of AJ proteins (see Fig. 7). Consistent with our study, VE-cad-
herin distribution in pulmonarymicrovascular endothelialcells
wasalteredbybloodserumobtainedfrom patientstreatedwith
IL2 (41). Although our investigation was focused on AJs, it is
important to note that tight junctions are also involved in
restricting paracellular permeability in endothelial cells. It is
likely that activation of BMECs also inuences thebarrier func-
tion of tight junctions (48).
Our studyoers adeeperunderstandingof themechanismof
IL2-induced brain edema,which alongwith lung edemalimits
the eectiveness of IL2 cancer immunotherapy. This IL2-
evokedmechanism includes Tyr-685 phosphorylation of VE-
cadherin in BMECs (Fig. 8A) that is rapid andpersists up to24h
poststimulation, coinciding with the loss of AJs at endothelial
cell borders. It is noteworthythatotherVE-cadherin phosphor-
ylation sites havebeendescribed in regulatingAJ stability, and
theycontribute todestabilizationof theAJ complex in response
to agonistsother than IL2 (9, 16, 17, 49). Thus, more than one
phosphorylationsitewithin VE-cadherin, alongwith other IL2-
inducedsignalingevents,maycontribute to increasedendothe-
lial permeability.
We also discovered that IL2 stimulation resulted in the loss
of SHP2 protein in BMECs (Fig. 8B). SHP2 is one of several
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FIGURE 9. Diagrammatic depiction of IL2-induced activation of brain microvascular endothelial cells. IL2 interacts with the constitutively expressed
intermediate anity IL2R complex (IL2R and IL2R ), leading todegradationof I B and freeingNF B tobe translocated to thenucleus. ThereinNF B initiates
transcriptionof its target genes, including twoproinammatorymediators, namely cytokine IL6 andchemokineMCP1, culminating in a feed-forwardenhance-
ment of the inammatory process (left). In parallel, IL2 induces destabilization of adherens junctions through an increase in VE-cadherin (VE-cad) phosphory-
lation concomitant with a decrease in SHP2 phosphatase protein levels. An elevated VE-cadherin phosphorylation state results in diminished interaction
between the constituents of the adherens junction complex, in particular p120 and -catenin ( -cat). Furthermore, activation of the brain microvascular
endothelial monolayer leads to increased F-actin stress ber formation. Loss of adherens junction interaction between adjoining endothelial cells increases
monolayer permeability (right). Thus, IL2 interactionwith its cognate receptor onBMECs leads to a shift fromaquiescent to an “activated” phenotypeof BMECs
and an increase in endothelial monolayer permeability.
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phosphatasesresponsible for VE-cadherin dephosphorylation
linked to maintenance of endothelial monolayer barrier func-
tion (9, 15, 46). The loss of SHP2 protein following IL2 stimu-
lation enhances the phosphorylation status of VE-cadherin
and/or its adaptor proteins and exacerbates the destabiliza-
tion of AJs. Modication of protein-tyrosine phosphatases,
including SHP2, as opposedto kinases has beenproposedas
the principal driver in modulating VE-cadherin phosphory-
lation levels (9).
In summary, our study provides new evidencethat IL2 acti-
vatesBMECs andleadstodeteriorationof their barrier function
(see Fig. 9). A better understanding of IL2 action on brain
microvascular endothelium, the cardinal component of the
brain’s neurovascular unit, may aid in the developmentof new
measures to protect the central nervous system against IL2-
induced VLS complicating high dose IL2 cancer immunother-
apyand shed light on the role of IL2 in autoimmune inamma-
tion associatedwith several brain diseases.
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Background: The role of CRADD in endothelial cells is unknown.
Results: CRADD attenuatesresponses to proinammatory agonists in endothelial cells and stabilizes their barrier function.
Conclusion: CRADD plays a pivotal role in maintaining the integrity of the endothelial barrier.
Signicance: Understanding the role of CRADD as a physiologic rheostat of perturbedendothelial cells informs development
of CRADD-based measures to stabilize endothelial integrity.
A hallmark of inammation, increased vascular permeability, is
induced in endothelial cells bymultiple agonists through stimulus-
coupled assembly of the CARMA3 signalosome, which contains
the adaptor protein BCL10. Previously, we reported that BCL10 in
immune cells is targeted by the “death” adaptor CRADD/RAIDD
(CRADD), which negatively regulates nuclear factor B (NF B)-
dependent cytokine and chemokine expression in T cells (Lin, Q.,
Liu, Y., Moore, D. J., Elizer, S. K., Veach, R. A., Hawiger, J., and
Ruley, H. E. (2012) J. Immunol . 188, 2493–2497). This novel anti-
inammatory CRADD-BCL10 axis prompted us to analyze
CRADD expression and its potential anti-inammatory action in
non-immune cells. We focused our study on microvascular endo-
thelial cells becausethey play a key role in inammation. We found
that CRADD-decient murine endothelial cells display heightened
BCL10-mediated expression of the pleotropic proinammatory
cytokine IL-6 and chemokine monocyte chemoattractant pro-
tein-1 (MCP-1/CCL2) in response toLPS and thrombin. Moreover,
these agonists also induce signicantly increased permeability in
cradd / , as compared with cradd / , primary murine endothe-
lial cells. CRADD-decient cells displayed more F-actin polymeri-
zation with concomitant disruption of adherens junctions. In turn,
increasing intracellular CRADD bydelivery ofa novel recombinant
cell-penetrating CRADD protein (CP-CRADD) restored endothe-
lial barrier function and suppressed the induction of IL-6 and
MCP-1 evoked by LPS and thrombin. Likewise, CP-CRADD
enhanced barrier function in CRADD-sucient endothelial cells.
These results indicate that depletion of endogenousCRADD com-
promises endothelial barrier function in response to inammatory
signals. Thus, wedeneanovel function for CRADD in endothelial
cells as an inducible suppressor of BCL10 , a key mediator of
responses to proinammatory agonists.
Inammation represents a fundamental mechanism of dis-
easescausedbymicrobial, autoimmune, metabolic, and physi-
cal insults. For example,theactionofmicrobial insults onendo-
thelial cells in severemicrobial infections evolving into sepsis
leads to endothelial dysfunction that contributes to major
organ failure, disseminated intravascular coagulation, and
acute respiratory distress syndrome (1). To counteract the del-
eterious action of proinammatory cytokines and chemokines,
an intracellular negative feedback system has evolved to limit
the duration and strength of proinammatory signaling. This
system is comprised of intracellular physiologic proteins that
control excessive inammatory responses. They include inter-
leukin-1 receptor-associated kinase (IRAK) 2-M, an inhibitory
member of the IRAK family, the inhibitor of nuclear factor B
(NF B) transcription factors I B, the suppressors of cytokine
signaling (SOCS) proteins that inhibit activated STAT tran-
scription factors, and the ubiquitin-modifying enzyme A20
(2–5). Recently, we added the “death” adaptor caspase and
receptor interacting protein adaptorwith deathdomain/recep-
tor interacting protein-associated ICH-1/CED-3 homologous
protein with a deathdomain (CRADD/RAIDD), hereafter des-
ignated as CRADD, to this list. CRADD negatively regulates
NF B-dependentcytokine andchemokineexpression in T cells
by targeting the NH 2-terminal caspase recruitment domain
(CARD) of B-cell CLL/Lymphoma 10 (BCL10) (6). In immune
cells, the CARD of BCL10 functions as an oligomerization
region and interacts with the CARD of the CARD membrane-
associated guanylate kinase (CARMA ) 1 (6, 7), which is
required for activation of the NF B pathway (8 –12). In non-
immune cells, such as endothelial cells, a CARMA3 signalo-
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domain; K/D, knockdown; LMEC, lung microvascular endothelial cells;
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some containing BCL10 and mucosa-associated lymphoid tis-
sue lymphoma translocation protein 1 (MALT1), operates to
regulatetheNF B signalingpathway(13, 14). Disruption of the
CARMA3 signalosome by genetic deletion of Bcl10 leads to
dramatic reduction of vascular inammation, illustrating that
BCL10 is an essentialcomponentof the signalingcomplex (15).
The CARMA3 signalosomealso modulates endothelial bar-
rier function in response to proinammatory agonists that
induce increased vascular permeability (16). Induction of vas-
cular permeability causes swelling, oneof the four classic signs
of inammation, dueto theaction of proinammatory agonists
sensedby their cognatereceptors expressedon microvascular
endothelialcells (17). The CARMA3 signalosomeamplies sig-
naling in response to proinammatory agonists and mediates
stimulus-dependent nuclear reprogramming (13–15, 18), which
dependson transcription factors NF B and AP-1 (13, 16, 18,
19). Thus, the CARMA3 signalosome plays a pivotal role in
shifting microvascular endothelial cells from a resting to acti-
vated state, integrating signaling pathwaysevokedby recogni-
tion of diverse agonists. This signalingpromulgatesan inam-
matory response, based in part on disruption of endothelial
barrier function by altering cell-cell junctions that include
adherens junctions and tight junctions (20, 21). These main-
staysof endothelialmonolayer integrity dynamically guardbar-
rier function in major organsthat contain an extensivenetwork
of microcirculation, such as lungs, kidneys, liver, and brain.
Vascular endothelial cadherin (VE-cadherin) is a strictly endo-
thelial specic cell adhesionmolecule and the major determi-
nant of endothelial cell contact integrity. Its adhesivefunction
requires associationwith the cytoplasmic catenin protein p120
(22). LPS and thrombin induce F-actin reorganization and sub-
sequent reductions in VE-cadherin at endothelial cell junc-
tions, resulting in increasedvascular permeability (22–24). The
target of CRADD, BCL10, and its eector, NF B, have been
implicated in mediating thesechanges(25–27).
Here weanalyzedthepotential role of CRADD in endothelial
cell homeostasis by employing three approaches: (i) reduction
of CRADD expression in murine endothelial cells with shRNA,
(ii) analysis of microvascular endothelial cells isolated from
CRADD-decient mice (6), and (iii) intracellular delivery of a
novel recombinant cell-penetrating CRADD protein homolog
(CP-CRADD) to CRADD-decient and sucient endothelial
cells. We documented a protective role for CRADD in main-
taining the permeability barrier of primary lungmicrovascular
endothelial cells (LMEC) by demonstrating increased agonist-
induced permeability of cradd / LMEC monolayers com-
paredwith cradd / LMEC monolayers. Moreover, treatment
with CP-CRADD restored barrier function in endothelial
monolayers of human andmurine cells challengedwith proin-
ammatory agonists.
EXPERIMENTAL PROCEDURES
Mice—Wild-type cradd / and knock-out cradd / mice
weregeneratedandmaintained as previously described(6). All
work with animals wascarried out in strict accordancewith the
recommendations in the Guide for the Care and Use of Labo-
ratory Animals of the National Institutes of Health, and
approved by the Vanderbilt University Institutional Animal
Care and Use Committee.
Endothelial Cell Culture—Primary human umbilical vein
endothelial cells were purchased from ScienCell and cultured
in ECM (ScienCell). Primary murine LMEC were isolated from
cradd / and cradd / mice using a lung dissociation kit and
puried by immunomagnetic separation,with anti-CD45-con-
jugated and anti-CD31-conjugated MicroBeads according to
protocols providedbythemanufacturer (Miltenyi Biotec), then
cultured in collagen-coated tissue culture dishes with EBM-2
(Lonza) supplementedwith 5%heat-inactivatedFBS, 25 g/ml
of endothelialmitogen(Biomedical Technologies), and1%pen-
icillin/streptomycin solution (Mediatech). The human lung
microvascular endothelialcell line HPMEC-ST1.6R wasgener-
ously provided by C. J. Kirkpatrick (28) and cultured in M199
(Mediatech) supplementedwith 10%heat-inactivated FBS, 25
g/mlof endothelialmitogen,50 g/mlof heparin (Sigma), and
1% penicillin/streptomycin. The endothelial cell line LEII
(mouse lung capillary) was a kind gift from T. Maciag (29).
EA.hy926, EOMA, and SVEC4 –10 cell lines were purchased
from ATCC. LEII and cell lines from ATCC were cultured in
DMEM (Mediatech) supplementedwith 10%heat-inactivated
FBS and 1%penicillin/streptomycin.
Immunoprecipitation and Immunoblot Analysis—Antibod-
ies to CRADD (Proteintech Group), BCL10 and NF B p65/
RelA (Santa Cruz) were used for immunoblot analyses. GAPDH,
-actin, or TATA-binding protein (TBP) antibodies (Abcam)
wereusedfor normalization of cytosolic andnuclear extracts as
indicated in the gure legends. Complexes were immunopre-
cipitated from cell lysates with antibody to IRAK-1 (Santa
Cruz) and protein A/G-agarose beads(Thermo) then analyzed
by quantitative immunoblotting using antibodies to IRAK-1
and BCL10. All immunoblots were analyzedwith the LI-COR
Odyssey Infrared Imaging System as previously described (6,
30).
Lentiviral shRNA Knockdown of CRADD and BCL10 in
Endothelial Cells—Lentiviral packagingand shRNA transduc-
tion wereperformed as previously described(31). CRADD and
BCL10 knockdown (K/D) eciency was assessedat the tran-
script and protein level after 96 h, when shRNA-mediated
knockdown experiments were performed.
RT-PCR Analysis—Total RNA wasisolatedfor RT-PCR anal-
ysis using TRIzol reagent (Invitrogen) and reverse-transcribed
using the iScript cDNA synthesis kit (Bio-Rad). Targets were
amplied by PCR using PCR Master Mix (Promega) with spe-
cic primers listed in Table 1 for the indicatedproteinmRNAs.
PCR products were separated on 1% agarose gels. Ethidium
bromide-stained gels were imaged on a Gel Doc EZ Imager
(Bio-Rad) andanalyzedwith ImageLab 5.0 softwaretoquantify
bands.
Cytokine/ChemokineAssays—Cytokines and chemokines in
tissueculture mediawereassayedbycytometric beadarray (BD
Biosciences) in theVanderbilt Flow Cytometry Core according
to themanufacturer’s instructions and as describedpreviously
(6). In some experiments, cells were treated with CP-CRADD
or non-CP-CRADD before stimulation.
ImmunouorescenceStaining and FluorescenceMicroscopy—
LMEC or LEII cells wereplated into Lab-Tek II chamber slides
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(Thermo Scientic) and stimulated with LPS or thrombin
(Sigma) as indicated. After stimulation, cells were xed in 4%
paraformaldehyde (Electron Microscopy Sciences), then
washed in PBS and permeabilized with 0.1% Triton X-100
(Invitrogen). For immunouorescence staining, cells were
blocked with 5% normal goat serum (Jackson Immuno-
Research) before overnight incubation at 4 °C with antibodies
to NF B p65/RelA (Abcam) or VE-Cadherin and p120 (Santa
Cruz) followed by incubation with Alexa 488- (Invitrogen) or
Cy-3-labeled (Jackson ImmunoResearch) secondary antibod-
ies. Alexa 488-labeledphalloidin (Cytoskeleton, Inc.) was used
to visualize F-actin polymerization in permeabilized cells.
Slides weremountedwith ProLong Gold Antifade reagentcon-
tainingDAPI (Invitrogen) to stain nuclei. Imageswerecaptured
with MetaMorph software on an Axioplan wideeld micro-
scopein theVanderbilt Cell ImagingCore facility using 40 or
63 oil immersion objectives, as indicated.
Design, Preparation, and Intracellular Delivery of Recombi-
nant CRADD Proteins—Design, production, and analysis of
recombinantmurine CRADD proteins followedour previously
published protocols (30, 32). Plasmid constructs for wild type
(non-CP-CRADD) and cell penetrating (CP-CRADD) were
produced using standard molecular biology techniques. CP-
CRADD contains amembrane-translocatingmotif that enables
it to cross the plasma membrane. Proteins were isolated from
bacterial inclusion bodiesusingpreviously describedprotocols
(30, 32) and dialyzed into DMEM supplementedwith 1%peni-
cillin/streptomycin and 66 M PEG3350. LPS content in all
recombinant protein preparationswasbelowthe levelof detec-
tion (0.06 EU/ml) by Limulus assay (Endosafe, Charles River),
performed according to the manufacturer’s instructions. To
conrm intracellular delivery of CP-CRADD, human ST1.6R
endothelial cells were treated for 1 h with equimolar concen-
trations (10 M) of non-CP-CRADD and CP-CRADD or
mediumalone. The cells werewashedwith warmDMEM with-
out serum and treatedwith 7 g/ml of proteinase K (Sigma) for
10min to removeproteins attachedto thecell surface, followed
by awashin warmDMEM supplementedwith 5%FBS. Pelleted
cells were lysed in RIPA buer supplementedwith protease
inhibitors (Sigma). Lysates were clearedby centrifugation then
analyzed by immunoblotting using antibodies to CRADD and
-actin. Although somemembrane-associatednon-CP-CRADD
is detected by immunoblotting, CP-CRADD is 2–3-fold more
abundantwhen recombinant proteins are normalized to endoge-
nous CRADD or -actin.
Endothelial Cell Permeability—LMEC (1 104, passage 3 or
4) isolated from cradd / and cradd / mice, or human
ST1.6R cells were seededonto 24-well Transwell insets (Costar)
pre-coatedwith type I collagenand incubateduntil conuent.
Conuent monolayerswere serum-starved in 0.5%heat-inacti-
vated FBS for 24 h, then left unstimulated or stimulated with
vascular permeability inducers as indicated. In some experi-
ments, cells were treatedwith CP-CRADD or non-CP-CRADD
before stimulation. Monolayer permeability was assessed by
detection of FITC-dextran in the lower chamber at various
times after addition of 1 mg/ml of 10-kDa FITC-dextran or the
molar equivalent of 70-kDa FITC-dextran (Invitrogen) to the
top chamber. We determined that the relative uorescence of
70-kDa FITC-dextran is 6-fold greater than that of 10-kDa
FITC-dextran at equalmolarities.
Statistical Analyses—Data analysis and statistical calcula-
tions were performed using Prism (GraphPad). Cytokine and
chemokine levels in cultured cell supernatants,andnuclear lev-
els of p65/RelA were compared using an unpaired t test with
Welch’s correction for unequal standard deviations. Quanti-
cation of RT-PCR bandswas used to calculate the fold-change
in transcripts comparedwith non-transduced cells stimulated
with LPS or thrombin and statistical dierences were deter-
mined by Student’s t test. For permeability experiments, the p
values shown compare the area under the curve calculated for
each condition, analyzed by an unpaired t test with Welch’s
correction for unequal standard deviations. Additional evalua-
tion ofpermeabilitycurvesbyrepeatedmeasurestwo-wayanal-
ysis of variance resulted in ap valueof 0.0001 for all indicated
comparisons. In all experiments, apvalueof 0.05wasconsid-
ered signicant.
RESULTS
The outcome of inammation depends on the balance
between proinammatory mediators and anti-inammatory
suppressors.Our prior studiesin immune cells (T lymphocytes)
establishedthatCRADD inhibits pro-inammatory signalingat
the levelof BCL10-dependent NF B activation (6, 7). We inves-
tigatedthe possibility of a similar function for CRADD in non-
immune cells (endothelial cells) in which BCL10 plays a pivotal
role in the CARMA3 signalosome-dependentactivation of the
NF B pathway.
Expression of CRADD in Endothelial Cells—We hypothe-
sized that CRADD could negativelyregulateBCL10, an essen-
tial component of the CARMA3 signalosome assembled in
endothelial cells following their response to proinammatory
stimuli. To test this hypothesis,werst examinedexpressionof
CRADD mRNA and protein in primary human endothelial
cells, primary murine LMEC, andhuman andmurine endothe-
lial cell lines. We show by RT-PCR (Fig. 1A) and immunoblot
analysis (Fig. 1B) that the human umbilical vein endothelial
cell, LMEC, and endothelial cell lines constitutively express
CRADD.
TABLE 1
Oligonucleotide PCR primer sequences used in the current study
Gene Primer sequences (5 to 3 )
hCRADD Forward 5-AGTACTCCGCTCACTTCGC-3
Reverse 5-CTGCAGGCAGGTCGGTCAT-3
mCRADD Forward 5-GAAGAAATGGAAGCCAGAG-3
Reverse 5-CTGTAGGCAGCTCGGCTG-3
hBCL10 Forward 5-CCCGCTCCGCCTCCTCTCCTT-3
Reverse 5-GGCGCTTCTTCCGGGTCCG-3
mBCL10 Forward 5-GAGAGCATCCACTGTCATG-3
Reverse 5-GGAGAAACATCTCACTTGAG-3
mTNF- Forward 5-GCGACGTGGAACTGGCAGAAG-3
Reverse 5-GGTACAACCCATCGGCTGGCA-3
mIL-6 Forward 5-TTCCATCCAGTTGCCTTCTTGG-3
Reverse 5-CTTCATGTACTCCAGGTAG-3
mIL-1 Forward 5-CTCTAGAGCACCATGCTACAGAC-3
Reverse 5-TGGAATCCAGGGGAAACACTG-3
m -actin Forward 5-TTCTTTGCAGCTCCTTCGTTGCCG-3
Reverse 5-TGGATGGCTACGTACATGGCTGGG-3
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The Anti-inammatory Action of CRADD Is Dependenton
BCL10 —We previously identied BCL10 as a direct target of
CRADD responsible for suppressionof T cell receptor agonist-
evoked signaling in T lymphocytes (6). This new function of
CRADD is dependent on its CARD domain, which binds to
BCL10 and impedes its interaction with CARMA1 (6). Thus,
the CRADD-BCL10 axis prevents formation of a complete
CARMA1 signalosomerequired for activation of theNF B sig-
naling pathway in immune cells (6). BCL10 is expressed in
endothelial cells (Fig. 1C ), consistent with other reports that
also documentedexpression of CARMA3 andMALT1 (15, 16,
18). BCL10 has been identied as an important mediator of
NF B activation, and is recruited to Toll-like receptor 4 (TLR4)
signalingcomplexesin responseto LPS stimulation by interact-
ing with IRAK-1 (33, 34). We conrmed this interaction in
LPS-stimulated LMEC from cradd / mice and human lung
microvascular endothelialHPMEC-ST1.6R cells byshowingstim-
ulus- andtime-dependentassociationofBCL10 with IRAK-1 (Fig.
1D). We chose HPMEC-ST1.6R cells because they display the
major constitutive and inducible endothelial cell characteristics
and show an angiogenicresponse on Matrigel similar to that of
primary human endothelial cells isolated from umbilical vein
(HUVEC), lung (HPMEC), and skin (HDMEC) (28).
Subsequently,wedemonstratedthat the regulatory action of
CRADD dependson BCL10 in stimulated endothelial cells by
employingshRNA knockdown of CRADD and/or BCL10 (Fig.
2,A andB). Upon stimulation with theTLR4 agonistLPS, or the
proteinase-activated receptor 1 (PAR-1) agonist thrombin,
CRADD K/D LEII cells display signicantly increased tran-
scripts for cytokines TNF- , IL-6, and IL-1 (Fig. 3). Consistent
with increased expression of IL-6 mRNA transcripts, IL-6 pro-
tein expression was also increased in response to LPS and
thrombin (Fig. 2, C andD, right). Thus, endothelialproduction
of this pleotropic cytokine andpermeability inducer (35) is neg-
atively controlled by CRADD, regulating signaling pathways
evokedbytwodistinct agonists,LPS andthrombin, in endothe-
lial cells. Although CRADD K/D cells produced more IL-6 in
responseto LPS or thrombin, BCL10 K/D endothelial cells dis-
played the oppositeeect (Fig. 2, C and D, left). Simultaneous
reduction in CRADD and BCL10 expression (CRADD/BCL10
K/D) abrogated the increased IL-6 expression observed in
CRADD-decient cells stimulatedwith LPS and thrombin (Fig.
2, C andD, right). Thus, increased IL-6 expression in CRADD-
depletedcells dependson BCL10. This enhancement of LPS-
induced signaling to the nucleus in CRADD K/D LEII cells
resulted in predicteddownstreamactivation eventsas demon-
strated by elevated levels of nuclear NF B RelA/p65 (p65) in
LPS-stimulated CRADD K/D cells comparedwith LPS-stimu-
lated control cells (Fig. 2E).
Proinammatory Agonist-induced Cytokine Expression Is
Suppressedby ReplenishingEndogenousCRADD with a Novel
Recombinant Cell Penetrating (CP) Protein, CP-CRADD— We
reasonedthatbyincreasing theintracellular contentofCRADD
in endothelial cells we can attenuate their responses to proin-
ammatory agonists. Consistent with our prior evidencewith
recombinant cell penetrating SOCS1 and -3 that inhibited
inammation and apoptosis (30, 32, 36), we developed a novel
recombinant CP-CRADD protein (Fig. 4A) to restore CRADD
protein in CRADD-decient endothelial cells and analyze its
regulatory function. Purity and yields of the recombinant
CRADD protein homologswerecomparable(Fig. 4B). Intracel-
lular delivery of CP-CRADD wasveried in humanandmurine
endothelial cells by immunoblot analysis (Fig. 4C ) before use
in functional assays, which ultimately provided proof of CP-
CRADD intracellular activity.
As nal evidence of the negative regulatory function of
CRADD in endothelial cells, CP-CRADD protein delivery to
CRADD-depleted LEII cells (CRADD K/D) signicantly sup-
pressedbothLPS- and thrombin-induced IL-6 expression (Fig.
5A). Consistent with the changes in protein expression,
increased mRNA transcripts for TNF- , IL-6, and IL-1 in
CRADD K/D cells werereducedbytreatmentwith CP-CRADD
to the levels displayed by CRADD-sucient LEII cells after
stimulation with LPS or thrombin (see Fig. 3, B and C ). More-
over, treatmentwith CP-CRADD signicantly reducedthe IL-6
protein in CRADD-sucient LEII control cells stimulatedwith
LPS, althougha similar reduction in IL-6 inducedby thrombin
in the control LEII cells was not apparent (Fig. 5A).
FIGURE 1. Expression of CRADD and BCL10 in human and mouse endothelial cells and association of BCL10 with IRAK-1 in the proinammatory TLR4
signaling pathway induced by LPS. CRADD mRNA and protein expression in endothelial cells was assessed by RT-PCR (A) and immunoblot analysis (B). C,
BCL10mRNAwas assessedby RT-PCR in endothelial cells. In RT-PCR analyses, humannegative control (HNC) andmousenegative control (MNC) reactionswere
performed using human or mouse primers, respectively, without cDNA. In immunoblot analyses, mouse spleen and liver extracts derived from cradd / and
cradd / mice served as positive ( / ) and negative ( / ) controls for CRADD protein, respectively, and -actin served as a cellular protein loading control.
D, co-immunoprecipitation of BCL10 with IRAK-1 is stimulus- and time-dependent. Primary cradd / LMEC cells or human ST1.6 R endothelial cells were
stimulated with 1 g/ml of LPS for the indicated times. Protein complexes precipitated with anti-IRAK-1 (IP) from cell lysates were immunoblotted (IB) with
antibodies to the indicated proteins. All gels and blots shown are representative of three independent experiments.
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We next compared the inammatory response to LPS in
LMEC derived from previously characterized cradd / and
wild-type cradd / control mice (6). As shown in Fig. 1B ,
LMEC isolated from cradd / mice are decient in CRADD
protein, whereasLMEC from wild-type cradd / mice contain
endogenousCRADD. Concordant with results obtainedin LEII
cells, primary LMEC isolated from cradd / mice also dis-
played an enhanced response to LPS stimulation compared
with LMEC from wild-type cradd / mice (Fig. 5B). Treatment
with CP-CRADD suppressed IL-6 production of LMEC from
cradd / mice by 43%,and, signicantly, in LMEC from cradd /
mice, CP-CRADD supplemented endogenous CRADD to
reduce their IL-6 production in response to LPS by 35% (Fig.
5C ). This benecialeectof CRADD augmentationwasfurther
explored in the human lungmicrovascular endothelial cell line
HPMEC-ST1.6R. The enhancedproduction of IL-6 andmono-
cyte chemoattractant protein-1 (MCP-1/CCL2) in response to
LPS wascounteractedbytreatmentwith CP-CRADD, reducing
their expression by 40 and 47%, respectively (Fig. 5D). Addi-
tionally, thrombin-induced IL-6 and MCP-1 were reduced by
63 and 64%, respectively. The chemokine MCP-1 is known to
induce reorganization of tight junctions proteins and increase
endothelial permeability (37). Thus, intracellular delivery of
recombinant CP-CRADD complemented the negative regu-
lation of cytokine/chemokine expression by endogenous
CRADD. The contrast betweenthe results from ST1.6R cells
andcontrol LEII cells (Fig. 5A) maybeattributedto lowexpres-
sion of IL-6 by LEII cells in response to thrombin.
Agonist-induced Endothelial Monolayer Permeability Is
Enhanced in CRADD-decient Endothelial Cells—We analyzed
the role of CRADD in maintaining endothelialbarrier function
by rst comparing permeability of LMEC monolayers from
cradd / and cradd / mice. This assay was basedon moni-
toring the passageof FITC-labeled dextran through themono-
layer. In the absence of stimulation, there was no dierence
in permeability between monolayers from cradd / and
cradd / LMEC (Fig. 6A). We then testedthe barrier function
of primary LMEC in agonist-inducedpermeability assays. Pro-
inammatory agonistsLPS and thrombin inducedsignicantly
increasedpermeability in cradd / LMEC monolayersas com-
paredwith cradd / LMEC monolayers (Fig. 6, B andC ). Nota-
bly, agonist-inducedpermeability of endothelialmonolayers to
bothsmall and largetracers (10-kDa FITC-dextran and70-kDa
FITC-dextran, respectively) was similar (Fig. 6, D–F). CP-CRADD
treatment restored barrier function to cradd / LMEC (Fig. 6,
G and H ) stimulated with either LPS or thrombin, providing
FIGURE 2. Expression of IL-6 induced by proinammatory agonists in CRADD-depleted endothelial cells is dependent on BCL10. CRADD (A) and BCL10
(B) protein knockdown (K/D) induced by shRNA transduction in LEII cells was assessed by immunoblot analysis after 96 h. Shown are immunoblots and
mean S.D. of proteins from at least 3 independent immunoblots normalized to -actin and GAPDH cellular protein loading controls for CRADD and BCL10,
respectively, with calculation of percent suppression of CRADD and BCL10. C and D, LEII cells were transduced with control, CRADD, and/or BCL10 shRNA as
indicated for 96 h then treatedwith 100 ng/ml of LPS (C) or 1.5 units/ml of thrombin (D). IL-6 in culturemedia wasmeasured 24 h after stimulation. Results are
presented asmean S.D. from three independent experiments performed in duplicate (***, p 0.0001 by t test). E, LEII cells were transducedwith control, or
CRADD shRNA as indicated for 96 h then treated with 10 ng/ml of LPS for 1 h. Nuclear translocation of NF B p65/RelA (p65) was assessed by immunouores-
cence stainingand immunoblot analysis of nuclear extracts. Shownare immunouorescence and immunoblot images representativeof at least 3 independent
experiments. Quantication of immunoblots is based on analysis of 6 lanes and shown as mean S.D. of proteins normalized to TBP nuclear protein loading
control in that lane. Magnication 40, scalebars 5 m. (*, p 0.05 by t test.)
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denitive proof of the negativeregulatory function of CRADD
in endothelial cells. Moreover, in CRADD-sucient human
ST1.6R cell monolayers, thrombin-induced permeability was
reduced by supplementation with CP-CRADD (Fig. 6I ), sug-
gestingthat supplementationof endogenousCRADD with CP-
CRADD may stabilize endothelial barrier function during pro-
tracted inammatory signaling.
F-Actin Polymerization and Adherens JunctionsAre Altered
in CRADD-decient Cells—Stimulation of endothelial cell
monolayers with agonists triggers morphological changes
through reorganization of the actin cytoskeleton, leading to
increased permeability (25, 38– 40). We explored the mecha-
nism of increased agonist-induced permeability in CRADD-
decient endothelial monolayers by investigating changes in
F-actin organization (Fig. 7) and the adherens junction protein
VE-cadherin and its adaptor p120 (Fig. 8) in cradd / and
cradd / LMEC stimulated with the permeability inducers
LPS or thrombin.
Unstimulated LMEC from both cradd / and cradd /
mice stained with uorescent phalloidin exhibited an actin
cytoskeletonwith thin F-actin bers sparsely crossing thebody
of cells (Fig. 7, A andB). LPS andthrombin stimulation induced
changes in F-actin organization (Fig. 7, C–F), displaying a
strong pattern of polymerized actin with prominently thick
F-actin ber bundles. However, loss of peripheral F-actin and
more prominent retraction of the cell mass toward the center
were evident in cradd / LMEC, leading to increased gaps in
themonolayer (indicated by arrows) (Fig. 7, D and F).
Immunostaining for the adherens junction protein VE-cad-
herin and its adaptor p120 produced a strong signal, which
appearedas a contiguousline of varied thickness alongcell bor-
ders in quiescentendothelial cells (Fig. 8, A and B). Pleasenote
that unstimulated cradd / endothelial cells displayed a spin-
dle-like shape rather than the typical cobblestone pattern of
cradd / endothelialcells. LPS and thrombin stimulation trig-
gered a striking distortion of theVE-cadherin/p120 contiguous
border pattern with a visible reduction of VE-cadherin/p120
peripheral staining (Fig. 8, C–F). Stimulated cradd / LMEC
FIGURE 3. Endothelial CRADD suppresses mRNA expression of cytokines
TNF , IL-6, and IL-1 in response to proinammatory agonists. Murine
lung capillary endothelial LEII cells were left non-transduced (N), or were
transduced with shRNA for CRADD knockdown (KD), or with scrambled con-
trol shRNA (C). After 96 h, control and CRADD K/D LEII cells were left unstimu-
lated (U) or stimulatedwith 1 g/ml of LPS (L) or with 10 units/ml of thrombin
(T) for 24 h. Some CRADD K/D cells were treated with CP-CRADD (CP) or non-
CP-CRADD (non-CP) for 2 h before stimulation. -Actin was used as a control
for RT-PCR. A, in unstimulated cells, CRADD expression is reduced by shRNA
targetingCRADDbut not by non-target scrambled shRNA. LPS (B) and throm-
bin (C) stimulation increased transcripts for TNF , IL-6, and IL-1 in cells not
transducedwith shRNA. Knockdown of CRADDwith shRNA targeting CRADD
further increases mRNA expression. Treatment with CP-CRADD reduces
expression to that of cells without CRADD knockdown. Gels shown are repre-
sentative of 3 independent experiments. Graphs represent quantication of
bands from three gels. Values from unstimulated samples were set as back-
ground and NL or NT bands were set to 1. Fold-change from stimulated non-
transduced samples (NL or NT) are shown as S.D. from three independent
experiments (NS, not signicant; *, p 0.05; **, p 0.01; ***, p 0.001 by t
test).
FIGURE 4. Design, purity, and intracellular delivery of recombinant CP-
CRADD. A, schematic representation of full-length wild-type CRADD, show-
ing dierent functional domains of the protein including the CARD domain
(green) and Death domain (blue). Non-CP-CRADD lacks the membrane trans-
locatingmotif but contains anN-terminalHis6 tag (black),whereasCP-CRADD
contains the N-terminal His6 tag (black), followed by a 12-amino acid mem-
brane-translocating motif (red). B, protein staining with Coomassie Blue dis-
plays recombinant non-CP-CRADD (25 kDa) andCP-CRADD (26 kDa) proteins.
BSA is shown between them for size reference. C, tracking intracellular deliv-
ery of CP-CRADD by protease resistance and quantitative immunoblotting.
Left, lysates from ST1.6R cells incubated for 1 h with equimolar doses (10 M)
of non-CP-CRADD or CP-CRADD, then treated with proteinase K to remove
extracellular proteins. Right, recombinant protein preparations added to
cells. All samples were run on the same gel and immunoblotted with an anti-
CRADDantibody that recognizesbothendogenous and recombinantCRADD
in cell lysates as indicated. Immunoblot is representative of two independent
experiments performed in triplicate.
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displayed a more dramatic disturbance in the border pattern
compared with cradd / LMEC, evidenced by areas of de-
cient staining surrounding thegapsformed in the initially inte-
gral monolayer (indicated by arrows) (Fig. 8, D and F). These
results indicate that BCL10-mediated F-actin disorganization
(27) and adherens junction disruption are controlled by
CRADD.
DISCUSSION
Here we show that the intracellular adaptor CRADD is
expressedin non-immune cells. In primary human andmurine
endothelial cells, CRADD is involved in maintaining their
integrity by acting as a negativeregulator of the inammatory
response.We documentthat this physiologicaction of CRADD
is dependenton its interaction with BCL10 , a key componentof
the CARMA3 signalosome in microvascular endothelial cells.
This anti-inammatory function of CRADD in endothelialcells
is consistent with its role as a negativeregulator of the BCL10-
containing CARMA1 signalosome in immune cells, as docu-
mentedin our initial study of CRADD (6). BCL10 interacts not
only with CARMA1, which is restricted to cells of the immune
system, but alsowith its close homolog,CARMA3, which has a
much broader expression pattern including endothelial and
epithelial cells (13–16, 18, 41, 42). Therefore, expression of
CRADD in endothelialandother cell types,e.g.epithelial cells,3
follows that of BCL10 andmay also provide an anti-inamma-
tory CRADD-BCL10 axis in those cells. CRADD interaction
with BCL10 transcends its engagementin the CARMA3 signa-
losome as BCL10 is known to interact with IRAK-1 (34).
CRADD negatively regulates LPS-triggered signaling to the
nucleusmediatedbyNF B (seeFig. 2E), a process that depends
3 H. Qiao and J. Hawiger, unpublished data.
FIGURE 5. Intracellular delivery of CP-CRADD suppresses agonist-induced IL-6 and MCP-1 expression in wild-type and CRADD-decient endothelial
cells. A, after a 2-h treatment of control or CRADD K/D LEII cells with equimolar doses (6 M) of non-CP-CRADD or CP-CRADD, cells were stimulated with 100
ng/ml of LPS (left) or 1.5 units/ml of thrombin (right). B, LMECwere isolated from cradd / and cradd / mice. Cells were stimulated with 100 ng/ml of LPS. C,
LMEC isolated from cradd / and cradd / micewere treated for 3 hwith equimolar doses (11 M) of non-CP-CRADDor CP-CRADD, then stimulatedwith 100
ng/ml of LPS.D,human ST1.6R endothelial cellswere treated for 3 hwith equimolar doses (11 M) of non-CP-CRADDor CP-CRADD, then stimulated as inA. IL-6
and MCP-1 in culture media were measured 24 h after stimulation. Results are presented as mean S.D. from three independent experiments performed in
duplicate (*, p 0.05; **, p 0.01; ***, p 0.0001 by t test).
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on TLR4-evoked activation of IRAK-1 that binds BCL10 (34).
Hence CRADD targetingof BCL10 may reduce theoutcomeof
LPS action on endothelial cells.
Although direct involvement of the CARMA3 signalosome
in the LPS/TLR4 pathway is unclear, previous studies have
reportedthatBCL10 andMALT1 playmajor roles bymediating
NF B activation via the IRAK-1-BCL10-MALT1-TRAF6-
TAK1 cascade in the LPS/TLR4 pathway (43, 44). An investi-
gation of Bcl10/Malt1-mediated NF B signaling in non-im-
mune cells showed that IL-6 production was blocked in the
absenceof BCL10 (45). Our results, basedon co-immunopre-
cipitation analysis (Fig. 1D) and BCL10 silencing (Fig. 2), also
demonstrate BCL10 involvement in the LPS/TLR4 signaling
pathway. This pathway is negativelyregulatedby CRADD and
its novel recombinant cell-penetrating homologCP-CRADD.
Thrombin/PAR-1 signaling to mobilize NF B for nuclear
translocation depends on initial protein kinase C activation,
with subsequentstepsmediatedbyBCL10 toengagethecanon-
ical NF B machinery and shift endothelial function toward an
“activated” phenotype(46–50). As documentedin our current
study, thrombin dramatically increased cytokine and chemo-
kine production and signicantly induced permeability of the
endothelialmonolayer. The CARMA3 signalosomelinks PAR-
1-evoked signaling to activation of the I B kinase signaling
complex assembledaround TRAF6 through ubiquitination of
the NF B essential modulator (NEMO/IKK ), the regulatory
subunitof the I B kinase complex (51). In immune cells, BCL10
activates the NF B pathwaythrough the NF B essentialmod-
ulator (52). Although there are signicant dierences in how
the CARMA1 and CARMA3 signalosomescommunicate with
PAR-1 and other receptors, such as the choice of 3-phospho-
inositide-dependent protein kinase 1 and -arrestin 2, the
CARMA3 signalosomeshares its positiveregulatorBCL10 with
the CARMA1 signalosome found in lymphocytes (18). Hence
FIGURE6.Endothelial permeability of CRADD-decient primary murine LMEC and CRADD-sucient human ST1. 6Rendothelialmonolayers is regulated
by CP-CRADD. A–C, LMEC isolated from cradd / and cradd / mice were grown to conuence on Transwell inserts and left unstimulated (A) or stimulated
with 1 g/ml of LPS for 24 h (B) or 10 units/ml of thrombin for 6 h (C). D–F, permeability of 10-kDa compared with 70-kDa FITC-dextran. LMEC isolated from
cradd / mice (D and E) were stimulated with LPS (D) or thrombin (E) as in B and C. F, human ST1.6R cells were stimulated with 30 units/ml of thrombin for 20
min.G andH, LMEC isolated from cradd / mice were treated for 3 h with equimolar doses (12 M) of non-CP-CRADD or CP-CRADD, then stimulatedwith LPS
(G) or thrombin (H) as in B and C. I, human ST1.6R cells were stimulatedwith thrombin as in F. To assess permeability, FITC-dextran (10 kDa in A–C andG–I) was
added to each insert anduorescence in the lower chamberwasmeasured at the indicated times. Results are presented asmean S.D. in relative uorescence
units (RFU) from three independent experiments performed in duplicate (p values shown were determined by t test of the area under the curves from 3
independent experiments).
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BCL10 presents itself as an easy target for CRADD negative
regulationof bothCARMA1 andCARMA3 signalosomesin ago-
nist-stimulated immune andnon-immune cells, respectively.
BCL10 has emergedas a key positive mediator of inam-
matory signals, as it has beenreported to interact with other
CARD domain-containing proteins, including CARD 9, 10,
11, and 14, which are thought to function as upstream regu-
lators in NF B signaling (43– 45, 53). Independent of NF B
signaling, BCL10 is also linked to remodelingof F-actin (27),
which is connected to transmembrane junctional proteins
that control the barrier function of endothelial cells (26, 40).
As the non-immune mainstays of the blood-tissue barrier,
endothelial cells are connectedby highly regulatedtight and
adherens junctions, which control paracellular leakage of
plasma uid and proteins that contribute to increased endo-
thelial permeability (54, 55). LPS induces F-actin remodeling
through activation of a Src family kinase and TNF receptor-
associated factor 6 (TRAF6) (56 –58). As shown in Fig. 7,
CRADD-decient cells demonstrate an altered pattern of
F-actin polymerization in response to LPS and thrombin
stimulation compared with CRADD-sucient cells. There-
fore, CRADD, by targetingBCL10, plays an important role in
the negative regulation of BCL10-mediated F-actin poly-
merization. CRADD deciency thereby increases inducible
but not constitutive permeability of endothelial monolayers
compared with CRADD-sucient endothelium.
Proinammatory agonist-induced stress ber formation
overlaps with redistributed VE-cadherin (59), an endotheli-
um-specic member of the cadherin family of adhesionpro-
teins found in adherens junctions. Inside the cell, VE-cad-
herin interacts with its adaptor p120. As shown in Fig. 8, the
VE-cadherin/p120 systemwas highly perturbed in CRADD-
decient cells upon their stimulation with proinammatory
agonists. Thus, the evidence presented here points to
another important role for endothelial CRADD as an induc-
ible physiologicregulator of vascular permeability, a cardinal
sign of inammation.
Previous studies have demonstrated that the proinamma-
tory cytokine IL-6 (35) and chemokine MCP-1 (37) contribute
to increased endothelial permeability. This study shows signif-
icantly increased IL-6 andMCP-1 expression byCRADD-de-
cient endothelial cells in response to LPS and thrombin, sug-
gestingthat depletionof endogenousCRADD by inammatory
signaling may contribute to the enhanced action of IL-6 and
MCP-1 as endothelialpermeability inducers. We showthat the
changes induced by inammatory signaling are sucient to
allow permeability to large molecules (Fig. 6, D–F), such as
plasmaproteins. In turn, reduction of BCL10-mediated inam-
matory signalingby a novel recombinant protein, CP-CRADD,
oers a new strategy to control vascular inammatory
responses not only in non-immune cells (endothelial cells) as
demonstratedin this studybutalso in immune cells. CRADD is
also expressed in human brain microvascular endothelial cells
(60), suggestingits potential anti-inammatory function there
as well.
In summary, this study provides new evidencethat CRADD
plays a pivotal role in maintaining the integrity of endothelial
monolayers. A better appreciation of the role of CRADD in
endothelium may contribute to a deeper understanding of
endothelialdysfunction and inform thedevelopmentof a novel
treatment for inammatory vascular disorders.
FIGURE 7. F-actin polymerization and cellular contraction are enhanced in
cradd / as compared with cradd / LMEC monolayers after stimulation
with LPS or thrombin. LMEC isolated from cradd / and cradd / mice were
growntoconuence, then leftunstimulated (AandB) or stimulatedwith1 g/ml
of LPS for 24 h (C and D) or 10 units/ml of thrombin for 6 h (E and F). Cells were
stained with Alexa 488-labeled phalloidin (green) to visualize F-actin. Nuclei are
counterstained with DAPI (blue). Arrows indicate gaps in the monolayer caused
by cellular retraction in stimulated cells. Images are representative of at least 3
independent experiments. Magnication 63, scalebars 1 m.
FIGURE 8. CRADD deciency exacerbates the loss of monolayer integrity in
LPS- or thrombin-stimulated LMEC monolayers analyzed by immunouo-
rescence of VE-cadherin and p120. LMEC isolated fromcradd / andcradd /
mice were grown to conuence, then left unstimulated (A and B) or stimulated
with 1 g/ml of LPS for 24h (CandD) or 10units/ml of thrombin for 6h (Eand F).
Cells were immunostained with p120 (red) and VE-cadherin (green). Nuclei are
counterstained with DAPI (blue). Arrows indicate disruption of both proteins in
cell membranes of stimulated cradd / LMEC. Images are representative of at
least 3 independent experiments. Magnication 63, scalebars 1 m.
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Abstract
Lipopolysaccharide (LPS) is a potent microbial virulence factor that can trigger production of proinammatory mediators
involved in the pathogenesis of localized and systemic inammation. Importantly, the role of nuclear transport of stress
responsive transcription factors in this LPS-generated ‘‘genomic storm’’ remains largely undened. We developed a new
nuclear transport modier (NTM) peptide, cell-penetrating cSN50.1, which targets nuclear transport shuttles importin a5
and importin b1, to analyze its eect in LPS-induced localized (acute lung injury) and systemic (lethal endotoxic shock)
murine inammation models. We analyzed a human genome database to match 46 genes that encode cytokines,
chemokines and their receptors with transcription factors whose nuclear transport is known to be modulated by NTM. We
then tested the eect of cSN50.1 peptide on proinammatory gene expression in murine bone marrow-derived
macrophages stimulated with LPS. This NTM suppressed a proinammatory transcriptome of 37 out of 84 genes analyzed,
without altering expression of housekeeping genes or being cytotoxic. Consistent with gene expression analysis in primary
macrophages, plasma levels of 23 out of 26 LPS-induced proinammatory cytokines, chemokines, and growth factors were
signicantly attenuated in a murine model of LPS-induced systemic inammation (lethal endotoxic shock) while the anti-
inammatory cytokine, interleukin 10, was enhanced. This anti-inammatory reprogramming of the endotoxin-induced
genomic response was accompanied by complete protection against lethal endotoxic shock with prophylactic NTM
treatment, and 75% protection when NTM was rst administered after LPS exposure. In a murine model of localized lung
inammation caused by direct airway exposure to LPS, expression of cytokines and chemokines in the bronchoalveolar
space was suppressed with a concomitant reduction of neutrophil tracking. Thus, calming the LPS-triggered ‘‘genomic
storm’’ by modulating nuclear transport with cSN50.1 peptide attenuates the systemic inammatory response associated
with lethal shock as well as localized lung inammation.
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Introduction
Bacterial endotoxin, known as lipopolysaccharide(LPS), is one
of themostpotentmicrobial virulence factors in the pathogenesis
of localized and systemicinammationcausedby Gram-negative
bacteria [1]. LPS is the primary componentof theGram-negative
bacterial outer membrane and the most proinammatory of all
bacterial pathogen-associatedmolecular patterns recognized by
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128
Toll-like receptors (TLRs). TLRs are expressedon multiple cell
types, includingmyeloid and lymphoid cells, vascular endothelial
cells, and respiratory epithelial cells [2,3]. Binding of LPS to its
cognatereceptor, TLR4, induces robust signalingto the nucleus
mediatedby a cascadeof signaltransducersengagedin a streamof
protein-protein interactions and posttranslationalmodications
[4], culminating in nuclear translocation of NF- kB along with
other stress-responsivetranscription factors (SRTFs), including
activator protein-1 (AP-1), nuclear factor of activated T cells
(NFAT), and signal transducer and activator of transcription 1
(STAT-1) [5]. These SRTFs, either alone or in various combina-
tions, regulate the genomic responseto Gram-negative bacteria
and other microbial agents [5]. Similarly, SRTFs respond to
signalingpathwaysemanatingfrom cytokine/chemokinereceptors
[6,7].
SRTFs and other nuclear proteins larger than 45 kDa are
transportedto the nucleusby a set of adaptor proteinsknown as
importins (Imp)/karyopherins a which in tandemwith importin
b1, ferry the SRTF cargo to the nucleus [5,6,8,9]. Therein, they
activate a plethora of genesthat encode inammatory cytokines
and chemokines,signal transducers(cyclooxygenase,nitric oxide
synthase),and cell adhesionmolecules, a responsedenotedas a
‘‘genomic storm’’. The conceptof a ‘‘genomic storm’’ inducedby
trauma and burns in critically injured patientswas extendedto
subjects challenged with bacterial endotoxin, and therefore
representsa fundamentalhuman responseto severeinammatory
stress [10]. A tidal wave of geneexpressionraises blood levels of
cytokines and chemokines and mobilizes expression of other
mediators. Cumulatively, these products of genomic reprogram-
ming induce fever, endothelial instability and detachment,
disseminatedintravascular coagulation, acute lung inammation
(ALI), acute respiratory distresssyndrome (ARDS), and multiple
organ dysfunction,culminating in vascular collapse refractory to
uid resuscitation(septicshock), and death [11,12].
Though promptinitiationof anti-microbial therapy is crucial in
limiting the extent of Gram-negative bacterial infections [13],
residual circulating LPS can sustain productionof inammatory
mediatorsby bloodleukocytesand microvascularendothelialcells
[14]. Given the plethora of proinammatorymediators that are
produced[15], focusingtherapyon singleinammatorymolecules
will likely not alleviate the morbidity associatedwith this disease
[16]. Rather, a more comprehensivecountermeasureto reduce
the ow of SRTFs to the nucleuswouldbe preferable.Therefore,
we hypothesizedthat targetingthe nuclear transport machinery,
which integrates multiple signaling pathways emanating from
endotoxin-stimulatedTLR4 and from subsequently produced
cytokinesand chemokines[5], would calm the ‘‘genomic storm’’.
Thus, it would be plausible to reduce lethal endotoxic shock
(systemic inammation) while also attenuating expression of
inammatory mediators in the lungs (localized inammation).
Using computer-basedanalysisof a public database,we identied
the regulatoryelementsin 46 humangenesthat encodemediators
of inammation. These regulatory elements are recognized by
SRTFs dependenton nuclear translocationmediatedby importins
a and b [5,7]. To testour hypothesis,weusedthenext generation
NTM, cSN50.1, a highly soluble28 amino acid cell-penetrating
peptide[6] that targetsImp a5 and Imp b1 [9]. We assessedits
impact on the inammatory transcriptome of primary bone
marrow-derived macrophages stimulated with LPS. Then, we
compared the action of NTM in primary macrophages with
in vivo analysis in murine models of systemic and localized
inammation inducedby LPS.
Here we report that the modulatingnuclear transportwith the
cell-penetrating NTM, cSN50.1 peptide, leads to selective
attenuation of the LPS-induced transcriptome of murine bone
marrow-derived macrophagesand striking suppressionof LPS-
induced systemic endotoxic shock and localized lung inamma-
tion. These resultssupporttheconceptof targetingnuclear import
of transcription factors as a means to control the LPS-induced
‘‘genomic storm’’ and its resultantinammatory responses.
Materials and Methods
Peptide synthesis and purication
Highly soluble cell-penetrating NTM peptide cSN50.1
(Table 1), was synthesized, puried, and lter-sterilized as
describedelsewhere[6,9].
Transcription Factor/Targeted Gene pair selection
Human genes encoding the cytokines, chemokines, receptors
and growth factors studiedin this manuscript, were analyzed for
specic binding sites of transcription factors whose nuclear
translocation was previously shown to be modulated by NTM
(Table 2). The prediction process was conductedbased on the
presenceof a binding site in the promoter region of the targeted
gene. To accomplish this task we employedthe UCSC Genome
Browser publicly available on the website of the Center for
Biomolecular Science and Engineering at the University of
California Santa Cruz (UCSC Genome Bioinformatics, http://
genome.ucsc.edu).
Isolation and cultivation of bone marrow-derived
macrophages (BMDMs)
Bone marrow cells were isolated from femurs and tibias of
C57BL/6 mice and suspended in Dulbecco’s Modied Eagle
Medium supplementedwith 10% FBS, 10 mM HEPES, 100 U/
ml penicillin, 100 mg/ml streptomycin, and 20% L929-condi-
tioned medium. Non-adherent cells were removed and culture
media replacedevery three days. Cells were used in experiments
after 10 daysof culturefor up to 2 weeksaftermaturation.Prior to
use in experiments,culturepurity of adherentcellswas veriedby
uorescence-activatedcell sorting where $ 95% were MAC3 +,
CD11b +, CD3 –, CD11c – and B220–. Viability was $ 80% as
determinedby trypan blue exclusion.
LPS treatment of BMDMs and quantitative real-time PCR
(qRT-PCR)
BMDMs were left unstimulated for preparation of control
RNA, or stimulated with 2 ng/ml LPS from E. coli O127:B8
(Sigma) and concurrently treatedwith cSN50.1 (30 mM) or saline
(diluent). After incubation at 37uC for 6 h, RNA was prepared
from cellsusingtheQiagen RNeasy Kit (Qiagen)and convertedto
cDNA using the RT 2 First Strand Kit, then analyzed using the
RT 2 Proler PCR array system(Qiagen) accordingthemanufac-
turer’s instructions.
Ethics statement
All animal handling and experimental procedures were
performedin strict accordancewith the recommendationsin the
Guide for theCare andUse of Laboratory Animals of theNational
Institutesof Health. The protocolwasapprovedby theVanderbilt
University Animal Care and Use Program (Permit Number:
A3227-01), which has been accredited by the American Associ-
ation of Accreditation of Laboratory Animal Care International
(le # 000020). Animals were housed in groups of ve in the
animal care facility of Vanderbilt University in a 12 hour light/
dark cycle. Regular rodent chow and water were provided ad
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libitum. After administration of inammatory agonists,mice are
carefully monitored and any that exhibit end2 stage symptoms
consistentwith acute toxic shock are euthanizedas soon as it is
apparent they will not recover.
Murine models of LPS-induced systemic (lethal shock)
and localized (lung) inammation
Randomized groupsof ve femaleC57BL/6 mice (The Jackson
Laboratory) 8–12 weeksof age (, 20 g weight)and LPS from E.
coli O127:B8 (Sigma) were used in all animal experiments. To
evaluatetheprotectiveecacyof NTM (cSN50.1 peptide)against
systemicinammation, twomodelsof lethal endotoxicshockwere
used: high-dose LPS; or low-dose LPS under conditions of
metabolic stress imposed by 2-amino-2-deoxy-D-galactosamine
(D-Gal), which sensitizesmice to the proinammatory action of
LPS [17]. In the high-doseLPS model, 800 mg LPS in 0.2 ml
saline was administeredby intraperitoneal (i.p.) injection. In the
LPS +D-Gal model, mice were injectedi.p. with 1 mg of LPS and
20 mg of D-Gal, each in 0.2 ml saline. Two NTM treatment
protocols, prophylactic and therapeutic,were testedin the high-
dose LPS model. In the prophylactic protocol, mice were given
NTM (cSN50.1 peptide,0.66 mg/injection), or diluent (saline)by
i.p. injectionsof 0.2 ml at 30 min beforeand 30, 90, 150, 210, 360
and 720 min after LPS challenge, while in the therapeutic
protocol, NTM was administeredat 15, 90, 150, 210, 360, and
720 min post-LPS challenge. Blood samples (, 40 mL) were
collectedfrom the saphenousvein in heparinized tubes(Sarstedt)
before and at 2, 4, 6 and 24 h post-LPS challenge. All injected
reagentswere sterile and prepared in pyrogen-freesaline. These
experimentsare basedon thedeathof animals as an experimental
endpoint, so mice were allowed to progressto a moribund state
beforebeingeuthanizedby isouraneasphyxiation.Since multiple
organ systems are aected in the mechanism of systemic
inammation, any pain medication may inadvertently interfere
with the progressionof endotoxicshock. Therefore, we could not
useagentsthat alleviatepain. However, weattemptedtominimize
the amount of pain experienced by the animals by closely
monitoringmice, at least hourly for the rst 24 hours and three
timesa day thereafter,and euthanizingany mice that exhibit end-
stagesymptomsconsistentwith acute toxic shock (lack of reaction
to cage motion, or any of the following signs: ataxia, paralysis,
cyanosis, or severe respiratory distress)as soon as it is apparent
they will not recover. Any surviving mice were euthanizedafter
72 h.
For induction of localized acute lung inammation, intranasal
instillationsof 50 ng of LPS in 50 mL saline (25 mL/nostril) were
performed under ketamine/xylazine anesthesia (0.2 ml of 6.7
mg/ml ketamine and 1.3 mg/ml xylazine administered by i.p.
injection). Mice were treated with NTM (cSN50.1 peptide,
0.66 mg/injection) or diluent (saline) administeredby i.p. injec-
tionsof 0.2 ml at 30 min beforeand at 30, 90, and 120 min after
LPS challenge. Six hours post-LPS challenge, mice were
euthanized by isourane asphyxiation. Bronchoalveolar lavage
(BAL) collection and dierential cell counts were performed as
previouslydescribed[18]. For comparison,BAL wasalsocollected
from naı¨ve mice not exposedto any intranasal instillation before
euthanasia.
Analysis of chemokines, cytokines, and growth factors in
BAL uid and plasma
The eect of cSN50.1 on expressionof chemokines,cytokines
and growth factors was analyzed in cell-free BAL uid or blood
plasmafrommice by cytometricbeadarray (BD BioSciences)or a
32-analyte Milliplex mouse panel (Millipore) according to the
manufacturers’ instructions. Analytes included eotaxin, granulo-
cyte colony-stimulatingfactor (G-CSF), granulocytemacrophage
colony-stimulatingfactor (GM-CSF), interferon gamma (IFN- c),
interleukin(IL) 2 1a , IL-1 b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-
9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IFN- c-
induced protein 10 (IP-10), keratinocyte chemoattractant(KC),
leukemia inhibitory factor (LIF), LPS-induced CXC chemokine
(LIX), macrophagecolony-stimulatingfactor (M-CSF), monocyte
chemoattractantprotein-1(MCP-1), monokineinducedby gamma
interferon (MIG), macrophageinammatory protein (MIP) 2 1a ,
MIP-1 b, MIP-2, regulated upon activation normal T-cell
expressed, and presumably secreted (RANTES), tumor necrosis
factor alpha (TNF- a), and vascular endothelial growth factor
(VEGF).
Statistical analyses
Threshold cycle valuesfrom qRT-PCR were exportedto Excel
and analyzed using the Qiagen web-based PCR Array Data
Analysis Software. Genes showinga . 0.5 log fold changeversus
control were considered signicant. Other data analysis and
statistical calculations were performed using Prism (GraphPad).
Cell countsand chemokine,cytokine, and growthfactor levels in
BAL were comparedusingthe non-parametricMann–Whitney U
test. Survival data were analyzed by the log-rank test. Cytokine,
chemokineand growth factor levels in plasma collectedfrom the
sameanimals at dierenttime pointswere evaluatedby repeated
measurestwo-wayanalysis of variance with Sidak’s post-test.A p
value of , 0.05 was consideredsignicant.
Results
Design and characterization of the next generation NTM,
cSN50.1 peptide, and its previous congeners
A fragment-linkedpeptidestrategyto analyze signal-dependent
nuclear transport is based on fusing a motif from the nuclear
localization sequence(NLS) region of the NF- kB1/p50 subunit
Table 1. Amino acid sequence of cSN50.1 peptide and its congeners SN50 and cSN50.
Peptide Sequence MW [Da] Solubi lity in Water
[mg/mL] [mM]
SN50 AAVALLPAVL LALLAP VQRKRQKLMP 2781 13 4.7
cSN50 AAVALLPAVL LALLAP CYVQRKRQKLMPC 3149 38 12.1
cSN50.1 AAVALLPAVL LALLAP CVQRKRQKLMPC 2986 100 33.5
Fragment-linked peptides comprising the Signal Sequence Hydrophobic Region of Fibroblast Growth Factor 4 (bolded) and the NLS region of NFkB1/p50 (italicized)
were analyzed for their solubility in water. In cSN50 and cSN50.1, an intra-molecular disulde bond is formed between the two cysteines, which cyclizes the NLS motif.
doi:10.1371/journal.pone.0110183.t001
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with the signal sequencehydrophobic region (SSHR) of human
broblast growth factor 4 [7,19]. NLS- and SSHR-containing
NTMs (SN50, cSN50 and cSN50.1; see Table 1 for their
composition and solubility) were designed to function at the
nuclear transport level by bindingto importinsa during stimulus-
initiated signalingand therebymodulatenuclear import of NLS-
bearing SRTFs. The SSHR motif allows peptides to cross the
plasma membraneof cells in culture or in experimentalanimals
throughan ATP- and endosome-independentmechanism[20]. In
this study, we used cSN50.1, an improved version of our
previously described cell-penetratingNTM peptides [6,9,21,22]
that showsincreasedsolubility(100 mg/ml) in water, comparedto
cSN50 (38 mg/ml) and SN50 (13 mg/ml) (see Table 1), thereby
increasing its potency[6,21]. The functionalutility of NTMs has
been reported in numerous preclinical models of inammation
caused by microbial and autoimmune insults [18,21–26]. Most
recently, and unexpectedly, we found that cSN50.1 not only
modulatesnuclear transport of SRTFs such as NF- kB, but also
sterol regulatory element-bindingprotein (SREBP) transcription
factors that regulatelipid homeostasis[6].
NTM has a calming eect on the ‘‘genomic storm’’
induced by LPS in primary macrophages
Recently, it wasshownthat injectionof bacterialendotoxininto
healthy adult volunteers was associatedwith a robust genomic
responsein combinedblood leukocytepopulations[10]. Among
the genes reported in that study, several encoded cytokines,
chemokines, and their receptors as reected by transcriptome
analysis. We used a publicly available database to match genes
encoding mediators of inammation with transcription factors
containing nuclear targeting motifs known to require nuclear
transportshuttlesrecognizedby cSN50.1 [6] (Table 2). We found
that all 46 proinammatorygenesare potentiallyregulatedby NF-
kB1, 34 genesby STAT-1, 32 genesby c-Jun, and 19 genesby
SREBP1. Most of these genesare combinatorially regulatedby
two or more transcription factors that are transported to the
nucleusas monomersor homodimers/heterodimersby importins
a and b. Their transport function is modulatedby NTMs that
encompasscell penetratingSN50, cSN50, and cSN50.1 peptides
[6,9] (Table 1). It is thus plausible that cSN50.1 peptide can
suppress expression of multiple proinammatory genes by
modulatingnuclear transport of transcription factors analyzed in
Table 2.
We testedthis hypothesisthroughanalysis of the proinamma-
tory transcriptomein bonemarrow-derivedmacrophages.These
primary cells are one of the main myeloid lineagetargetsof LPS
[27]. A mouse inammatory cytokine/chemokine and receptor
PCR array allowedus to assessthe eectsof NTM on 84 genes
compared to untreated controls. Remarkably, NTM modied
expressionof 37 of the 84 genestested.While NTM suppressed
gene expression in LPS-activated inammatory pathways
(Figure 1), it did not alter gene expressionof ve housekeeping
genes (Gusb, Hprt1 , Hsp90ab1, Gapdh, Actb, , 0.5 fold change
versus control, not shown). Genes encodingmost cytokines and
CC chemokineswere down-regulatedby NTM whereasthosefor
most CC chemokine receptors, cytokine receptors, and CX
chemokinesand their receptorswere not aected. There were a
fewnotableexceptions:LIX/CXCL5, MIG/CXCL9, and IP-10/
CXCL10. Importantly, this suppressionof genomic changesby
NTM in primary macrophages challenged with LPS was not
associated with changes in cell viability (data not shown),
indicating that NTM has no adverseeecton cell growth. Thus,
targeting nuclear transport pathways for LPS-activated SRTFs
with cSN50.1 peptidepreventeda ‘‘genomic storm’’ by reducing
transcription of a wide array of genesthat encodemediators of
inammation in primary macrophages.
NTM attenuates LPS-induced systemic inammation in
the form of lethal endotoxic shock accompanied by a
burst of proinammatory cytokines and chemokines in
blood
After analysis of the primary macrophage response to LPS
modulatedby NTM, we studiedits eecton twomodelsof LPS-
induced systemic inammation exempliedby lethal shock. In a
high-doseLPS model, both prophylactic and therapeuticNTM
treatmentprotocolswere employed.In the prophylacticprotocol,
the rst dose of NTM was administeredbefore LPS challenge
while in the therapeuticprotocol,NTM treatmentwasbegunafter
LPS administration.As shownin Figure 2A, animals treatedwith
NTM by the prophylactic protocol in the high-doseLPS model
were completely protected, compared to only 10% survival in
saline-treated control animals (p, 0.0001). Strikingly, when a
therapeuticNTM treatmentprotocolwas employedin the high-
dose LPS model, 75% of mice survived, compared to 100%
mortality in the saline-treated control group (Figure 2B, p,
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Figure 1. qRT-PCR -based gene expression analysis of LPS-
challenged BMDMs in the absence or presence of NTM. Ccl
family chemokines, Cx chemokines and Cc receptors, and cytokines,
receptors and miscellaneous factors from an 84 gene array exhibiting a
. 0.5 log fold change in LPS-stimulated primary macrophages
compared to unstimulated control cells.
doi:10.1371/journal.pone.0110183.g001
Nuclear Transport Modulation Reduces Inammation
PLOS ONE | www.plosone.org 5 October 2014 | Volume 9 | Issue 10 | e110183
132
0.0001). Thus, NTM was highly eectiveagainst high-doseLPS
with both prophylacticand therapeuticprotocols.
To further evaluatethe eectivenessof the NTM, we testedits
anti-inammatory eect under conditions of metabolic stress
imposedby D-Gal, which sensitizesmice to LPS [17]. In contrast
to thehigh-doseLPS model,which requiresat least800 mg of LPS
per 20 gmousefor inductionof lethal shock, only 1 mg of LPS per
20 g mouse is required for lethality whenmice are metabolically
stressedwith D-Gal, and deathoccursmuch more rapidly (5–7 h
after low-doseLPS +D-gal comparedto 16–20 h post-LPS in the
high-dosemodel). Consistentwith resultsfrom the high-doseLPS
shock model, prophylactic NTM treatment aorded robust
protection(90%) in mice challengedwith LPS +D-Gal. In contrast,
no mice survived in the control group treated with saline
(Figure 2C, p, 0.0005).
We analyzed the strikinggain in survival of NTM-treated mice
that were challenged with LPS in the context of systemic
proinammatorycytokineand chemokineproduction.As expect-
ed, in the prophylactic protocol, NTM treatment engendered
signicant inhibition of 11 out of 13 proinammatory cytokines
whoseplasma levelswere increasedby LPS challenge(Figure 3A,
upper). An exceptionwas the anti-inammatory cytokine, IL-10,
whichwaselevated. 2 fold in NTM-treated animals. In parallel, a
wide array of LPS-elevated chemokinesand growth factors was
suppressedin NTM-treated mice (Figure 3A, lower). Overall, of
26 cytokines, chemokinesand growth factors elevatedin plasma
after LPS challenge, 23 were reduced by NTM treatment, two
were unchanged(eotaxin/CCL11 and IL-5, not shown)and one
was increased(IL-10). Plasma levelsof the remainingsix of the 32
analytes testedwere not increasedby administrationof LPS (not
shown).These resultsare consistentwith the genomicresponseof
primary macrophagesin the qRT-PCR analysis (see Figure 1),
indicating that NTM, under the conditions of these in vivo
experiments, suppresses expression of multiple mediators of
inammation. A comparable trend in suppressionof proinam-
matory cytokinesand chemokinesTNF- a , IL-6, IFN- c andMCP-
1 was observedin mice treatedwith NTM when employingthe
therapeuticprotocol, albeit to a lesserdegree.Interestinglyin the
therapeuticprotocol, IL-10 is suppressedinsteadof enhancedby
NTM (Figure 3B), consistentwith suppressionof the Il10 genein
primary macrophages(seeFigure 1).
Cumulatively, our results indicate that NTM aords robust
protection of mice from LPS-induced systemic inammation in
two distinct models of lethal shock. Concurrently, we noted a
striking reprogrammingof the inammatory responsethat entails
suppressionof many proinammatory cytokinesand chemokines
in plasma.
NTM attenuates proinammatory cytokine and
chemokine expression after direct airway exposure to
LPS
We next sought to correlate our transcriptome analysis of
primary macrophages with the production of inammatory
mediators in the bronchoalveolar space in a murine model of
LPS-induced ALI. After challengingmice intranasally with LPS,
we analyzed inammatorymediatorsand cell populationsin BAL
uid. We determinedthat i.p. administrationof NTM suppressed
the LPS-induced increase of 14 out of 32 proinammatory
chemokines,cytokinesand growth factors analyzed in BAL uid
(Figure 4). Consistent with genomic reprogramming in primary
macrophages(see Figure 1), NTM treatmenteectivelyreduced
chemokines linked to lung inammation by their roles in
mediating inammatory cell migration to the lung: MCP-1/
CCL2, MIP-1 a/CCL3, and LIX/CXCL5. Suppressedproduc-
tion of cytokines IL-1 a , IL-1 b, IFN- c, and IL-13 also correlated
with results from BMDMs. Conversely, some inammatory
mediators, such as MIG, were not induced by direct airway
exposureto LPS, whileTNF- a , MIP-1 b/CCL4, RANTES/CCL5
and IP-10/CXCL10 were inducedby LPS but not suppressedby
NTM treatment.However, thesediscrepanciesbetweenthe qRT-
PCR assayand BAL analysiscan be attributedto thedierentcell
populationspresentin each assay. NTM did reduceBAL levelsof
a numberof other inammatorymediatorsthatwerenot analyzed
by qRT-PCR: cytokines LIF, IL-9, and IL-12p70; chemokine
MIP-2/CXCL2; and growthfactorsG-CSF, M-CSF, and VEGF,
Figure 2. NT M t reatmen t enhance s s urvival from lethal
endotoxic shock. Survival curves for mice challenged i.p. with high-
dose LPS (A and B) or low-dose LPS+D-Gal (C). In (A) and (C) mice were
administered the rst NTM (cSN50.1 peptide) treatment 30 min before
LPS challenge (prophylactic protocol), while in (B), the rst treatment
was administered 15 min after LPS challenge (therapeutic protocol).
Saline injections were administered to control mice challenged with LPS
following the same treatment schedule in each protocol, as described in
‘‘Materials and Methods’’. ***p, 0.0005 by log rank test.
doi:10.1371/journal.pone.0110183.g002
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which is implicatedin vascularpermeability[28]. Overall, analysis
of BAL documents the eectivenessof NTM in suppressing
mediatorsof ALI after direct airway exposureto LPS.
Suppression of chemokines MCP-1/CCL2, MIP-1 a/CCL3,
MIP-1 b/CCL4, and LIX/CXCL5 in the inammatorytranscrip-
tomeanalysis of NTM-treated primary macrophagesand in BAL
followingdirect airway exposureto LPS, led us to postulatethat
NTM wouldreduceleukocytetrackingto the lung. As shownin
Figure 5, weobserveda 5-fold reductionin total cell countin BAL
uid from mice treatedwith NTM in comparison to the saline-
treated control group (p, 0.005), reducing the total cell count in
BAL fromNTM-treated mice to thatof naivemice. A reductionin
neutrophils(, 80%, p, 0.05) accountedfor mostof the dierence
in BAL cellularity. Tracking of monocytes/macrophages,the
primary cell type detected in BAL uid from naı¨ve mice was
moderately reduced (30%), but not signicantly. Lymphocytes
represented less than 1% of cells detected in BAL and their
numbers were unchangedby NTM treatment (Figure 5). Thus,
migrationof neutrophilsto the bronchoalveolarspacein response
to direct airway exposure to LPS, which evokes a robust
expressionof chemokinegenes,is profoundlyreducedby systemic
administration of NTM. As neutrophils are the main source of
oxidative stress to the delicate structure of the blood-air barrier
[29], NTM’s suppressionof chemokinesresponsiblefor massive
neutrophiltracking to the bronchoalveolarspacemay engender
a new approach to lung cytoprotection. Thus, LPS-induced
respiratory and systemicblood inammatory responsesand their
lethal outcomesare averted.
Discus sion
Cumulatively, our resultsdocumentthe essentialrole of nuclear
transport in developmentof a ‘‘genomic storm’’ and its sequelae
inducedby bacterial endotoxin.This evidencerestson the design
and applicationof a highly solubleNTM, cSN50.1 peptide,which
targets nuclear transport shuttles required for translocation of
proinammatory SRTFs and metabolism-regulatingSREBPs.
The emergingconceptof a ‘‘genomic storm’’ in critically injured
patients has been extended to human subjects challengedwith
bacterialendotoxin[10]. Our analysisof 46 genesencodinga wide
array of mediators of inammation (see Table 2) indicated that
these genes are regulated by a group of transcription factors
responsiblefor proinammatory and metabolic signaling to the
nucleus. As nuclear translocation of these transcription factors
depends on nuclear transport machinery, we showed how
modulation of this machinery with a cell-penetrating peptide
targeting Imp a5 and Imp b1 calms the ‘‘genomic storm’’
triggered by bacterial endotoxin in primary BMDMs, and
attenuates systemic and localized inammation. These results
obtained in murine macrophagesare congruent with the gene
expressionprole of human peripheralbloodleukocytesfollowing
endotoxin challenge [30]. Though it was recently asserted that
humansand mice display discordantgenomicresponsesto severe
injury [31], subsequentreanalysisof the datasetsemployedin that
study indicates that the gene expression proles in the mouse
modelswere highly similar to human responses[30].
We showthat cSN50.1 had a profoundsuppressing eecton the
inammatory transcriptome of LPS-stimulated primary macrophag-
es. T his effect was paralleled by suppression of multiple cytokines,
chemokines and, growth factors in plasma in response to LP S.
Furthermore, NTM protectedmice from lethality in two endotoxic
shockmodels. NTM also attenuated proinammatory cytokinesand
chemokinesin inamedlungs accompanied by reducedtrafcking of
neutrophils to the LPS-challenged bronchoalveolar space. T hese
Figure 3. NTM treatmen t reduces plasma levels of multiple
cytokines, chemokin es and growth factors induced by LPS. (A)
Wild type C57BL/6 mice were challenged i.p. with a lethal dose of LPS
(800 mg) and treated with i.p. injections of NTM (cSN50.1 peptide) or
diluent (saline) following a prophylactic protocol as in Figure 4A. Blood
was collected at baseline and 2 or 6 h after LPS challenge and a
multiplex assay was used to measure 32 analytes in plasma. Twenty-
four analytes were signicantly altered by NTM treatment, as
determined by repeated measures two-way analysis of variance with
Sidak’s post-test. Twenty-three were reduced, while anti-inammatory
IL-10 was increased by NTM treatment. Results are shown as the %
inhibition or increase by NTM compared to saline control set to 100% at
the time point demonstrating maximal expression for that analyte.
n= 10 animals/group. (B) Comparison of prophylactic and therapeutic
NTM treatment protocols on selected plasma cytokine and chemokine
levels in the high-dose LPS model of endotoxic shock. Data are
presented as mean 6 standard error, n= 5 2 10 animals/group.
doi:10.1371/journal.pone.0110183.g003
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results indicate that the more soluble, next generation NT M
modulates nuclear signaling induced by LPS, thereby effectively
reducing its deleterious eects in systemic (endotoxic shock) and
localized (lung) inflammation.
NTM is rapidly delivered(within30–60 min after i.p. injection)
througha receptor-andendocytosis-independentmechanism[20]
to mouse blood cells and organs where it reaches sucient
intracellular concentration to engender localized (lung) and
systemic (endotoxic shock) anti-inammatory eects. Thus, the
microvascularcompartmentofmultipleorgansthat are vulnerable
to LPS toxicity (e.g. lungs, liver, and kidneys) can be protected
[18,22]. Unlike anti-inammatory glucocorticosteroids which
produced discordant results in sepsis clinical trials [32,33] and
have potentially adverse side eects on metabolic balance (e.g.
hyperglycemia and hyperlipidemia) [34–36], NTM not only
suppressespulmonary and systemic inammation induced by
LPS but also correctedmetabolicderangementsin an experimen-
tal model of hyperlipidemia by targeting nuclear transport of
SREBPs [6]. This new functionof cSN50.1 resultedin signicant
amelioration of hyperlipidemia and hyperglycemia. Metabolic
dysregulation is a consequenceof the systemic action of LPS,
which in turn acceleratesthe vascular complicationsof hyperlip-
idemia [37–39]. SREBPs lack an NLS for bindingto importinsa
and are shuttledto the nucleus by binding to Imp b1 [40]. We
Figure 4. LPS-induce d expression of chemokin es, cytokines, and growth factors in the lung is suppressed by NTM. Fourteen
cytokines, chemokines and growth factors elevated in BAL after direct airway exposure to LPS are signicantly suppressed by NTM (cSN50.1 peptide)
treatment. Data are presented as mean 6 standard error, n= 4 naı¨ve and 8–9 NTM- or saline-treated animals/group from 3 independent experiments.
*p, 0.05, **p, 0.005, and ***p, 0.0005 by Mann-Whitney U test comparing LPS-challenged groups.
doi:10.1371/journal.pone.0110183.g004
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discoveredthat theSSHR motifof cSN50.1 bindsImp b1, thereby
reducingnuclear translocationof SREBP-1 and 2 2. To thebestof
our knowledge, the immunoregulatory function of SREBP1
toward genes that encode proinammatory cytokines and
chemokinesis not well understood.
Three interwoven mechanisms of LPS-induced systemic
inammation: endothelial injury, apoptosis, and microvascular
dysfunction, depend on modulation of a nuclear transport-
regulatedgenomicresponse[5,22,41,42]. Signicantly, we docu-
mented that systemic production of proinammatory cytokines,
chemokinesand growth factors, which contribute to the subse-
quentdevelopmentof endotoxicshock,wasattenuated,whileonly
IL-10 was increased by NTM, and only in plasma. Whereas
elevation of IL-10 is notable in the prole of cytokine and
chemokine responses in human sepsis studies [43–45], other
critical proinammatorymediatorsare consistentlysuppressedby
NTM, and NTM treatment is highly protective against lethal
shock. Since many small transcriptionfactors (, 45 kDa) essential
to cell viability can traverse the nuclear pore without assistance
from importinsa and b [46], which are the targetsof NTM [6], it
is unlikely that NTM is involved in their nucleocytoplasmic
tracking. Thus, targeted modulation of nuclear transport of
proinammatory SRTFs, the master regulatorsof innate immu-
nity and inammation, and SREBPs, the master regulators of
metabolic inammation, oers a new approach to suppressionof
inammatory, metabolic, and apoptotic mediators in the lung,
liver, and other organs to interrupt rapidly progressingmicrovas-
cular injury induced by bacterial endotoxin. Importantly, in
polymicrobial sepsisand a pulmonary anthrax model, additionof
NTM to antimicrobial therapy improvedthe outcomein termsof
clearance of bacteria and survival [24,26]. These studiesmilitate
againstthe notion that usingNTM to modulatenuclear transport
of SRTFs would compromise the outcomeof microbial inam-
matory diseases.
Important to these considerations of novel countermeasures
toward LPS toxicity is the rise of multidrug-resistantGram-
negativebacterial infectionsin intensivecare units throughoutthe
United States, Europe, and Asia. These infectionscause localized
and systemic inammation leading to septic shock and are a
growing concern in immunocompromisedhosts [47,48]. Alarm-
ingly, Gram-negative bacteria are isolated from 62% of patients
with severe sepsis; approximately half of these cases result in
individualsdependentuponmechanicalventilation[49]. The rate
of acquiringbacterialpneumoniaincreasesup to 21% in intubated
patientsand rises even higher as the lengthof intubationpersists
[50–52]. In total, Gram-negative bacteria account for more than
30% of hospital-acquiredinfectionscausingpneumonia[53].
A cardinal feature of localized inammation of the lungs
(pneumonia and ARDS) caused by Gram-negative bacteria is
endothelialand epithelial injury [29]. The responseto microbial
virulence factors leads to uncontrolledproduction of proinam-
matory chemokines and cytokines that contribute to collateral
damageof the air-blood barrier. We postulatethat simultaneous
reductionof multipleproinammatorycytokinesand chemokines
inducedby direct airway exposureto LPS has a salutary eecton
other lung-associatedinammatory cells. For example, intracellu-
lar deliveryof NTM signicantlyreducedtrackingof neutrophils
to the bronchoalveolar space. At least three NTM-suppressed
cytokines, IL-6, IL-17, and IFN- c, throughtheir localized action,
contribute to the disruption of lung endothelial and epithelial
barriers [54,55], manifested by migration of leukocytes to the
bronchoalveolarspace, leakinessof plasma proteins therein, and
impairment of respiratory function. Consistent with localized
suppressionof LIX, MCP-1, MIP-1 a , and MIP-2 by NTM, a
signicantmigration of neutrophilsto the bronchoalveolarspace
was attenuated,thereby reducing potential oxidant injury to the
respiratory epithelium and vascular endothelium. Systemic sup-
pressionby NTM of chemokinesIP-10, MCP-1, MIG, MIP-1 b
and RANTES in plasma is also of signicancedue to their role in
induction of inammatory cell migration to the bronchoalveolar
space [56,57].
The need for new therapeuticapproachesto protect lungsand
othermajor organs from LPS-induced injury is apparentas there
is currently no available FDA-approved drug to counteract
collateral organ injury during sepsis, ALI, and ARDS [11]. The
prospect for an eective countermeasure based on a single
cytokine/chemokinetarget for monoclonal antibodiesor soluble
cytokine receptorantagonists[58–60] is dimmedby the potential
for signicant redundancy in cytokine signaling. We have now
demonstratedthe benecialeectsof NTM in twodiversemodels
of localized lung inammation: one induced by LPS, a potent
agonist of TLR4-expressing myeloid, endothelial, and epithelial
cells as documentedin this study, and the second, induced by
staphylococcal enterotoxin B, a superantigenic immunotoxin,
which is a robust agonistof T cell receptor-expressingcells [18].
Our ndings document the potential utility of targeting the
nuclear transport shuttles with cell-penetrating peptides to
simultaneously suppress production of multiple cytokines and
chemokinesand potentially correct metabolic derangements[6].
Survivors of sepsis have strikingly lower levels of NF- kB in the
nuclear compartmentof peripheralbloodmononuclearleukocytes
than non-survivors [61]. Using an established formula for
extrapolating a human equivalent dose from the animal dose
Figure 5. LPS-in duced cellular tracking to lungs is reduced in
NTM-treated mice. Cell counts in BAL fluid collected from
unchallenged mice (naı¨ve) and 6 h after direct airway exposure to
LPS, with i.p. NTM peptide (cSN50.1) or diluent control (saline)
treatment. The LPS-induced increase in total cells is comprised primarily
of neutrophils. Neutrophil tracking to BAL is signicantly reduced by
NTM treatment while monocytes/macrophages and lymphocytes are
not aected. Data are presented as mean 6 standard error, n= 4 naı¨ve
and 5–7 NTM- or saline-treated animals/group from two independent
experiments. *p, 0.05, **p, 0.005 by Mann-Whitney U test comparing
LPS-challenged groups.
doi:10.1371/journal.pone.0110183.g005
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through normalization to body surface area [62], the eective
cSN50.1 peptide dose of 0.66 mg/20 g mouse translates to a
manageablehuman dose of 200 mg/70 kg. This is similar to a
standardoral doseof ibuprofen,a non-steroidalanti-inammatory
drug, which at a daily intravenousdose of 800 mg, was proven
ineectivein reducing shock, ARDS, and mortality in a human
sepsis trial [63]. However, further studies will be required to
determinethe pharmacokinetics,toxicity, and therapeuticecacy
of NTMs.
Given its ecientdelivery to the lungsand rapid action, a cell-
penetratingNTM peptidetargetingnuclear import of SRTFs and
SREBPs may represent a much-neededadjunctive therapy to
complementantimicrobials that targetGram-negative bacteria in
systemic(endotoxicshock)and localized(lung)infections.In sucha
combinedtreatment, antimicrobialswould limit the proliferation
of Gram-negative bacteria that shed LPS and express exotoxins
while the collateral damage to lungs and other organs through
uncontrolled inammation would be containedby NTM. Thus,
the serious and costly consequencesof Gram-negative infections
can be potentiallyreduced.
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